Bartter syndrome

Mendelian MONDO:0015231 Pathograph 9 renal tubulopathy salt-wasting nephropathy

Bartter syndrome is a group of autosomal recessive (and one X-linked) renal tubular salt-wasting disorders characterized by impaired sodium chloride reabsorption in the thick ascending limb of the loop of Henle. The hallmark biochemical triad is hypokalemic hypochloremic metabolic alkalosis, hyperreninemia with secondary hyperaldosteronism, and normal to low blood pressure. Five genetic types are recognized: Type 1 (SLC12A1/NKCC2), Type 2 (KCNJ1/ROMK), Type 3 (CLCNKB/ClC-Kb), Type 4A (BSND/Barttin), Type 4B (digenic CLCNKA+CLCNKB), and Type 5 (MAGED2, X-linked transient). Types 1, 2, 4, and 5 typically present antenatally with polyhydramnios and premature birth, while Type 3 (classic Bartter) presents in childhood with failure to thrive, polyuria, polydipsia, and growth retardation. Type 4 is distinguished by concurrent sensorineural hearing loss due to barttin co-expression in the inner ear. Long-term complications include chronic kidney disease (11% in one cohort) and growth impairment despite treatment.

Ask OpenScientist

Ask a research question about Bartter syndrome. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).

Submitting...

Do not include personal health information in your question. Questions and results are cached in your browser's local storage.

0
Mappings
0
Definitions
2
Inheritance
9
Pathophysiology
0
Histopathology
19
Phenotypes
9
Pathograph
6
Genes
6
Treatments
6
Subtypes
0
Differentials
0
Datasets
0
Trials
0
Models
55
References
2
Deep Research
🏷

Classifications

Harrison's Chapter
kidney disorder hereditary disease
Channelopathy
epithelial channelopathy
👪

Inheritance

2
Autosomal recessive (Types 1-4) HP:0000007
Types 1, 2, 3, 4A, and 4B follow autosomal recessive inheritance.
Autosomal recessive inheritance
Show evidence (1 reference)
PMID:30519073 SUPPORT Human Clinical
"All these four types are recessive disorders."
Review confirms all four classical Bartter types are autosomal recessive.
X-linked recessive (Type 5) HP:0001419
Type 5 (MAGED2) follows X-linked recessive inheritance and is characteristically transient.
X-linked recessive inheritance
Show evidence (1 reference)
PMID:34926352 SUPPORT Human Clinical
"Mutations in the MAGED2 gene can cause X-linked acute early-onset polyhydramnios with a severe but transient form of antenatal Bartter's syndrome."
Case report confirms X-linked inheritance and transient nature of MAGED2-associated Bartter syndrome.
◆

Subtypes

6
Type 1 (Antenatal, NKCC2)
Caused by loss-of-function mutations in SLC12A1, encoding the sodium-potassium-chloride cotransporter NKCC2 in the thick ascending limb. Presents antenatally with polyhydramnios, premature birth, and severe salt wasting. Nephrocalcinosis is common.
Show evidence (1 reference)
PMID:30519073 SUPPORT Human Clinical
"In type I BS, symptoms are usually present at birth with severe salt wasting, hyposthenuria, increased production of PGE2, and failure to thrive. Some of these symptoms already occur in utero and can cause polyhydramnios and premature delivery. A common feature is marked hypercalciuria, which..."
Review describes the clinical features of Type 1 Bartter syndrome including antenatal presentation and nephrocalcinosis.
Type 2 (Antenatal, ROMK)
Caused by loss-of-function mutations in KCNJ1, encoding the renal outer medullary potassium channel (ROMK). Presents antenatally similar to Type 1 with polyhydramnios and prematurity. Transient hyperkalemia in the neonatal period is characteristic.
Show evidence (1 reference)
PMID:19096086 SUPPORT Human Clinical
"transient neonatal hyperkalaemia was present in two-thirds of the children with KCNJ1 mutations"
French cohort study confirms transient hyperkalemia as a distinguishing feature of KCNJ1/Type 2 Bartter syndrome.
Type 3 (Classic, ClC-Kb)
Caused by loss-of-function mutations in CLCNKB, encoding the chloride channel ClC-Kb. Presents in infancy or childhood with hypokalemic alkalosis, failure to thrive, polyuria, polydipsia, and growth retardation. Generally milder than antenatal forms; nephrocalcinosis is less common.
Show evidence (1 reference)
PMID:19096086 SUPPORT Human Clinical
"three patients had no history of polyhydramnios or premature birth and had CLCNKB mutations according to a less severe renal sodium wasting"
Confirms that CLCNKB patients can present without antenatal features, consistent with classic (less severe) phenotype.
Type 4A (With sensorineural deafness, Barttin)
Caused by loss-of-function mutations in BSND, encoding barttin, the essential beta-subunit of ClC-Ka and ClC-Kb chloride channels. Presents antenatally with polyhydramnios, severe salt wasting, and sensorineural hearing loss due to barttin expression in the stria vascularis of the inner ear.
Show evidence (1 reference)
PMID:19096086 SUPPORT Human Clinical
"Deafness at diagnosis was constant in patients with BSND mutations"
Cohort study confirms universal sensorineural deafness in BSND/Type 4A patients.
Type 4B (Digenic, ClC-Ka + ClC-Kb)
Caused by simultaneous loss-of-function mutations in both CLCNKA and CLCNKB. Phenotypically similar to Type 4A with antenatal presentation and sensorineural deafness.
Show evidence (1 reference)
PMID:30519073 SUPPORT Human Clinical
"type IVb is a digenic disorder with mutations in both CLCNKA and CLCNKB genes, which can lead to impairment in the functioning of two chloride channels and as a result, severe salt wasting and deafness."
Review confirms digenic nature and deafness phenotype of Type 4B.
Type 5 (Transient antenatal, MAGED2)
Caused by loss-of-function mutations in MAGED2 on the X chromosome. Presents with severe antenatal polyhydramnios and salt wasting that typically resolves spontaneously in the first months of life.
Show evidence (1 reference)
PMID:30519073 SUPPORT Human Clinical
"This phenotype is characterized by the spontaneous resolution of polyuria, a decrease in the concentrations of renin and aldosterone, as well as a decrease in urinary PGE2 levels."
Review describes the transient and self-resolving nature of MAGED2-associated Bartter syndrome.
⚙

Pathophysiology

9
ClC-K/Barttin Chloride Channel Dysfunction (Type 4)
In type 4 Bartter syndrome, BSND loss-of-function or digenic CLCNKA/CLCNKB disruption impairs the ClC-K/barttin chloride-channel system shared by renal epithelia and the inner ear. This links the renal salt-wasting branch to the sensorineural-hearing branch without implying that all Bartter subtypes cause deafness.
Chloride transmembrane transport link ↓ DECREASED
Downstream
Impaired NaCl Reabsorption in Thick Ascending Limb Defective ClC-K/barttin channel function in Henle-loop epithelia impairs epithelial salt transport, feeding into the renal NaCl reabsorption defect.
Inner Ear Chloride Transport Defect (Type 4) The same type 4 ClC-K/barttin channel system is required in the inner ear; barttin mutations impair potassium secretion in the stria vascularis and vestibular labyrinth, while dual ClC-K channel mutations impair inner-ear channel function.
Show evidence (2 references)
PMID:30519073 SUPPORT Other
"Mutations in the BSND gene cause type IVa BS and result in impairment of barttin insertion in the plasma membrane of CLC-Kb and CLC-Ka channels in the Henle’s loop as well as in the inner ear, which interfere with epithelial salt transport."
Review links BSND-associated type 4A Bartter syndrome to defective ClC-K/barttin channel handling in both renal epithelia and inner ear.
PMID:30519073 SUPPORT Other
"type IVb is a digenic disorder with mutations in both CLCNKA and CLCNKB genes, which can lead to impairment in the functioning of two chloride channels and as a result, severe salt wasting and deafness."
Review supports the analogous type 4B mechanism in which dual ClC-K channel disruption produces both renal salt wasting and deafness.
Impaired NaCl Reabsorption in Thick Ascending Limb
The primary defect in Bartter syndrome is impaired sodium chloride reabsorption in the thick ascending limb (TAL) of the loop of Henle. NKCC2 (apical) mediates electroneutral entry of Na+, K+, and 2Cl-; ROMK recycles K+ back to the lumen to sustain NKCC2 activity; and ClC-Kb (with barttin) provides basolateral Cl- exit. Loss of any component disrupts the entire transcellular NaCl transport pathway.
Thick ascending limb epithelial cell link
Sodium ion transport link ↓ DECREASED Renal sodium ion transport link ↓ DECREASED Chloride transmembrane transport link ↓ DECREASED
Downstream
Compensatory Distal Sodium Reabsorption and Potassium Wasting
Loss of Medullary Concentration Gradient
Impaired Paracellular Cation Reabsorption
Show evidence (1 reference)
PMID:30519073 SUPPORT Other
"The main ion channel at the luminal membrane is NKCC2 (furosemide-sensitive sodium–potassium–chloride cotransporter), which belongs to a family of sodium-coupled electrolyte transporters, encoded by the solute carrier family of SLC12A genes. NKCC2 is responsible for carrying sodium from the..."
Review describes the molecular physiology of NKCC2-mediated NaCl transport in the TAL that is disrupted in Bartter syndrome.
Compensatory Distal Sodium Reabsorption and Potassium Wasting
Reduced NaCl reabsorption in the TAL increases sodium delivery to the distal convoluted tubule and collecting duct. Enhanced sodium reabsorption through ENaC in principal cells, driven by secondary hyperaldosteronism, creates a lumen-negative potential that drives potassium and hydrogen ion secretion, producing hypokalemia and metabolic alkalosis.
Kidney collecting duct principal cell link
Potassium ion homeostasis link ↓ DECREASED Potassium ion transmembrane transport link ↑ INCREASED
Downstream
Renin-Angiotensin-Aldosterone System Activation
Show evidence (1 reference)
PMID:30519073 SUPPORT Other
"patients with BS present hyperreninemic hyperaldosteronism with normal/low blood pressure, reduced peripheral resistance, and hyporesponsiveness to antihypertensives."
Review describes the hyperaldosteronism with paradoxically normal/low blood pressure due to the tubular defect.
Renin-Angiotensin-Aldosterone System Activation
Chronic volume depletion from renal salt wasting stimulates the juxtaglomerular apparatus to increase renin secretion, resulting in hyperreninemia and secondary hyperaldosteronism. Despite elevated aldosterone, blood pressure remains normal or low because the primary renal tubular defect prevents effective sodium retention.
Juxtaglomerular complex cell link Macula densa epithelial cell link
Renin secretion into blood stream link ↑ INCREASED
Downstream
Prostaglandin E2 Overproduction
Show evidence (1 reference)
PMID:30519073 SUPPORT Other
"In patients with BS, reduced reabsorption of chloride occurs due to the genetic defects, and an increase in chloride delivery to the macula densa with an abnormal volume sensing ensues. Therefore, the control of filtration becomes uncoupled from volume status."
Review explains the macula densa-mediated RAAS activation mechanism in Bartter syndrome.
Loss of Medullary Concentration Gradient
NaCl reabsorption in the TAL is essential for generating the corticomedullary osmotic gradient required for urinary concentration. Impaired TAL transport reduces medullary tonicity, causing nephrogenic diabetes insipidus-like polyuria, polydipsia, and isosthenuria.
Water transport link ↓ DECREASED
Show evidence (1 reference)
PMID:30519073 SUPPORT Other
"Transepithelial salt movement into the medullary inter-stitium, together with the low permeability of the luminal membrane of the TAL to water, is important to allow the kidneys to develop interstitial hypertonicity and support the urinary concentrating ability."
Review explains the role of TAL NaCl reabsorption in maintaining the medullary osmotic gradient required for urinary concentration.
Prostaglandin E2 Overproduction
Hypokalemia and volume depletion stimulate renal prostaglandin E2 synthesis, which further inhibits NaCl reabsorption in the TAL and stimulates renin release, creating a positive feedback loop that amplifies salt wasting and electrolyte disturbances.
Prostaglandin biosynthetic process link ↑ INCREASED
Show evidence (1 reference)
PMID:30519073 SUPPORT Other
"This impaired entry of sodium and chloride into the macula densa increases the expression of cyclooxygenase-2 (COX2) stimulating the renal production of prostaglandin E2 (PGE2), also resulting in afferent arteriolar dilatation and activation of renin release by JGA."
Review describes the COX2/PGE2 pathway activation in Bartter syndrome and its role in amplifying RAAS activation.
Impaired Paracellular Cation Reabsorption
NKCC2-mediated K+ recycling through ROMK generates a lumen-positive transepithelial voltage in the TAL that drives paracellular reabsorption of Ca2+ and Mg2+. Loss of this voltage in Types 1 and 2 causes hypercalciuria (leading to nephrocalcinosis) and hypomagnesemia.
Thick ascending limb epithelial cell link
Magnesium ion homeostasis link ↓ DECREASED
Downstream
Nephrocalcinosis
Show evidence (1 reference)
PMID:30519073 SUPPORT Other
"Henle’s loop has another important role in the reabsorption of divalent cations such as calcium (Ca2+) and magnesium (Mg2+), which are reabsorbed by a passive paracellular mechanism secondary to the driving force produced by active salt reabsorption."
Review explains the paracellular divalent cation reabsorption mechanism that is disrupted when TAL NaCl transport fails.
Nephrocalcinosis
Hypercalciuria from impaired paracellular calcium reabsorption in the TAL leads to medullary calcium deposition. Nephrocalcinosis is most prominent in Types 1 and 2 and is less common in Type 3.
Show evidence (1 reference)
PMID:19096086 SUPPORT Human Clinical
"Nephrocalcinosis was constant in KCNJ1 and SLC12A1 but not in BSND and CLCNKB patients."
Cohort study confirms nephrocalcinosis is universal in Types 1 and 2 but absent in Types 3 and 4.
Inner Ear Chloride Transport Defect (Type 4)
Barttin is co-expressed with ClC-Ka and ClC-Kb in the stria vascularis of the inner ear, where chloride channels are essential for endolymph potassium secretion. Loss of barttin (Type 4A) or both ClC-K channels (Type 4B) disrupts the endocochlear potential, causing sensorineural hearing loss.
Chloride ion homeostasis link ↓ DECREASED
Show evidence (1 reference)
PMID:30519073 SUPPORT Other
"In type IVa, barttin mutations impair potassium secretion in the stria vascularis and the vestibular labyrinth, whereas in type IVb mutations they occur in both chloride channels impairing their normal function in the inner ear."
Review describes the inner ear pathophysiology in both Type 4A and 4B Bartter syndrome.
⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.
Pathograph: causal mechanism network for Bartter syndrome Interactive directed graph showing how pathophysiology mechanisms, phenotypes, genetic factors and variants, experimental models, environmental triggers, and treatments relate through causal and linked edges.
●

Phenotypes

19
Cardiovascular 1
Ventricular Arrhythmia OCCASIONAL Ventricular arrhythmia (HP:0004308)
Show evidence (1 reference)
PMID:39445629 SUPPORT Human Clinical
"Although considered benign entities, major adverse cardiovascular events may complicate both syndromes, in form of ventricular arrhythmias leading to palpitations, syncope or sudden cardiac death, microvascular cardiac dysfunction and exercise-induced myocardial contractile deficit."
Narrative review highlights arrhythmic and cardiovascular complications of Bartter and Gitelman syndromes despite their usual normotensive phenotype.
Ear 1
Sensorineural Hearing Impairment VERY_FREQUENT Sensorineural hearing impairment (HP:0000407)
Show evidence (2 references)
PMID:19096086 SUPPORT Human Clinical
"Deafness at diagnosis was constant in patients with BSND mutations"
French cohort confirms universal sensorineural deafness in Type 4A Bartter syndrome.
PMID:30519073 SUPPORT Human Clinical
"type IVb is a digenic disorder with mutations in both CLCNKA and CLCNKB genes, which can lead to impairment in the functioning of two chloride channels and as a result, severe salt wasting and deafness."
Review confirms deafness also occurs in Type 4B (digenic).
Genitourinary 2
Polyuria VERY_FREQUENT Polyuria (HP:0000103)
Show evidence (1 reference)
PMID:36993809 SUPPORT Human Clinical
"BS is characterized by polyuria, failure to thrive, hypokalemia, metabolic alkalosis, hyperreninemia, and hyperaldosteronism."
Korean multicenter study lists polyuria as cardinal feature.
Chronic Kidney Disease OCCASIONAL Chronic kidney disease (HP:0012622)
Show evidence (2 references)
PMID:36993809 SUPPORT Human Clinical
"Despite management, a significant portion of this population exhibited growth impairment, while 11% developed CKD G3-G5."
Korean multicenter study documents CKD progression in 11% of 54 Bartter patients over median 8-year follow-up.
PMID:19096086 SUPPORT Human Clinical
"Three patients developed chronic renal failure: one with KCNJ1 mutations during the second decade of age and two with CLCNKB and BSND mutations and without nephrocalcinosis during the first year of life."
French cohort identifies CKD across genotypes, not always linked to nephrocalcinosis.
Metabolism 2
Hypokalemia VERY_FREQUENT Hypokalemia (HP:0002900)
Show evidence (1 reference)
PMID:36993809 SUPPORT Human Clinical
"BS is characterized by polyuria, failure to thrive, hypokalemia, metabolic alkalosis, hyperreninemia, and hyperaldosteronism."
Korean multicenter study listing hypokalemia as a cardinal feature.
Dehydration FREQUENT Dehydration (HP:0001944)
Show evidence (1 reference)
PMID:24906263 SUPPORT Human Clinical
"Postnatally newborns suffer from recurrent episodes of severe dehydration and electrolyte imbalance which can lead to fatal outcome."
Case report describes the severity of recurrent dehydration episodes in antenatal Bartter syndrome.
Musculoskeletal 1
Muscle Weakness OCCASIONAL Muscle weakness (HP:0001324)
Show evidence (1 reference)
PMID:32997650 SUPPORT Human Clinical
"a 26-year-old man who presented with generalized body weakness and hypokalemia and was ultimately diagnosed with Bartter syndrome type II"
Case report of late-onset Type 2 Bartter presenting with generalized weakness from hypokalemia.
Nervous System 1
Polydipsia VERY_FREQUENT Polydipsia (HP:0001959)
Prenatal and Birth 2
Polyhydramnios VERY_FREQUENT Polyhydramnios (HP:0001561)
VERY_FREQUENT within antenatal subtypes; not typical of Type 3 (classic).
Show evidence (1 reference)
PMID:19096086 SUPPORT Human Clinical
"The onset of polyhydramnios, birth term, height and weight were similar for all groups"
French cohort confirms polyhydramnios is consistent across all antenatal Bartter genotypes.
Premature Birth VERY_FREQUENT Premature birth (HP:0001622)
VERY_FREQUENT within antenatal subtypes; not typical of Type 3 (classic).
Show evidence (1 reference)
PMID:24906263 SUPPORT Human Clinical
"Antenatal Bartter syndrome is characterized by severe polyhydramnios in mother leading to premature delivery."
Case report confirms premature delivery as a hallmark of antenatal Bartter syndrome.
Growth 2
Failure to Thrive VERY_FREQUENT Failure to thrive (HP:0001508)
Show evidence (1 reference)
PMID:30519073 SUPPORT Human Clinical
"This syndrome is associated with an increased antenatal and neonatal mortality because many patients fail to thrive."
Review confirms failure to thrive as a major feature of Bartter syndrome.
Short Stature FREQUENT Short stature (HP:0004322)
Show evidence (1 reference)
PMID:36993809 SUPPORT Human Clinical
"At the last follow-up of 8 years after the initial diagnosis, 41% had short stature (height less than 3rd percentile)"
Korean multicenter study quantifies frequency of short stature in Bartter syndrome patients.
Other 7
Hypokalemic Hypochloremic Metabolic Alkalosis VERY_FREQUENT Hypokalemic hypochloremic metabolic alkalosis (HP:0004909)
Show evidence (1 reference)
PMID:30519073 SUPPORT Human Clinical
"Bartter syndrome (BS) is currently recognized as a rare inherited renal tubular disorder that affects around 1 in 1,000,000 of the population, caused by a defective salt reabsorption in the thick ascending limb (TAL) of loop of Henle, resulting in salt wasting, hypokalemia, and metabolic..."
Review defines the hallmark biochemical triad of Bartter syndrome.
Increased Circulating Renin VERY_FREQUENT Increased circulating renin concentration (HP:0000848)
Show evidence (1 reference)
PMID:30519073 SUPPORT Human Clinical
"patients with BS present hyperreninemic hyperaldosteronism with normal/low blood pressure"
Review confirms hyperreninemia as a defining feature of Bartter syndrome.
Secondary Hyperaldosteronism VERY_FREQUENT Secondary hyperaldosteronism (HP:0011741)
Show evidence (1 reference)
PMID:36993809 SUPPORT Human Clinical
"BS is characterized by polyuria, failure to thrive, hypokalemia, metabolic alkalosis, hyperreninemia, and hyperaldosteronism."
Korean multicenter study confirms hyperaldosteronism as cardinal feature.
Hypercalciuria FREQUENT Hypercalciuria (HP:0002150)
Show evidence (1 reference)
PMID:36305432 SUPPORT Human Clinical
"all the ten hypercalciuric patients with aBS had nephrocalcinosis at the time of diagnosis and the last visit"
Turkish cohort shows hypercalciuria in antenatal Bartter is consistently associated with nephrocalcinosis.
Hypomagnesemia OCCASIONAL Hypomagnesemia (HP:0002917)
Hyperprostaglandinuria Hyperprostaglandinuria (HP:0003527)
Show evidence (1 reference)
PMID:30519073 SUPPORT Human Clinical
"severe salt wasting, hyposthenuria, increased production of PGE2, and failure to thrive"
Review confirms increased PGE2 production as a feature of antenatal Bartter syndrome.
Nephrocalcinosis FREQUENT Nephrocalcinosis (HP:0000121)
Show evidence (1 reference)
PMID:19096086 SUPPORT Human Clinical
"Nephrocalcinosis was constant in KCNJ1 and SLC12A1 but not in BSND and CLCNKB patients."
Cohort study confirms nephrocalcinosis is constant in Types 1 and 2 (SLC12A1 and KCNJ1) but absent in Types 3 and 4.
🧬

Genetic Associations

6
SLC12A1 (Loss-of-function)
Show evidence (1 reference)
PMID:30519073 SUPPORT Human Clinical
"Type I BS is genetically heterogeneous and >63 mutations have been reported, including missense/nonsense mutations, splicing mutations, small insertions, and small deletions."
Review describes the genetic heterogeneity of SLC12A1 mutations in Type 1 Bartter syndrome.
KCNJ1 (Loss-of-function)
Show evidence (1 reference)
PMID:30519073 SUPPORT Human Clinical
"More than 40 KCNJ1 mutations, causing loss of function of ROMK channel, have been described and most of these are missense/nonsense mutations in the exon 2, which encode an important domain of ROMK."
Review confirms the diversity of KCNJ1 loss-of-function mutations.
CLCNKB (Loss-of-function)
Show evidence (1 reference)
PMID:30519073 SUPPORT Human Clinical
"More than 75 mutations in the CLCNKB gene have been described, and the effect of the kind of mutation in the phenotype is not clearly related."
Review describes the extensive mutational spectrum and phenotypic variability of CLCNKB mutations.
BSND (Loss-of-function)
Show evidence (1 reference)
PMID:21158220 SUPPORT Human Clinical
"Bartter syndrome type IV, also known as Bartter syndrome with sensorineural deafness (BSND), is caused by loss-of-function mutations in the BSND gene, which encodes barttin, an accessory subunit of chloride channels located in the kidney and inner ear."
Case report confirms BSND encodes barttin, required for chloride channels in kidney and inner ear.
CLCNKA (Loss-of-function)
Show evidence (1 reference)
PMID:30519073 SUPPORT Human Clinical
"type IVb is a digenic disorder with mutations in both CLCNKA and CLCNKB genes, which can lead to impairment in the functioning of two chloride channels and as a result, severe salt wasting and deafness."
Review confirms digenic CLCNKA+CLCNKB mutations cause Type 4B.
MAGED2 (Loss-of-function)
Show evidence (1 reference)
PMID:30519073 SUPPORT Human Clinical
"MAGE-D2 encodes melanoma-associated antigen D2, which interacts with NKCC2 and increases their cell-surface expression and activity. Mutations in MAGE-D2 reduce this expression of NKCC2 in the TAL and in the NCCT (thiazide-sensitive sodium chloride cotransporter), which is expressed in the DCT."
Review describes the molecular function of MAGED2 in cotransporter trafficking and consequence of loss-of-function.
💊

Treatments

6
Potassium Supplementation
Action: potassium supplementation Ontology label: pharmacotherapy MAXO:0000058
Agent: potassium chloride ↗
Oral potassium chloride replacement is the cornerstone of management, often requiring high doses to maintain serum potassium above 3.0 mEq/L.
Show evidence (1 reference)
PMID:36993809 SUPPORT Human Clinical
"Potassium chloride supplements and potassium-sparing diuretics were administered in 94% and 68% of patients, respectively. The mean dosage of potassium chloride supplements was 5.0 and 2.1 mEq/day/kg for patients younger and older than 18 years, respectively."
Korean multicenter study quantifies potassium supplementation dosing in 54 Bartter patients.
Indomethacin
Action: pharmacotherapy MAXO:0000058
Agent: indomethacin ↗
Prostaglandin synthesis inhibitor (NSAID) that reduces urinary prostaglandin E2, improves electrolyte balance, and promotes growth in children with Bartter syndrome.
Show evidence (1 reference)
PMID:19096086 SUPPORT Human Clinical
"In most cases, water/electrolyte supplementation + indomethacin led to catch-up growth."
French cohort demonstrates indomethacin plus electrolyte supplementation leads to catch-up growth.
Potassium-Sparing Diuretics
Action: pharmacotherapy MAXO:0000058
Agent: spironolactone ↗ amiloride ↗ eplerenone ↗
Aldosterone antagonists (spironolactone, eplerenone) and direct ENaC inhibitors (amiloride) used to counteract potassium-wasting effects of secondary hyperaldosteronism. In the Korean multicenter study, 68% of patients received potassium-sparing diuretics.
Show evidence (2 references)
PMID:30519073 SUPPORT Other
"The classical pharmacological therapy includes potassium chloride supplementation, prostaglandin inhibitor (indomethacin), and aldosterone antagonist (spironolactone)."
Review confirms spironolactone as part of the classical pharmacological treatment triad for Bartter syndrome.
PMID:36993809 SUPPORT Human Clinical
"Potassium chloride supplements and potassium-sparing diuretics were administered in 94% and 68% of patients, respectively."
Korean cohort confirms 68% of patients received potassium-sparing diuretics.
Magnesium Supplementation
Action: magnesium supplementation Ontology label: pharmacotherapy MAXO:0000058
Oral magnesium replacement for patients with hypomagnesemia, particularly those with Types 1 and 2.
Renal Transplantation
Action: organ transplantation MAXO:0010039
Considered for patients who progress to end-stage renal disease, which can occur in Type 4. Transplantation corrects the electrolyte abnormalities since the defect is intrinsic to the native kidney.
Show evidence (1 reference)
PMID:36993809 SUPPORT Human Clinical
"impaired kidney function was observed in six patients [chronic kidney disease (CKD) G3, n = 4; CKD G5, n = 2]"
Korean study shows some patients progress to advanced CKD, supporting the need for renal transplantation in severe cases.
Genetic Counseling
Action: genetic counseling MAXO:0000079
Family counseling regarding autosomal recessive or X-linked recessive inheritance patterns, carrier testing, and prenatal diagnosis options.
🔬

Biochemical Markers

7
Serum Potassium (DECREASED)
Show evidence (1 reference)
PMID:19096086 SUPPORT Human Clinical
"patients with CLCNKB had the lowest potassium (P = 0.006 versus KCNJ1 and P = 0.034 versus SLC12A1)"
Cohort study quantifies hypokalemia across genotypes, with CLCNKB patients having the most severe potassium depletion.
Serum Chloride (DECREASED)
Show evidence (1 reference)
PMID:19096086 SUPPORT Human Clinical
"patients with CLCNKB had the lowest potassium (P = 0.006 versus KCNJ1 and P = 0.034 versus SLC12A1) and chloride plasma concentrations (P = 0.039 versus KCNJ1 and P = 0.024 versus SLC12A1)"
Cohort study documents hypochloremia across genotypes, worst in Type 3.
Serum Bicarbonate (INCREASED)
Show evidence (1 reference)
PMID:19096086 SUPPORT Human Clinical
"the highest bicarbonataemia (P = 0.026 versus KCNJ1 and P = 0.014 versus SLC12A1)"
Cohort study confirms elevated bicarbonate, most severe in CLCNKB patients.
Plasma Renin Activity (INCREASED)
Plasma Aldosterone (INCREASED)
Urinary Calcium (INCREASED)
Urinary Prostaglandin E2 (INCREASED)
{ }

Source YAML

click to show 
name: Bartter syndrome
creation_date: "2026-04-22T00:00:00Z"
updated_date: "2026-05-09T04:45:11Z"
category: Mendelian
synonyms:
- Bartter syndrome
- salt-wasting tubulopathy
- hyperprostaglandin E syndrome
description: >-
  Bartter syndrome is a group of autosomal recessive (and one X-linked) renal
  tubular salt-wasting disorders characterized by impaired sodium chloride
  reabsorption in the thick ascending limb of the loop of Henle. The hallmark
  biochemical triad is hypokalemic hypochloremic metabolic alkalosis,
  hyperreninemia with secondary hyperaldosteronism, and normal to low blood
  pressure. Five genetic types are recognized: Type 1 (SLC12A1/NKCC2), Type 2
  (KCNJ1/ROMK), Type 3 (CLCNKB/ClC-Kb), Type 4A (BSND/Barttin), Type 4B
  (digenic CLCNKA+CLCNKB), and Type 5 (MAGED2, X-linked transient). Types 1,
  2, 4, and 5 typically present antenatally with polyhydramnios and premature
  birth, while Type 3 (classic Bartter) presents in childhood with failure to
  thrive, polyuria, polydipsia, and growth retardation. Type 4 is distinguished
  by concurrent sensorineural hearing loss due to barttin co-expression in the
  inner ear. Long-term complications include chronic kidney disease (11% in
  one cohort) and growth impairment despite treatment.
disease_term:
  preferred_term: Bartter syndrome
  term:
    id: MONDO:0015231
    label: Bartter syndrome
classifications:
  harrisons_chapter:
  - classification_value: kidney disorder
  - classification_value: hereditary disease
  channelopathy_category:
    classification_value: epithelial channelopathy
parents:
- renal tubulopathy
- salt-wasting nephropathy
prevalence:
- population: Global
  notes: >-
    Estimated prevalence approximately 1 per 1,000,000.
  evidence:
  - reference: PMID:30519073
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      Bartter syndrome (BS) is currently recognized as a rare inherited renal
      tubular disorder that affects around 1 in 1,000,000 of the population
    explanation: >-
      Comprehensive review directly states the estimated prevalence of
      Bartter syndrome.
inheritance:
- name: Autosomal recessive (Types 1-4)
  inheritance_term:
    preferred_term: Autosomal recessive inheritance
    term:
      id: HP:0000007
      label: Autosomal recessive inheritance
  description: >-
    Types 1, 2, 3, 4A, and 4B follow autosomal recessive inheritance.
  evidence:
  - reference: PMID:30519073
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      All these four types are recessive disorders.
    explanation: >-
      Review confirms all four classical Bartter types are autosomal
      recessive.
- name: X-linked recessive (Type 5)
  inheritance_term:
    preferred_term: X-linked recessive inheritance
    term:
      id: HP:0001419
      label: X-linked recessive inheritance
  description: >-
    Type 5 (MAGED2) follows X-linked recessive inheritance and is
    characteristically transient.
  evidence:
  - reference: PMID:34926352
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Mutations in the MAGED2 gene can cause X-linked acute early-onset
      polyhydramnios with a severe but transient form of antenatal Bartter's
      syndrome.
    explanation: >-
      Case report confirms X-linked inheritance and transient nature of
      MAGED2-associated Bartter syndrome.
has_subtypes:
- name: Type 1
  display_name: Type 1 (Antenatal, NKCC2)
  description: >-
    Caused by loss-of-function mutations in SLC12A1, encoding the
    sodium-potassium-chloride cotransporter NKCC2 in the thick ascending limb.
    Presents antenatally with polyhydramnios, premature birth, and severe
    salt wasting. Nephrocalcinosis is common.
  evidence:
  - reference: PMID:30519073
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      In type I BS, symptoms are usually present at birth with severe salt
      wasting, hyposthenuria, increased production of PGE2, and failure to
      thrive. Some of these symptoms already occur in utero and can cause
      polyhydramnios and premature delivery. A common feature is marked
      hypercalciuria, which may lead to nephrocalcinosis and/or osteopenia.
    explanation: >-
      Review describes the clinical features of Type 1 Bartter syndrome
      including antenatal presentation and nephrocalcinosis.
- name: Type 2
  display_name: Type 2 (Antenatal, ROMK)
  description: >-
    Caused by loss-of-function mutations in KCNJ1, encoding the renal outer
    medullary potassium channel (ROMK). Presents antenatally similar to Type 1
    with polyhydramnios and prematurity. Transient hyperkalemia in the
    neonatal period is characteristic.
  evidence:
  - reference: PMID:19096086
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      transient neonatal hyperkalaemia was present in two-thirds of the
      children with KCNJ1 mutations
    explanation: >-
      French cohort study confirms transient hyperkalemia as a distinguishing
      feature of KCNJ1/Type 2 Bartter syndrome.
- name: Type 3
  display_name: Type 3 (Classic, ClC-Kb)
  description: >-
    Caused by loss-of-function mutations in CLCNKB, encoding the chloride
    channel ClC-Kb. Presents in infancy or childhood with hypokalemic
    alkalosis, failure to thrive, polyuria, polydipsia, and growth
    retardation. Generally milder than antenatal forms; nephrocalcinosis is
    less common.
  evidence:
  - reference: PMID:19096086
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      three patients had no history of polyhydramnios or premature birth and
      had CLCNKB mutations according to a less severe renal sodium wasting
    explanation: >-
      Confirms that CLCNKB patients can present without antenatal features,
      consistent with classic (less severe) phenotype.
- name: Type 4A
  display_name: Type 4A (With sensorineural deafness, Barttin)
  description: >-
    Caused by loss-of-function mutations in BSND, encoding barttin, the
    essential beta-subunit of ClC-Ka and ClC-Kb chloride channels. Presents
    antenatally with polyhydramnios, severe salt wasting, and sensorineural
    hearing loss due to barttin expression in the stria vascularis of the
    inner ear.
  evidence:
  - reference: PMID:19096086
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Deafness at diagnosis was constant in patients with BSND mutations
    explanation: >-
      Cohort study confirms universal sensorineural deafness in BSND/Type 4A
      patients.
- name: Type 4B
  display_name: Type 4B (Digenic, ClC-Ka + ClC-Kb)
  description: >-
    Caused by simultaneous loss-of-function mutations in both CLCNKA and
    CLCNKB. Phenotypically similar to Type 4A with antenatal presentation
    and sensorineural deafness.
  evidence:
  - reference: PMID:30519073
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      type IVb is a digenic disorder with mutations in both CLCNKA and
      CLCNKB genes, which can lead to impairment in the functioning of two
      chloride channels and as a result, severe salt wasting and deafness.
    explanation: >-
      Review confirms digenic nature and deafness phenotype of Type 4B.
- name: Type 5
  display_name: Type 5 (Transient antenatal, MAGED2)
  description: >-
    Caused by loss-of-function mutations in MAGED2 on the X chromosome.
    Presents with severe antenatal polyhydramnios and salt wasting that
    typically resolves spontaneously in the first months of life.
  evidence:
  - reference: PMID:30519073
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      This phenotype is characterized by the spontaneous resolution of
      polyuria, a decrease in the concentrations of renin and aldosterone, as
      well as a decrease in urinary PGE2 levels.
    explanation: >-
      Review describes the transient and self-resolving nature of
      MAGED2-associated Bartter syndrome.
genetic:
- name: SLC12A1
  gene_term:
    preferred_term: SLC12A1
    term:
      id: hgnc:10910
      label: SLC12A1
  association: Loss-of-function
  presence: Positive
  features: >-
    Encodes NKCC2, the apical sodium-potassium-2-chloride cotransporter
    in the thick ascending limb. Loss-of-function abolishes electroneutral
    NaCl reabsorption. More than 63 mutations reported including missense,
    nonsense, splicing, and small insertions/deletions.
  subtype: Type 1
  evidence:
  - reference: PMID:30519073
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Type I BS is genetically heterogeneous and >63 mutations have been
      reported, including missense/nonsense mutations, splicing mutations,
      small insertions, and small deletions.
    explanation: >-
      Review describes the genetic heterogeneity of SLC12A1 mutations in
      Type 1 Bartter syndrome.
- name: KCNJ1
  gene_term:
    preferred_term: KCNJ1
    term:
      id: hgnc:6255
      label: KCNJ1
  association: Loss-of-function
  presence: Positive
  features: >-
    Encodes ROMK, the apical potassium recycling channel in the thick
    ascending limb. Loss-of-function impairs potassium recycling needed for
    NKCC2 activity. More than 40 mutations described.
  subtype: Type 2
  evidence:
  - reference: PMID:30519073
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      More than 40 KCNJ1 mutations, causing loss of function of ROMK
      channel, have been described and most of these are missense/nonsense
      mutations in the exon 2, which encode an important domain of ROMK.
    explanation: >-
      Review confirms the diversity of KCNJ1 loss-of-function mutations.
- name: CLCNKB
  gene_term:
    preferred_term: CLCNKB
    term:
      id: hgnc:2027
      label: CLCNKB
  association: Loss-of-function
  presence: Positive
  features: >-
    Encodes ClC-Kb, the basolateral chloride channel in the thick ascending
    limb and distal nephron. Loss-of-function impairs chloride exit from
    tubular epithelial cells. Considerable phenotypic variability with
    antenatal, classic, and Gitelman-like presentations. Also involved in
    digenic Type 4B (combined CLCNKA+CLCNKB loss-of-function).
  subtype: Type 3
  evidence:
  - reference: PMID:30519073
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      More than 75 mutations in the CLCNKB gene have been described, and the
      effect of the kind of mutation in the phenotype is not clearly related.
    explanation: >-
      Review describes the extensive mutational spectrum and phenotypic
      variability of CLCNKB mutations.
- name: BSND
  gene_term:
    preferred_term: BSND
    term:
      id: hgnc:16512
      label: BSND
  association: Loss-of-function
  presence: Positive
  features: >-
    Encodes barttin, the beta-subunit required for trafficking and function of
    both ClC-Ka and ClC-Kb chloride channels. Loss-of-function affects kidney
    and inner ear.
  subtype: Type 4A
  evidence:
  - reference: PMID:21158220
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Bartter syndrome type IV, also known as Bartter syndrome with
      sensorineural deafness (BSND), is caused by loss-of-function mutations
      in the BSND gene, which encodes barttin, an accessory subunit of
      chloride channels located in the kidney and inner ear.
    explanation: >-
      Case report confirms BSND encodes barttin, required for chloride
      channels in kidney and inner ear.
- name: CLCNKA
  gene_term:
    preferred_term: CLCNKA
    term:
      id: hgnc:2026
      label: CLCNKA
  association: Loss-of-function
  presence: Positive
  features: >-
    Encodes ClC-Ka, a basolateral chloride channel predominantly expressed in
    the thin ascending limb. Digenic loss-of-function mutations in both CLCNKA
    and CLCNKB cause Type 4B Bartter syndrome with sensorineural deafness.
  subtype: Type 4B
  evidence:
  - reference: PMID:30519073
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      type IVb is a digenic disorder with mutations in both CLCNKA and
      CLCNKB genes, which can lead to impairment in the functioning of two
      chloride channels and as a result, severe salt wasting and deafness.
    explanation: >-
      Review confirms digenic CLCNKA+CLCNKB mutations cause Type 4B.
- name: MAGED2
  gene_term:
    preferred_term: MAGED2
    term:
      id: hgnc:16353
      label: MAGED2
  association: Loss-of-function
  presence: Positive
  features: >-
    Encodes melanoma-associated antigen D2, which is required for proper
    trafficking of NKCC2 and NCC to the apical membrane. Loss-of-function
    causes transient antenatal Bartter syndrome on the X chromosome.
  subtype: Type 5
  evidence:
  - reference: PMID:30519073
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      MAGE-D2 encodes melanoma-associated antigen D2, which interacts with
      NKCC2 and increases their cell-surface expression and activity.
      Mutations in MAGE-D2 reduce this expression of NKCC2 in the TAL and in
      the NCCT (thiazide-sensitive sodium chloride cotransporter), which is
      expressed in the DCT.
    explanation: >-
      Review describes the molecular function of MAGED2 in cotransporter
      trafficking and consequence of loss-of-function.
pathophysiology:
- name: ClC-K/Barttin Chloride Channel Dysfunction (Type 4)
  description: >-
    In type 4 Bartter syndrome, BSND loss-of-function or digenic
    CLCNKA/CLCNKB disruption impairs the ClC-K/barttin chloride-channel system
    shared by renal epithelia and the inner ear. This links the renal
    salt-wasting branch to the sensorineural-hearing branch without implying
    that all Bartter subtypes cause deafness.
  biological_processes:
  - preferred_term: Chloride transmembrane transport
    term:
      id: GO:1902476
      label: chloride transmembrane transport
    modifier: DECREASED
  evidence:
  - reference: PMID:30519073
    reference_title: "Bartter syndrome: causes, diagnosis, and treatment."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      Mutations in the BSND gene cause type IVa BS and result in impairment
      of barttin insertion in the plasma membrane of CLC-Kb and CLC-Ka
      channels in the Henle’s loop as well as in the inner ear, which
      interfere with epithelial salt transport.
    explanation: >-
      Review links BSND-associated type 4A Bartter syndrome to defective
      ClC-K/barttin channel handling in both renal epithelia and inner ear.
  - reference: PMID:30519073
    reference_title: "Bartter syndrome: causes, diagnosis, and treatment."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      type IVb is a digenic disorder with mutations in both CLCNKA and
      CLCNKB genes, which can lead to impairment in the functioning of two
      chloride channels and as a result, severe salt wasting and deafness.
    explanation: >-
      Review supports the analogous type 4B mechanism in which dual ClC-K
      channel disruption produces both renal salt wasting and deafness.
  downstream:
  - target: Impaired NaCl Reabsorption in Thick Ascending Limb
    description: >-
      Defective ClC-K/barttin channel function in Henle-loop epithelia impairs
      epithelial salt transport, feeding into the renal NaCl reabsorption
      defect.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:30519073
      reference_title: "Bartter syndrome: causes, diagnosis, and treatment."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: >-
        Mutations in the BSND gene cause type IVa BS and result in impairment
        of barttin insertion in the plasma membrane of CLC-Kb and CLC-Ka
        channels in the Henle’s loop as well as in the inner ear, which
        interfere with epithelial salt transport.
      explanation: >-
        The review explicitly places the ClC-K/barttin defect in Henle-loop
        epithelial salt transport, supporting the renal downstream edge.
  - target: Inner Ear Chloride Transport Defect (Type 4)
    description: >-
      The same type 4 ClC-K/barttin channel system is required in the inner
      ear; barttin mutations impair potassium secretion in the stria vascularis
      and vestibular labyrinth, while dual ClC-K channel mutations impair
      inner-ear channel function.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:30519073
      reference_title: "Bartter syndrome: causes, diagnosis, and treatment."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: >-
        The sensory function of the inner ear becomes impaired in type IVa and
        IVb BS. In type IVa, barttin mutations impair potassium secretion in
        the stria vascularis and the vestibular labyrinth, whereas in type IVb
        mutations they occur in both chloride channels impairing their normal
        function in the inner ear.
      explanation: >-
        The review directly links type 4A and 4B chloride-channel defects to
        impaired inner-ear sensory function.
- name: Impaired NaCl Reabsorption in Thick Ascending Limb
  description: >-
    The primary defect in Bartter syndrome is impaired sodium chloride
    reabsorption in the thick ascending limb (TAL) of the loop of Henle.
    NKCC2 (apical) mediates electroneutral entry of Na+, K+, and 2Cl-;
    ROMK recycles K+ back to the lumen to sustain NKCC2 activity; and
    ClC-Kb (with barttin) provides basolateral Cl- exit. Loss of any
    component disrupts the entire transcellular NaCl transport pathway.
  cell_types:
  - preferred_term: Thick ascending limb epithelial cell
    term:
      id: CL:1001106
      label: kidney loop of Henle thick ascending limb epithelial cell
  biological_processes:
  - preferred_term: Sodium ion transport
    term:
      id: GO:0006814
      label: sodium ion transport
    modifier: DECREASED
  - preferred_term: Renal sodium ion transport
    term:
      id: GO:0003096
      label: renal sodium ion transport
    modifier: DECREASED
  - preferred_term: Chloride transmembrane transport
    term:
      id: GO:1902476
      label: chloride transmembrane transport
    modifier: DECREASED
  evidence:
  - reference: PMID:30519073
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      The main ion channel at the luminal membrane is NKCC2
      (furosemide-sensitive sodium–potassium–chloride cotransporter), which
      belongs to a family of sodium-coupled electrolyte transporters, encoded
      by the solute carrier family of SLC12A genes. NKCC2 is responsible for
      carrying sodium from the tubular lumen into the cell coupled with
      potassium and chloride.
    explanation: >-
      Review describes the molecular physiology of NKCC2-mediated NaCl
      transport in the TAL that is disrupted in Bartter syndrome.
  downstream:
  - target: Compensatory Distal Sodium Reabsorption and Potassium Wasting
    causal_link_type: DIRECT
  - target: Loss of Medullary Concentration Gradient
    causal_link_type: DIRECT
  - target: Impaired Paracellular Cation Reabsorption
    causal_link_type: DIRECT
- name: Compensatory Distal Sodium Reabsorption and Potassium Wasting
  description: >-
    Reduced NaCl reabsorption in the TAL increases sodium delivery to the
    distal convoluted tubule and collecting duct. Enhanced sodium reabsorption
    through ENaC in principal cells, driven by secondary hyperaldosteronism,
    creates a lumen-negative potential that drives potassium and hydrogen ion
    secretion, producing hypokalemia and metabolic alkalosis.
  cell_types:
  - preferred_term: Kidney collecting duct principal cell
    term:
      id: CL:1001431
      label: kidney collecting duct principal cell
  biological_processes:
  - preferred_term: Potassium ion homeostasis
    term:
      id: GO:0055075
      label: potassium ion homeostasis
    modifier: DECREASED
  - preferred_term: Potassium ion transmembrane transport
    term:
      id: GO:0071805
      label: potassium ion transmembrane transport
    modifier: INCREASED
  evidence:
  - reference: PMID:30519073
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      patients with BS present hyperreninemic hyperaldosteronism with
      normal/low blood pressure, reduced peripheral resistance, and
      hyporesponsiveness to antihypertensives.
    explanation: >-
      Review describes the hyperaldosteronism with paradoxically normal/low
      blood pressure due to the tubular defect.
  downstream:
  - target: Renin-Angiotensin-Aldosterone System Activation
    causal_link_type: DIRECT
- name: Renin-Angiotensin-Aldosterone System Activation
  description: >-
    Chronic volume depletion from renal salt wasting stimulates the
    juxtaglomerular apparatus to increase renin secretion, resulting in
    hyperreninemia and secondary hyperaldosteronism. Despite elevated
    aldosterone, blood pressure remains normal or low because the primary
    renal tubular defect prevents effective sodium retention.
  cell_types:
  - preferred_term: Juxtaglomerular complex cell
    term:
      id: CL:1000618
      label: juxtaglomerular complex cell
  - preferred_term: Macula densa epithelial cell
    term:
      id: CL:1000850
      label: macula densa epithelial cell
  biological_processes:
  - preferred_term: Renin secretion into blood stream
    term:
      id: GO:0002001
      label: renin secretion into blood stream
    modifier: INCREASED
  evidence:
  - reference: PMID:30519073
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      In patients with BS, reduced reabsorption of chloride occurs due to the
      genetic defects, and an increase in chloride delivery to the macula
      densa with an abnormal volume sensing ensues. Therefore, the control of
      filtration becomes uncoupled from volume status.
    explanation: >-
      Review explains the macula densa-mediated RAAS activation mechanism
      in Bartter syndrome.
  downstream:
  - target: Prostaglandin E2 Overproduction
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
- name: Loss of Medullary Concentration Gradient
  description: >-
    NaCl reabsorption in the TAL is essential for generating the
    corticomedullary osmotic gradient required for urinary concentration.
    Impaired TAL transport reduces medullary tonicity, causing nephrogenic
    diabetes insipidus-like polyuria, polydipsia, and isosthenuria.
  biological_processes:
  - preferred_term: Water transport
    term:
      id: GO:0006833
      label: water transport
    modifier: DECREASED
  evidence:
  - reference: PMID:30519073
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      Transepithelial salt movement into the medullary inter-stitium,
      together with the low permeability of the luminal membrane of the TAL
      to water, is important to allow the kidneys to develop interstitial
      hypertonicity and support the urinary concentrating ability.
    explanation: >-
      Review explains the role of TAL NaCl reabsorption in maintaining
      the medullary osmotic gradient required for urinary concentration.
- name: Prostaglandin E2 Overproduction
  description: >-
    Hypokalemia and volume depletion stimulate renal prostaglandin E2
    synthesis, which further inhibits NaCl reabsorption in the TAL and
    stimulates renin release, creating a positive feedback loop that
    amplifies salt wasting and electrolyte disturbances.
  biological_processes:
  - preferred_term: Prostaglandin biosynthetic process
    term:
      id: GO:0001516
      label: prostaglandin biosynthetic process
    modifier: INCREASED
  evidence:
  - reference: PMID:30519073
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      This impaired entry of sodium and chloride into the macula densa
      increases the expression of cyclooxygenase-2 (COX2) stimulating the
      renal production of prostaglandin E2 (PGE2), also resulting in afferent
      arteriolar dilatation and activation of renin release by JGA.
    explanation: >-
      Review describes the COX2/PGE2 pathway activation in Bartter syndrome
      and its role in amplifying RAAS activation.
- name: Impaired Paracellular Cation Reabsorption
  description: >-
    NKCC2-mediated K+ recycling through ROMK generates a lumen-positive
    transepithelial voltage in the TAL that drives paracellular reabsorption
    of Ca2+ and Mg2+. Loss of this voltage in Types 1 and 2 causes
    hypercalciuria (leading to nephrocalcinosis) and hypomagnesemia.
  cell_types:
  - preferred_term: Thick ascending limb epithelial cell
    term:
      id: CL:1001106
      label: kidney loop of Henle thick ascending limb epithelial cell
  biological_processes:
  - preferred_term: Magnesium ion homeostasis
    term:
      id: GO:0010960
      label: magnesium ion homeostasis
    modifier: DECREASED
  evidence:
  - reference: PMID:30519073
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      Henle’s loop has another important role in the reabsorption of divalent
      cations such as calcium (Ca2+) and magnesium (Mg2+), which are
      reabsorbed by a passive paracellular mechanism secondary to the driving
      force produced by active salt reabsorption.
    explanation: >-
      Review explains the paracellular divalent cation reabsorption mechanism
      that is disrupted when TAL NaCl transport fails.
  downstream:
  - target: Nephrocalcinosis
    causal_link_type: DIRECT
- name: Nephrocalcinosis
  description: >-
    Hypercalciuria from impaired paracellular calcium reabsorption in the TAL
    leads to medullary calcium deposition. Nephrocalcinosis is most prominent
    in Types 1 and 2 and is less common in Type 3.
  evidence:
  - reference: PMID:19096086
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Nephrocalcinosis was constant in KCNJ1 and SLC12A1 but not in BSND and
      CLCNKB patients.
    explanation: >-
      Cohort study confirms nephrocalcinosis is universal in Types 1 and 2
      but absent in Types 3 and 4.
- name: Inner Ear Chloride Transport Defect (Type 4)
  description: >-
    Barttin is co-expressed with ClC-Ka and ClC-Kb in the stria vascularis
    of the inner ear, where chloride channels are essential for endolymph
    potassium secretion. Loss of barttin (Type 4A) or both ClC-K channels
    (Type 4B) disrupts the endocochlear potential, causing sensorineural
    hearing loss.
  biological_processes:
  - preferred_term: Chloride ion homeostasis
    term:
      id: GO:0055064
      label: chloride ion homeostasis
    modifier: DECREASED
  evidence:
  - reference: PMID:30519073
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      In type IVa, barttin mutations impair potassium secretion in the stria
      vascularis and the vestibular labyrinth, whereas in type IVb mutations
      they occur in both chloride channels impairing their normal function in
      the inner ear.
    explanation: >-
      Review describes the inner ear pathophysiology in both Type 4A and 4B
      Bartter syndrome.
phenotypes:
- name: Hypokalemic Hypochloremic Metabolic Alkalosis
  category: Laboratory
  description: >-
    The biochemical hallmark of Bartter syndrome: persistent hypokalemia
    with hypochloremia and metabolic alkalosis resulting from renal
    potassium and chloride wasting.
  frequency: VERY_FREQUENT
  phenotype_term:
    preferred_term: Hypokalemic hypochloremic metabolic alkalosis
    term:
      id: HP:0004909
      label: Hypokalemic hypochloremic metabolic alkalosis
  evidence:
  - reference: PMID:30519073
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Bartter syndrome (BS) is currently recognized as a rare inherited renal
      tubular disorder that affects around 1 in 1,000,000 of the population,
      caused by a defective salt reabsorption in the thick ascending limb
      (TAL) of loop of Henle, resulting in salt wasting, hypokalemia, and
      metabolic alkalosis with relatively low levels of serum chloride.
    explanation: >-
      Review defines the hallmark biochemical triad of Bartter syndrome.
- name: Hypokalemia
  category: Laboratory
  description: >-
    Renal potassium wasting due to enhanced distal K+ secretion driven by
    increased sodium delivery and hyperaldosteronism.
  frequency: VERY_FREQUENT
  phenotype_term:
    preferred_term: Hypokalemia
    term:
      id: HP:0002900
      label: Hypokalemia
  evidence:
  - reference: PMID:36993809
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      BS is characterized by polyuria, failure to thrive, hypokalemia,
      metabolic alkalosis, hyperreninemia, and hyperaldosteronism.
    explanation: >-
      Korean multicenter study listing hypokalemia as a cardinal feature.
- name: Increased Circulating Renin
  category: Laboratory
  description: >-
    Elevated plasma renin activity due to chronic volume contraction and
    macula densa sensing of reduced luminal chloride.
  frequency: VERY_FREQUENT
  phenotype_term:
    preferred_term: Increased circulating renin concentration
    term:
      id: HP:0000848
      label: Increased circulating renin concentration
  evidence:
  - reference: PMID:30519073
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      patients with BS present hyperreninemic hyperaldosteronism with
      normal/low blood pressure
    explanation: >-
      Review confirms hyperreninemia as a defining feature of Bartter
      syndrome.
- name: Secondary Hyperaldosteronism
  category: Laboratory
  description: >-
    Elevated aldosterone levels driven by hyperreninemia, contributing to
    potassium wasting and metabolic alkalosis.
  frequency: VERY_FREQUENT
  phenotype_term:
    preferred_term: Secondary hyperaldosteronism
    term:
      id: HP:0011741
      label: Secondary hyperaldosteronism
  evidence:
  - reference: PMID:36993809
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      BS is characterized by polyuria, failure to thrive, hypokalemia,
      metabolic alkalosis, hyperreninemia, and hyperaldosteronism.
    explanation: >-
      Korean multicenter study confirms hyperaldosteronism as cardinal
      feature.
- name: Hypercalciuria
  category: Laboratory
  description: >-
    Increased urinary calcium excretion due to loss of the lumen-positive
    potential driving paracellular calcium reabsorption in the TAL.
    Prominent in Types 1 and 2.
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Hypercalciuria
    term:
      id: HP:0002150
      label: Hypercalciuria
  subtypes:
  - Type 1
  - Type 2
  evidence:
  - reference: PMID:36305432
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      all the ten hypercalciuric patients with aBS had nephrocalcinosis at
      the time of diagnosis and the last visit
    explanation: >-
      Turkish cohort shows hypercalciuria in antenatal Bartter is
      consistently associated with nephrocalcinosis.
- name: Hypomagnesemia
  category: Laboratory
  description: >-
    Renal magnesium wasting from impaired paracellular magnesium
    reabsorption in the TAL.
  frequency: OCCASIONAL
  phenotype_term:
    preferred_term: Hypomagnesemia
    term:
      id: HP:0002917
      label: Hypomagnesemia
- name: Hyperprostaglandinuria
  category: Laboratory
  description: >-
    Elevated urinary prostaglandin E2 excretion, particularly in antenatal
    forms. Contributes to fever, diarrhea, and vascular symptoms.
  phenotype_term:
    preferred_term: Hyperprostaglandinuria
    term:
      id: HP:0003527
      label: Hyperprostaglandinuria
  evidence:
  - reference: PMID:30519073
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      severe salt wasting, hyposthenuria, increased production of PGE2, and
      failure to thrive
    explanation: >-
      Review confirms increased PGE2 production as a feature of antenatal
      Bartter syndrome.
- name: Polyhydramnios
  category: Prenatal
  description: >-
    Fetal polyuria from salt wasting causes polyhydramnios, typically
    presenting in the second or third trimester. Characteristic of
    antenatal forms (Types 1, 2, 4, 5).
  frequency: VERY_FREQUENT
  phenotype_term:
    preferred_term: Polyhydramnios
    term:
      id: HP:0001561
      label: Polyhydramnios
  subtypes:
  - Type 1
  - Type 2
  - Type 4A
  - Type 4B
  - Type 5
  notes: >-
    VERY_FREQUENT within antenatal subtypes; not typical of Type 3 (classic).
  evidence:
  - reference: PMID:19096086
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The onset of polyhydramnios, birth term, height and weight were similar
      for all groups
    explanation: >-
      French cohort confirms polyhydramnios is consistent across all
      antenatal Bartter genotypes.
- name: Premature Birth
  category: Prenatal
  description: >-
    Polyhydramnios leads to premature labor and delivery, a major source
    of morbidity in antenatal Bartter syndrome.
  frequency: VERY_FREQUENT
  phenotype_term:
    preferred_term: Premature birth
    term:
      id: HP:0001622
      label: Premature birth
  subtypes:
  - Type 1
  - Type 2
  - Type 4A
  - Type 4B
  - Type 5
  notes: >-
    VERY_FREQUENT within antenatal subtypes; not typical of Type 3 (classic).
  evidence:
  - reference: PMID:24906263
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Antenatal Bartter syndrome is characterized by severe polyhydramnios in
      mother leading to premature delivery.
    explanation: >-
      Case report confirms premature delivery as a hallmark of antenatal
      Bartter syndrome.
- name: Failure to Thrive
  category: Constitutional
  description: >-
    Poor weight gain and growth failure from chronic electrolyte depletion
    and volume contraction.
  frequency: VERY_FREQUENT
  phenotype_term:
    preferred_term: Failure to thrive
    term:
      id: HP:0001508
      label: Failure to thrive
  evidence:
  - reference: PMID:30519073
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      This syndrome is associated with an increased antenatal and neonatal
      mortality because many patients fail to thrive.
    explanation: >-
      Review confirms failure to thrive as a major feature of Bartter
      syndrome.
- name: Short Stature
  category: Constitutional
  description: >-
    Growth retardation is common, particularly when diagnosis and treatment
    are delayed. In a Korean multicenter study, 41% had short stature at
    last follow-up.
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Short stature
    term:
      id: HP:0004322
      label: Short stature
  evidence:
  - reference: PMID:36993809
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      At the last follow-up of 8 years after the initial diagnosis, 41% had
      short stature (height less than 3rd percentile)
    explanation: >-
      Korean multicenter study quantifies frequency of short stature in
      Bartter syndrome patients.
- name: Polyuria
  category: Renal
  description: >-
    Impaired urinary concentration due to loss of the medullary osmotic
    gradient. Can be severe and lead to dehydration.
  frequency: VERY_FREQUENT
  phenotype_term:
    preferred_term: Polyuria
    term:
      id: HP:0000103
      label: Polyuria
  evidence:
  - reference: PMID:36993809
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      BS is characterized by polyuria, failure to thrive, hypokalemia,
      metabolic alkalosis, hyperreninemia, and hyperaldosteronism.
    explanation: >-
      Korean multicenter study lists polyuria as cardinal feature.
- name: Polydipsia
  category: Constitutional
  description: >-
    Compensatory increased fluid intake in response to polyuria and volume
    depletion.
  frequency: VERY_FREQUENT
  phenotype_term:
    preferred_term: Polydipsia
    term:
      id: HP:0001959
      label: Polydipsia
- name: Dehydration
  category: Constitutional
  description: >-
    Recurrent episodes of dehydration from salt and water wasting,
    especially in infancy.
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Dehydration
    term:
      id: HP:0001944
      label: Dehydration
  evidence:
  - reference: PMID:24906263
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Postnatally newborns suffer from recurrent episodes of severe
      dehydration and electrolyte imbalance which can lead to fatal outcome.
    explanation: >-
      Case report describes the severity of recurrent dehydration episodes
      in antenatal Bartter syndrome.
- name: Nephrocalcinosis
  category: Renal
  description: >-
    Medullary calcium deposition from chronic hypercalciuria. Most common
    in Types 1 and 2; less frequent in Type 3.
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Nephrocalcinosis
    term:
      id: HP:0000121
      label: Nephrocalcinosis
  subtypes:
  - Type 1
  - Type 2
  evidence:
  - reference: PMID:19096086
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Nephrocalcinosis was constant in KCNJ1 and SLC12A1 but not in BSND and
      CLCNKB patients.
    explanation: >-
      Cohort study confirms nephrocalcinosis is constant in Types 1 and 2
      (SLC12A1 and KCNJ1) but absent in Types 3 and 4.
- name: Sensorineural Hearing Impairment
  category: Neurological
  description: >-
    Bilateral sensorineural deafness resulting from impaired chloride
    transport in the stria vascularis of the inner ear. Specific to Type 4
    (barttin or digenic ClC-Ka/ClC-Kb mutations).
  frequency: VERY_FREQUENT
  phenotype_term:
    preferred_term: Sensorineural hearing impairment
    term:
      id: HP:0000407
      label: Sensorineural hearing impairment
  subtypes:
  - Type 4A
  - Type 4B
  evidence:
  - reference: PMID:19096086
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Deafness at diagnosis was constant in patients with BSND mutations
    explanation: >-
      French cohort confirms universal sensorineural deafness in Type 4A
      Bartter syndrome.
  - reference: PMID:30519073
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      type IVb is a digenic disorder with mutations in both CLCNKA and
      CLCNKB genes, which can lead to impairment in the functioning of two
      chloride channels and as a result, severe salt wasting and deafness.
    explanation: >-
      Review confirms deafness also occurs in Type 4B (digenic).
- name: Chronic Kidney Disease
  category: Renal
  description: >-
    A subset of Bartter syndrome patients develop chronic kidney disease over
    time, likely due to nephrocalcinosis, chronic hypokalemia, recurrent
    dehydration episodes, and long-term NSAID use. In a Korean multicenter
    study, 11% developed CKD G3-G5.
  frequency: OCCASIONAL
  phenotype_term:
    preferred_term: Chronic kidney disease
    term:
      id: HP:0012622
      label: Chronic kidney disease
  evidence:
  - reference: PMID:36993809
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Despite management, a significant portion of this population exhibited
      growth impairment, while 11% developed CKD G3-G5.
    explanation: >-
      Korean multicenter study documents CKD progression in 11% of 54
      Bartter patients over median 8-year follow-up.
  - reference: PMID:19096086
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Three patients developed chronic renal failure: one with KCNJ1
      mutations during the second decade of age and two with CLCNKB and BSND
      mutations and without nephrocalcinosis during the first year of life.
    explanation: >-
      French cohort identifies CKD across genotypes, not always linked to
      nephrocalcinosis.
- name: Muscle Weakness
  category: Musculoskeletal
  description: >-
    Hypokalemia-related skeletal muscle weakness, which can range from
    mild fatigue to severe episodic paralysis.
  frequency: OCCASIONAL
  phenotype_term:
    preferred_term: Muscle weakness
    term:
      id: HP:0001324
      label: Muscle weakness
  evidence:
  - reference: PMID:32997650
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      a 26-year-old man who presented with generalized body weakness and
      hypokalemia and was ultimately diagnosed with Bartter syndrome type II
    explanation: >-
      Case report of late-onset Type 2 Bartter presenting with generalized
      weakness from hypokalemia.
- name: Ventricular Arrhythmia
  category: Cardiovascular
  description: >-
    Chronic hypokalemia, hypomagnesemia, and neurohormonal abnormalities can
    produce clinically important cardiac arrhythmias in Bartter syndrome despite
    the usual absence of hypertension. Severe events may include syncope or
    sudden cardiac death.
  frequency: OCCASIONAL
  phenotype_term:
    preferred_term: Ventricular arrhythmia
    term:
      id: HP:0004308
      label: Ventricular arrhythmia
  evidence:
  - reference: PMID:39445629
    reference_title: "Cardiovascular and arrhythmic manifestations of Bartter's and Gitelman's syndromes: do not forget the heart. A narrative literature review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Although considered benign entities, major adverse cardiovascular events
      may complicate both syndromes, in form of ventricular arrhythmias leading
      to palpitations, syncope or sudden cardiac death, microvascular cardiac
      dysfunction and exercise-induced myocardial contractile deficit.
    explanation: >-
      Narrative review highlights arrhythmic and cardiovascular complications
      of Bartter and Gitelman syndromes despite their usual normotensive
      phenotype.
biochemical:
- name: Serum Potassium
  presence: DECREASED
  notes: Low serum potassium (typically 1.5-3.0 mEq/L)
  evidence:
  - reference: PMID:19096086
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      patients with CLCNKB had the lowest potassium (P = 0.006 versus KCNJ1
      and P = 0.034 versus SLC12A1)
    explanation: >-
      Cohort study quantifies hypokalemia across genotypes, with CLCNKB
      patients having the most severe potassium depletion.
- name: Serum Chloride
  presence: DECREASED
  notes: Low serum chloride
  evidence:
  - reference: PMID:19096086
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      patients with CLCNKB had the lowest potassium (P = 0.006 versus KCNJ1
      and P = 0.034 versus SLC12A1) and chloride plasma concentrations (P =
      0.039 versus KCNJ1 and P = 0.024 versus SLC12A1)
    explanation: >-
      Cohort study documents hypochloremia across genotypes, worst in Type 3.
- name: Serum Bicarbonate
  presence: INCREASED
  notes: Elevated serum bicarbonate reflecting metabolic alkalosis
  evidence:
  - reference: PMID:19096086
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      the highest bicarbonataemia (P = 0.026 versus KCNJ1 and P = 0.014
      versus SLC12A1)
    explanation: >-
      Cohort study confirms elevated bicarbonate, most severe in CLCNKB
      patients.
- name: Plasma Renin Activity
  presence: INCREASED
  notes: Markedly elevated plasma renin activity
- name: Plasma Aldosterone
  presence: INCREASED
  notes: Elevated plasma aldosterone concentration
- name: Urinary Calcium
  presence: INCREASED
  notes: Elevated urinary calcium excretion, especially in Types 1 and 2
- name: Urinary Prostaglandin E2
  presence: INCREASED
  notes: Elevated urinary PGE2, particularly prominent in antenatal forms
treatments:
- name: Potassium Supplementation
  description: >-
    Oral potassium chloride replacement is the cornerstone of management,
    often requiring high doses to maintain serum potassium above 3.0 mEq/L.
  treatment_term:
    preferred_term: potassium supplementation
    term:
      id: MAXO:0000058
      label: pharmacotherapy
    therapeutic_agent:
    - preferred_term: potassium chloride
      term:
        id: CHEBI:32588
        label: potassium chloride
  evidence:
  - reference: PMID:36993809
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Potassium chloride supplements and potassium-sparing diuretics were
      administered in 94% and 68% of patients, respectively. The mean dosage
      of potassium chloride supplements was 5.0 and 2.1 mEq/day/kg for
      patients younger and older than 18 years, respectively.
    explanation: >-
      Korean multicenter study quantifies potassium supplementation dosing
      in 54 Bartter patients.
- name: Indomethacin
  description: >-
    Prostaglandin synthesis inhibitor (NSAID) that reduces urinary
    prostaglandin E2, improves electrolyte balance, and promotes growth
    in children with Bartter syndrome.
  treatment_term:
    preferred_term: pharmacotherapy
    term:
      id: MAXO:0000058
      label: pharmacotherapy
    therapeutic_agent:
    - preferred_term: indomethacin
      term:
        id: CHEBI:49662
        label: indometacin
  evidence:
  - reference: PMID:19096086
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      In most cases, water/electrolyte supplementation + indomethacin led to
      catch-up growth.
    explanation: >-
      French cohort demonstrates indomethacin plus electrolyte
      supplementation leads to catch-up growth.
- name: Potassium-Sparing Diuretics
  description: >-
    Aldosterone antagonists (spironolactone, eplerenone) and direct ENaC
    inhibitors (amiloride) used to counteract potassium-wasting effects of
    secondary hyperaldosteronism. In the Korean multicenter study, 68% of
    patients received potassium-sparing diuretics.
  treatment_term:
    preferred_term: pharmacotherapy
    term:
      id: MAXO:0000058
      label: pharmacotherapy
    therapeutic_agent:
    - preferred_term: spironolactone
      term:
        id: CHEBI:9241
        label: spironolactone
    - preferred_term: amiloride
      term:
        id: CHEBI:2639
        label: amiloride
    - preferred_term: eplerenone
      term:
        id: CHEBI:31547
        label: eplerenone
  evidence:
  - reference: PMID:30519073
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      The classical pharmacological therapy includes potassium chloride
      supplementation, prostaglandin inhibitor (indomethacin), and
      aldosterone antagonist (spironolactone).
    explanation: >-
      Review confirms spironolactone as part of the classical pharmacological
      treatment triad for Bartter syndrome.
  - reference: PMID:36993809
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Potassium chloride supplements and potassium-sparing diuretics were
      administered in 94% and 68% of patients, respectively.
    explanation: >-
      Korean cohort confirms 68% of patients received potassium-sparing
      diuretics.
- name: Magnesium Supplementation
  description: >-
    Oral magnesium replacement for patients with hypomagnesemia, particularly
    those with Types 1 and 2.
  treatment_term:
    preferred_term: magnesium supplementation
    term:
      id: MAXO:0000058
      label: pharmacotherapy
- name: Renal Transplantation
  description: >-
    Considered for patients who progress to end-stage renal disease, which
    can occur in Type 4. Transplantation corrects the electrolyte
    abnormalities since the defect is intrinsic to the native kidney.
  treatment_term:
    preferred_term: organ transplantation
    term:
      id: MAXO:0010039
      label: organ transplantation
  evidence:
  - reference: PMID:36993809
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      impaired kidney function was observed in six patients [chronic kidney
      disease (CKD) G3, n = 4; CKD G5, n = 2]
    explanation: >-
      Korean study shows some patients progress to advanced CKD, supporting
      the need for renal transplantation in severe cases.
- name: Genetic Counseling
  description: >-
    Family counseling regarding autosomal recessive or X-linked recessive
    inheritance patterns, carrier testing, and prenatal diagnosis options.
  treatment_term:
    preferred_term: genetic counseling
    term:
      id: MAXO:0000079
      label: genetic counseling
datasets: []
references:
- reference: DOI:10.1016/j.bbrc.2013.10.129
  title: Treatment with 17-allylamino-17-demethoxygeldanamycin ameliorated symptoms of Bartter syndrome type IV caused by mutated Bsnd in mice
  found_in:
  - Bartter_Syndrome-deep-research-falcon.md
  findings:
  - statement: Treatment with 17-allylamino-17-demethoxygeldanamycin ameliorated symptoms of Bartter syndrome type IV caused by mutated Bsnd in mice
    supporting_text: Treatment with 17-allylamino-17-demethoxygeldanamycin ameliorated symptoms of Bartter syndrome type IV caused by mutated Bsnd in mice
- reference: DOI:10.1152/ajprenal.00522.2009
  title: Mutation of the Na<sup>+</sup>-K<sup>+</sup>-2Cl<sup>−</sup>cotransporter NKCC2 in mice is associated with severe polyuria and a urea-selective concentrating defect without hyperreninemia
  found_in:
  - Bartter_Syndrome-deep-research-falcon.md
  findings:
  - statement: The bumetanide-sensitive Na+-K+-2Cl−cotransporter NKCC2, located in the thick ascending limb of Henle's loop, plays a critical role in the kidney's ability to concentrate urine.
    supporting_text: The bumetanide-sensitive Na+-K+-2Cl−cotransporter NKCC2, located in the thick ascending limb of Henle's loop, plays a critical role in the kidney's ability to concentrate urine.
    evidence:
    - reference: DOI:10.1152/ajprenal.00522.2009
      reference_title: Mutation of the Na<sup>+</sup>-K<sup>+</sup>-2Cl<sup>−</sup>cotransporter NKCC2 in mice is associated with severe polyuria and a urea-selective concentrating defect without hyperreninemia
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: The bumetanide-sensitive Na+-K+-2Cl−cotransporter NKCC2, located in the thick ascending limb of Henle's loop, plays a critical role in the kidney's ability to concentrate urine.
      explanation: Deep research cited this publication as relevant literature for Bartter Syndrome.
- reference: DOI:10.1186/s12864-016-3035-1
  title: A missense mutation in solute carrier family 12, member 1 (SLC12A1) causes hydrallantois in Japanese Black cattle
  found_in:
  - Bartter_Syndrome-deep-research-falcon.md
  findings:
  - statement: A missense mutation in solute carrier family 12, member 1 (SLC12A1) causes hydrallantois in Japanese Black cattle
    supporting_text: A missense mutation in solute carrier family 12, member 1 (SLC12A1) causes hydrallantois in Japanese Black cattle
- reference: DOI:10.1186/s12920-024-01797-8
  title: Identification of a novel intronic mutation of MAGED2 gene in a Chinese family with antenatal Bartter syndrome
  found_in:
  - Bartter_Syndrome-deep-research-falcon.md
  findings:
  - statement: Antenatal Bartter syndrome is a life-threatening disease caused by a mutation in the MAGED2 gene located on chromosome Xp11.
    supporting_text: Antenatal Bartter syndrome is a life-threatening disease caused by a mutation in the MAGED2 gene located on chromosome Xp11.
    evidence:
    - reference: DOI:10.1186/s12920-024-01797-8
      reference_title: Identification of a novel intronic mutation of MAGED2 gene in a Chinese family with antenatal Bartter syndrome
      supports: SUPPORT
      evidence_source: OTHER
      snippet: Antenatal Bartter syndrome is a life-threatening disease caused by a mutation in the MAGED2 gene located on chromosome Xp11.
      explanation: Deep research cited this publication as relevant literature for Bartter Syndrome.
- reference: DOI:10.1186/s12929-014-0068-0
  title: Standardized, systemic phenotypic analysis of Slc12a1 I299F mutant mice
  found_in:
  - Bartter_Syndrome-deep-research-falcon.md
  findings:
  - statement: Standardized, systemic phenotypic analysis of Slc12a1 I299F mutant mice
    supporting_text: Standardized, systemic phenotypic analysis of Slc12a1 I299F mutant mice
- reference: DOI:10.1507/endocrj.ej23-0631
  title: 'Adult classic Bartter syndrome: a case report with 5-year follow-up and literature review'
  found_in:
  - Bartter_Syndrome-deep-research-falcon.md
  findings:
  - statement: 'Adult classic Bartter syndrome: a case report with 5-year follow-up and literature review'
    supporting_text: 'Adult classic Bartter syndrome: a case report with 5-year follow-up and literature review'
- reference: DOI:10.20944/preprints202407.1238.v1
  title: 'Sodium Deficiency Diseases: The Association With the Renin-Angiotensin-Aldosterone System, Aging and Inflammation'
  found_in:
  - Bartter_Syndrome-deep-research-falcon.md
  findings:
  - statement: Every individual at some point encounters the progressive biological process of aging which is considered one of the major risk factors for common diseases.
    supporting_text: Every individual at some point encounters the progressive biological process of aging which is considered one of the major risk factors for common diseases.
    evidence:
    - reference: DOI:10.20944/preprints202407.1238.v1
      reference_title: 'Sodium Deficiency Diseases: The Association With the Renin-Angiotensin-Aldosterone System, Aging and Inflammation'
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: Every individual at some point encounters the progressive biological process of aging which is considered one of the major risk factors for common diseases.
      explanation: Deep research cited this publication as relevant literature for Bartter Syndrome.
- reference: DOI:10.3389/fmed.2023.1099840
  title: 'Long-term outcome of Bartter syndrome in 54 patients: A multicenter study in Korea'
  found_in:
  - Bartter_Syndrome-deep-research-falcon.md
  findings:
  - statement: Bartter syndrome (BS) is a rare salt-wasting tubulopathy caused by mutations in genes encoding sodium, potassium, or chloride transporters of the thick ascending limb of the loop of Henle and/or the distal convoluted tubule of the kidney.
    supporting_text: Bartter syndrome (BS) is a rare salt-wasting tubulopathy caused by mutations in genes encoding sodium, potassium, or chloride transporters of the thick ascending limb of the loop of Henle and/or the distal convoluted tubule of the kidney.
    evidence:
    - reference: DOI:10.3389/fmed.2023.1099840
      reference_title: 'Long-term outcome of Bartter syndrome in 54 patients: A multicenter study in Korea'
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: Bartter syndrome (BS) is a rare salt-wasting tubulopathy caused by mutations in genes encoding sodium, potassium, or chloride transporters of the thick ascending limb of the loop of Henle and/or the distal convoluted tubule of the kidney.
      explanation: Deep research cited this publication as relevant literature for Bartter Syndrome.
- reference: DOI:10.3389/fped.2023.1034923
  title: 'A mosaic mutation in the CLCNKB gene causing Bartter syndrome: A case report'
  found_in:
  - Bartter_Syndrome-deep-research-falcon.md
  findings:
  - statement: Type III Bartter syndrome (BS) is an autosomal recessive disease caused by mutations in the CLCNKB (chloride voltage-gated channel Kb) gene that encodes CLC-Kb.
    supporting_text: Type III Bartter syndrome (BS) is an autosomal recessive disease caused by mutations in the CLCNKB (chloride voltage-gated channel Kb) gene that encodes CLC-Kb.
    evidence:
    - reference: DOI:10.3389/fped.2023.1034923
      reference_title: 'A mosaic mutation in the CLCNKB gene causing Bartter syndrome: A case report'
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: Type III Bartter syndrome (BS) is an autosomal recessive disease caused by mutations in the CLCNKB (chloride voltage-gated channel Kb) gene that encodes CLC-Kb.
      explanation: Deep research cited this publication as relevant literature for Bartter Syndrome.
- reference: DOI:10.3390/cells13100818
  title: Protein Quality Control of NKCC2 in Bartter Syndrome and Blood Pressure Regulation
  found_in:
  - Bartter_Syndrome-deep-research-falcon.md
  - Bartter_Syndrome-deep-research-openscientist.md
  findings:
  - statement: Mutations in NKCC2 generate antenatal Bartter syndrome type 1 (type 1 BS), a life-threatening salt-losing nephropathy characterized by arterial hypotension, as well as electrolyte abnormalities.
    supporting_text: Mutations in NKCC2 generate antenatal Bartter syndrome type 1 (type 1 BS), a life-threatening salt-losing nephropathy characterized by arterial hypotension, as well as electrolyte abnormalities.
    evidence:
    - reference: DOI:10.3390/cells13100818
      reference_title: Protein Quality Control of NKCC2 in Bartter Syndrome and Blood Pressure Regulation
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: Mutations in NKCC2 generate antenatal Bartter syndrome type 1 (type 1 BS), a life-threatening salt-losing nephropathy characterized by arterial hypotension, as well as electrolyte abnormalities.
      explanation: Deep research cited this publication as relevant literature for Bartter Syndrome.
- reference: PMID:38786040
  title: Protein Quality Control of NKCC2 in Bartter Syndrome and Blood Pressure Regulation.
  found_in:
  - Bartter_Syndrome-deep-research-openscientist.md
  findings:
  - statement: ER export appears to be a rate-limiting step in NKCC2 maturation and trafficking to the plasma membrane.
    supporting_text: Similar to several transmembrane proteins, export from the ER appears to be the rate-limiting step in the cotransporter's maturation and trafficking to the plasma membrane.
    evidence:
    - reference: PMID:38786040
      reference_title: Protein Quality Control of NKCC2 in Bartter Syndrome and Blood Pressure Regulation.
      supports: SUPPORT
      evidence_source: OTHER
      snippet: Similar to several transmembrane proteins, export from the ER appears to be the rate-limiting step in the cotransporter's maturation and trafficking to the plasma membrane.
      explanation: Deep research cited this publication as relevant literature for Bartter Syndrome.
- reference: DOI:10.3390/genes17040424
  title: Identification of Three Novel MAGED2 Variants Causing Antenatal Bartter Syndrome in Three Chinese Families
  found_in:
  - Bartter_Syndrome-deep-research-falcon.md
  findings:
  - statement: We aimed to report three novel MAGED2 variants associated with transient antenatal Bartter syndrome (TABS) and to summarize the prenatal and postnatal features of MAGED2-related TABS through case analysis and literature review.
    supporting_text: We aimed to report three novel MAGED2 variants associated with transient antenatal Bartter syndrome (TABS) and to summarize the prenatal and postnatal features of MAGED2-related TABS through case analysis and literature review.
    evidence:
    - reference: DOI:10.3390/genes17040424
      reference_title: Identification of Three Novel MAGED2 Variants Causing Antenatal Bartter Syndrome in Three Chinese Families
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: We aimed to report three novel MAGED2 variants associated with transient antenatal Bartter syndrome (TABS) and to summarize the prenatal and postnatal features of MAGED2-related TABS through case analysis and literature review.
      explanation: Deep research cited this publication as relevant literature for Bartter Syndrome.
- reference: DOI:10.3390/ijms25179332
  title: Untangling the Uncertain Role of Overactivation of the Renin–Angiotensin–Aldosterone System with the Aging Process Based on Sodium Wasting Human Models
  found_in:
  - Bartter_Syndrome-deep-research-falcon.md
  findings:
  - statement: Every individual at some point encounters the progressive biological process of aging, which is considered one of the major risk factors for common diseases.
    supporting_text: Every individual at some point encounters the progressive biological process of aging, which is considered one of the major risk factors for common diseases.
    evidence:
    - reference: DOI:10.3390/ijms25179332
      reference_title: Untangling the Uncertain Role of Overactivation of the Renin–Angiotensin–Aldosterone System with the Aging Process Based on Sodium Wasting Human Models
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: Every individual at some point encounters the progressive biological process of aging, which is considered one of the major risk factors for common diseases.
      explanation: Deep research cited this publication as relevant literature for Bartter Syndrome.
- reference: DOI:10.3390/medicina59091638
  title: 'Bartter Syndrome: A Systematic Review of Case Reports and Case Series'
  found_in:
  - Bartter_Syndrome-deep-research-falcon.md
  findings:
  - statement: Bartter syndrome (BS) is a rare group of autosomal-recessive disorders that usually presents with hypokalemic metabolic alkalosis, occasionally with hyponatremia and hypochloremia.
    supporting_text: Bartter syndrome (BS) is a rare group of autosomal-recessive disorders that usually presents with hypokalemic metabolic alkalosis, occasionally with hyponatremia and hypochloremia.
    evidence:
    - reference: DOI:10.3390/medicina59091638
      reference_title: 'Bartter Syndrome: A Systematic Review of Case Reports and Case Series'
      supports: SUPPORT
      evidence_source: OTHER
      snippet: Bartter syndrome (BS) is a rare group of autosomal-recessive disorders that usually presents with hypokalemic metabolic alkalosis, occasionally with hyponatremia and hypochloremia.
      explanation: Deep research cited this publication as relevant literature for Bartter Syndrome.
- reference: DOI:10.7759/cureus.36120
  title: 'A Rare Presentation of Adult-Onset Bartter Syndrome: A Case Report'
  found_in:
  - Bartter_Syndrome-deep-research-falcon.md
  findings:
  - statement: 'A Rare Presentation of Adult-Onset Bartter Syndrome: A Case Report'
    supporting_text: 'A Rare Presentation of Adult-Onset Bartter Syndrome: A Case Report'
- reference: DOI:10.7759/cureus.72406
  title: 'Bartter Syndrome With Recurrent Hypokalemic Periodic Paralysis: A Case Report'
  found_in:
  - Bartter_Syndrome-deep-research-falcon.md
  findings:
  - statement: 'Bartter Syndrome With Recurrent Hypokalemic Periodic Paralysis: A Case Report'
    supporting_text: 'Bartter Syndrome With Recurrent Hypokalemic Periodic Paralysis: A Case Report'
- reference: PMID:10779555
  title: Uncompensated polyuria in a mouse model of Bartter's syndrome.
  found_in:
  - Bartter_Syndrome-deep-research-openscientist.md
  findings:
  - statement: '2000 May 9;97(10):5434-9. doi: 10.1073/pnas.090091297.'
    supporting_text: '2000 May 9;97(10):5434-9. doi: 10.1073/pnas.090091297.'
    evidence:
    - reference: PMID:10779555
      reference_title: Uncompensated polyuria in a mouse model of Bartter's syndrome.
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: '2000 May 9;97(10):5434-9. doi: 10.1073/pnas.090091297.'
      explanation: Deep research cited this publication as relevant literature for Bartter Syndrome.
- reference: PMID:11115075
  title: Cyclooxygenase-2 expression is associated with the renal macula densa of patients with Bartter-like syndrome.
  found_in:
  - Bartter_Syndrome-deep-research-openscientist.md
  findings:
  - statement: Bartter-like syndrome (BLS) is a heterogeneous set of congenital tubular disorders that is associated with significant renal salt and water loss.
    supporting_text: Bartter-like syndrome (BLS) is a heterogeneous set of congenital tubular disorders that is associated with significant renal salt and water loss.
    evidence:
    - reference: PMID:11115075
      reference_title: Cyclooxygenase-2 expression is associated with the renal macula densa of patients with Bartter-like syndrome.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: Bartter-like syndrome (BLS) is a heterogeneous set of congenital tubular disorders that is associated with significant renal salt and water loss.
      explanation: Deep research cited this publication as relevant literature for Bartter Syndrome.
- reference: PMID:12081585
  title: Role of cyclooxygenase-2 in hyperprostaglandin E syndrome/antenatal Bartter syndrome.
  found_in:
  - Bartter_Syndrome-deep-research-openscientist.md
  findings:
  - statement: Hyperprostaglandin E syndrome/antenatal Bartter syndrome (HPS/aBS) is a congenital salt-losing tubulopathy with an induced expression of cyclooxygenase-2 (COX-2) in the macula densa probably leading to hyperreninemia.
    supporting_text: Hyperprostaglandin E syndrome/antenatal Bartter syndrome (HPS/aBS) is a congenital salt-losing tubulopathy with an induced expression of cyclooxygenase-2 (COX-2) in the macula densa probably leading to hyperreninemia.
    evidence:
    - reference: PMID:12081585
      reference_title: Role of cyclooxygenase-2 in hyperprostaglandin E syndrome/antenatal Bartter syndrome.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: Hyperprostaglandin E syndrome/antenatal Bartter syndrome (HPS/aBS) is a congenital salt-losing tubulopathy with an induced expression of cyclooxygenase-2 (COX-2) in the macula densa probably leading to hyperreninemia.
      explanation: Deep research cited this publication as relevant literature for Bartter Syndrome.
- reference: PMID:12122007
  title: Impaired renal NaCl absorption in mice lacking the ROMK potassium channel, a model for type II Bartter's syndrome.
  found_in:
  - Bartter_Syndrome-deep-research-openscientist.md
  findings:
  - statement: '2002 Oct 4;277(40):37871-80. doi: 10.1074/jbc.M205627200.'
    supporting_text: '2002 Oct 4;277(40):37871-80. doi: 10.1074/jbc.M205627200.'
    evidence:
    - reference: PMID:12122007
      reference_title: Impaired renal NaCl absorption in mice lacking the ROMK potassium channel, a model for type II Bartter's syndrome.
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: '2002 Oct 4;277(40):37871-80. doi: 10.1074/jbc.M205627200.'
      explanation: Deep research cited this publication as relevant literature for Bartter Syndrome.
- reference: PMID:12749662
  title: Successful management of an extreme example of neonatal hyperprostaglandin-E syndrome (Bartter's syndrome) with the new cyclooxygenase-2 inhibitor rofecoxib.
  found_in:
  - Bartter_Syndrome-deep-research-openscientist.md
  findings:
  - statement: '2003 Apr;4(2):249-51. doi: 10.1097/01.PCC.0000059422.26706.64.'
    supporting_text: '2003 Apr;4(2):249-51. doi: 10.1097/01.PCC.0000059422.26706.64.'
    evidence:
    - reference: PMID:12749662
      reference_title: Successful management of an extreme example of neonatal hyperprostaglandin-E syndrome (Bartter's syndrome) with the new cyclooxygenase-2 inhibitor rofecoxib.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: '2003 Apr;4(2):249-51. doi: 10.1097/01.PCC.0000059422.26706.64.'
      explanation: Deep research cited this publication as relevant literature for Bartter Syndrome.
- reference: PMID:1340758
  title: Calcium homeostasis and hypercalciuria in hyperprostaglandin E syndrome.
  found_in:
  - Bartter_Syndrome-deep-research-openscientist.md
  findings:
  - statement: '1992 Apr;120(4 Pt 1):546-54. doi: 10.1016/s0022-3476(05)82480-1.'
    supporting_text: '1992 Apr;120(4 Pt 1):546-54. doi: 10.1016/s0022-3476(05)82480-1.'
    evidence:
    - reference: PMID:1340758
      reference_title: Calcium homeostasis and hypercalciuria in hyperprostaglandin E syndrome.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: '1992 Apr;120(4 Pt 1):546-54. doi: 10.1016/s0022-3476(05)82480-1.'
      explanation: Deep research cited this publication as relevant literature for Bartter Syndrome.
- reference: PMID:16231363
  title: '"End-stage kidney" in longstanding bulimia nervosa.'
  found_in:
  - Bartter_Syndrome-deep-research-openscientist.md
  findings:
  - statement: '2005 Dec;38(4):383-5. doi: 10.1002/eat.20198. "End-stage kidney" in longstanding bulimia nervosa.'
    supporting_text: '2005 Dec;38(4):383-5. doi: 10.1002/eat.20198. "End-stage kidney" in longstanding bulimia nervosa.'
    evidence:
    - reference: PMID:16231363
      reference_title: '"End-stage kidney" in longstanding bulimia nervosa.'
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: '2005 Dec;38(4):383-5. doi: 10.1002/eat.20198. "End-stage kidney" in longstanding bulimia nervosa.'
      explanation: Deep research cited this publication as relevant literature for Bartter Syndrome.
- reference: PMID:16583241
  title: 'Type IV Bartter syndrome: report of two new cases.'
  found_in:
  - Bartter_Syndrome-deep-research-openscientist.md
  findings:
  - statement: '2006 Jun;21(6):766-70. doi: 10.1007/s00467-006-0090-x.'
    supporting_text: '2006 Jun;21(6):766-70. doi: 10.1007/s00467-006-0090-x.'
    evidence:
    - reference: PMID:16583241
      reference_title: 'Type IV Bartter syndrome: report of two new cases.'
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: '2006 Jun;21(6):766-70. doi: 10.1007/s00467-006-0090-x.'
      explanation: Deep research cited this publication as relevant literature for Bartter Syndrome.
- reference: PMID:18310267
  title: Molecular analysis of digenic inheritance in Bartter syndrome with sensorineural deafness.
  found_in:
  - Bartter_Syndrome-deep-research-openscientist.md
  findings:
  - statement: Bartter syndrome (BS) is a genetic disorder accompanied by hypokalaemic metabolic alkalosis.
    supporting_text: Bartter syndrome (BS) is a genetic disorder accompanied by hypokalaemic metabolic alkalosis.
    evidence:
    - reference: PMID:18310267
      reference_title: Molecular analysis of digenic inheritance in Bartter syndrome with sensorineural deafness.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: Bartter syndrome (BS) is a genetic disorder accompanied by hypokalaemic metabolic alkalosis.
      explanation: Deep research cited this publication as relevant literature for Bartter Syndrome.
- reference: PMID:1887027
  title: Hyperechoic renal medullary pyramids in infants and children.
  found_in:
  - Bartter_Syndrome-deep-research-openscientist.md
  findings:
  - statement: '1991 Oct;181(1):163-7. doi: 10.1148/radiology.181.1.1887027.'
    supporting_text: '1991 Oct;181(1):163-7. doi: 10.1148/radiology.181.1.1887027.'
    evidence:
    - reference: PMID:1887027
      reference_title: Hyperechoic renal medullary pyramids in infants and children.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: '1991 Oct;181(1):163-7. doi: 10.1148/radiology.181.1.1887027.'
      explanation: Deep research cited this publication as relevant literature for Bartter Syndrome.
- reference: PMID:21865213
  title: Genetic basis of Bartter syndrome in Korea.
  found_in:
  - Bartter_Syndrome-deep-research-openscientist.md
  findings:
  - statement: Genetic basis of Bartter syndrome in Korea
    supporting_text: Bartter syndrome (BS) is clinically classified into antenatal or neonatal BS (aBS) and classic BS (cBS) as well as five subtypes based on the underlying mutant gene; SLC12A1 (BS I), KCNJ1 (BS II), CLCNKB (BS III), BSND (BS IV) and CASR (BS V).
    evidence:
    - reference: PMID:21865213
      reference_title: Genetic basis of Bartter syndrome in Korea.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: Bartter syndrome (BS) is clinically classified into antenatal or neonatal BS (aBS) and classic BS (cBS) as well as five subtypes based on the underlying mutant gene; SLC12A1 (BS I), KCNJ1 (BS II), CLCNKB (BS III), BSND (BS IV) and CASR (BS V).
      explanation: Deep research cited this publication as relevant literature for Bartter Syndrome.
- reference: PMID:24039833
  title: SPAK deficiency corrects pseudohypoaldosteronism II caused by WNK4 mutation.
  found_in:
  - Bartter_Syndrome-deep-research-openscientist.md
  findings:
  - statement: '2013 Sep 11;8(9):e72969. doi: 10.1371/journal.pone.0072969. eCollection 2013.'
    supporting_text: '2013 Sep 11;8(9):e72969. doi: 10.1371/journal.pone.0072969. eCollection 2013.'
    evidence:
    - reference: PMID:24039833
      reference_title: SPAK deficiency corrects pseudohypoaldosteronism II caused by WNK4 mutation.
      supports: SUPPORT
      evidence_source: OTHER
      snippet: '2013 Sep 11;8(9):e72969. doi: 10.1371/journal.pone.0072969. eCollection 2013.'
      explanation: Deep research cited this publication as relevant literature for Bartter Syndrome.
- reference: PMID:2671327
  title: 'Hypercalciuria with Bartter syndrome: evidence for an abnormality of vitamin D metabolism.'
  found_in:
  - Bartter_Syndrome-deep-research-openscientist.md
  findings:
  - statement: '1989 Sep;115(3):397-404. doi: 10.1016/s0022-3476(89)80838-8.'
    supporting_text: '1989 Sep;115(3):397-404. doi: 10.1016/s0022-3476(89)80838-8.'
    evidence:
    - reference: PMID:2671327
      reference_title: 'Hypercalciuria with Bartter syndrome: evidence for an abnormality of vitamin D metabolism.'
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: '1989 Sep;115(3):397-404. doi: 10.1016/s0022-3476(89)80838-8.'
      explanation: Deep research cited this publication as relevant literature for Bartter Syndrome.
- reference: PMID:26857709
  title: Accentuated hyperparathyroidism in type II Bartter syndrome.
  found_in:
  - Bartter_Syndrome-deep-research-openscientist.md
  findings:
  - statement: Bartter syndrome (BS) may be associated with different degrees of hypercalciuria, but marked parathyroid hormone (PTH) abnormalities have not been described.
    supporting_text: Bartter syndrome (BS) may be associated with different degrees of hypercalciuria, but marked parathyroid hormone (PTH) abnormalities have not been described.
    evidence:
    - reference: PMID:26857709
      reference_title: Accentuated hyperparathyroidism in type II Bartter syndrome.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: Bartter syndrome (BS) may be associated with different degrees of hypercalciuria, but marked parathyroid hormone (PTH) abnormalities have not been described.
      explanation: Deep research cited this publication as relevant literature for Bartter Syndrome.
- reference: PMID:27068441
  title: SPAK and OSR1 play essential roles in potassium homeostasis through actions on the distal convoluted tubule.
  found_in:
  - Bartter_Syndrome-deep-research-openscientist.md
  findings:
  - statement: '2016 Sep 1;594(17):4945-66. doi: 10.1113/JP272311.'
    supporting_text: '2016 Sep 1;594(17):4945-66. doi: 10.1113/JP272311.'
    evidence:
    - reference: PMID:27068441
      reference_title: SPAK and OSR1 play essential roles in potassium homeostasis through actions on the distal convoluted tubule.
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: '2016 Sep 1;594(17):4945-66. doi: 10.1113/JP272311.'
      explanation: Deep research cited this publication as relevant literature for Bartter Syndrome.
- reference: PMID:27120771
  title: Polyhydramnios, Transient Antenatal Bartter's Syndrome, and MAGED2 Mutations.
  found_in:
  - Bartter_Syndrome-deep-research-openscientist.md
  findings:
  - statement: Three pregnancies with male offspring in one family were complicated by severe polyhydramnios and prematurity.
    supporting_text: Three pregnancies with male offspring in one family were complicated by severe polyhydramnios and prematurity.
    evidence:
    - reference: PMID:27120771
      reference_title: Polyhydramnios, Transient Antenatal Bartter's Syndrome, and MAGED2 Mutations.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: Three pregnancies with male offspring in one family were complicated by severe polyhydramnios and prematurity.
      explanation: Deep research cited this publication as relevant literature for Bartter Syndrome.
- reference: PMID:28012523
  title: Digenic mutations involving both the BSND and GJB2 genes detected in Bartter syndrome type IV.
  found_in:
  - Bartter_Syndrome-deep-research-openscientist.md
  findings:
  - statement: '2017 Jan;92:17-20. doi: 10.1016/j.ijporl.2016.10.028.'
    supporting_text: '2017 Jan;92:17-20. doi: 10.1016/j.ijporl.2016.10.028.'
    evidence:
    - reference: PMID:28012523
      reference_title: Digenic mutations involving both the BSND and GJB2 genes detected in Bartter syndrome type IV.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: '2017 Jan;92:17-20. doi: 10.1016/j.ijporl.2016.10.028.'
      explanation: Deep research cited this publication as relevant literature for Bartter Syndrome.
- reference: PMID:28095294
  title: A novel SLC12A1 gene mutation associated with hyperparathyroidism, hypercalcemia, nephrogenic diabetes insipidus, and nephrocalcinosis in four patients.
  found_in:
  - Bartter_Syndrome-deep-research-openscientist.md
  findings:
  - statement: '2017 Apr;97:121-125. doi: 10.1016/j.bone.2017.01.011.'
    supporting_text: '2017 Apr;97:121-125. doi: 10.1016/j.bone.2017.01.011.'
    evidence:
    - reference: PMID:28095294
      reference_title: A novel SLC12A1 gene mutation associated with hyperparathyroidism, hypercalcemia, nephrogenic diabetes insipidus, and nephrocalcinosis in four patients.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: '2017 Apr;97:121-125. doi: 10.1016/j.bone.2017.01.011.'
      explanation: Deep research cited this publication as relevant literature for Bartter Syndrome.
- reference: PMID:29092859
  title: Urinary bladder hypertrophy characteristic of male ROMK Bartter's mice does not occur in female mice.
  found_in:
  - Bartter_Syndrome-deep-research-openscientist.md
  findings:
  - statement: '2018 Mar 1;314(3):R334-R341. doi: 10.1152/ajpregu.00315.2017.'
    supporting_text: '2018 Mar 1;314(3):R334-R341. doi: 10.1152/ajpregu.00315.2017.'
    evidence:
    - reference: PMID:29092859
      reference_title: Urinary bladder hypertrophy characteristic of male ROMK Bartter's mice does not occur in female mice.
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: '2018 Mar 1;314(3):R334-R341. doi: 10.1152/ajpregu.00315.2017.'
      explanation: Deep research cited this publication as relevant literature for Bartter Syndrome.
- reference: PMID:30174009
  title: Two novel homozygous missense mutations identified in the BSND gene in Moroccan patients with Bartter's syndrome.
  found_in:
  - Bartter_Syndrome-deep-research-openscientist.md
  findings:
  - statement: '2018 Oct;113:46-50. doi: 10.1016/j.ijporl.2018.07.010.'
    supporting_text: '2018 Oct;113:46-50. doi: 10.1016/j.ijporl.2018.07.010.'
    evidence:
    - reference: PMID:30174009
      reference_title: Two novel homozygous missense mutations identified in the BSND gene in Moroccan patients with Bartter's syndrome.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: '2018 Oct;113:46-50. doi: 10.1016/j.ijporl.2018.07.010.'
      explanation: Deep research cited this publication as relevant literature for Bartter Syndrome.
- reference: PMID:32184353
  title: DHHC7-mediated palmitoylation of the accessory protein barttin critically regulates the functions of ClC-K chloride channels.
  found_in:
  - Bartter_Syndrome-deep-research-openscientist.md
  findings:
  - statement: '2020 May 1;295(18):5970-5983. doi: 10.1074/jbc.RA119.011049.'
    supporting_text: '2020 May 1;295(18):5970-5983. doi: 10.1074/jbc.RA119.011049.'
    evidence:
    - reference: PMID:32184353
      reference_title: DHHC7-mediated palmitoylation of the accessory protein barttin critically regulates the functions of ClC-K chloride channels.
      supports: SUPPORT
      evidence_source: OTHER
      snippet: '2020 May 1;295(18):5970-5983. doi: 10.1074/jbc.RA119.011049.'
      explanation: Deep research cited this publication as relevant literature for Bartter Syndrome.
- reference: PMID:33058840
  title: Eight novel KCNJ1 variants and parathyroid hormone overaction or resistance in 5 probands with Bartter syndrome type 2.
  found_in:
  - Bartter_Syndrome-deep-research-openscientist.md
  findings:
  - statement: '2020 Dec;511:248-254. doi: 10.1016/j.cca.2020.10.002.'
    supporting_text: '2020 Dec;511:248-254. doi: 10.1016/j.cca.2020.10.002.'
    evidence:
    - reference: PMID:33058840
      reference_title: Eight novel KCNJ1 variants and parathyroid hormone overaction or resistance in 5 probands with Bartter syndrome type 2.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: '2020 Dec;511:248-254. doi: 10.1016/j.cca.2020.10.002.'
      explanation: Deep research cited this publication as relevant literature for Bartter Syndrome.
- reference: PMID:34895150
  title: A novel MAGED2 variant in a Chinese preterm newborn with transient antenatal Bartter's syndrome with 4 years follow-up.
  found_in:
  - Bartter_Syndrome-deep-research-openscientist.md
  findings:
  - statement: Transient antenatal Bartter's syndrome caused by MAGED2 mutation is a rare X-linked recessive renal tubular disorder.
    supporting_text: Transient antenatal Bartter's syndrome caused by MAGED2 mutation is a rare X-linked recessive renal tubular disorder.
    evidence:
    - reference: PMID:34895150
      reference_title: A novel MAGED2 variant in a Chinese preterm newborn with transient antenatal Bartter's syndrome with 4 years follow-up.
      supports: SUPPORT
      evidence_source: OTHER
      snippet: Transient antenatal Bartter's syndrome caused by MAGED2 mutation is a rare X-linked recessive renal tubular disorder.
      explanation: Deep research cited this publication as relevant literature for Bartter Syndrome.
- reference: PMID:35628451
  title: Clinical and Genetic Characterization of Patients with Bartter and Gitelman Syndrome.
  found_in:
  - Bartter_Syndrome-deep-research-openscientist.md
  findings:
  - statement: '2022 May 18;23(10):5641. doi: 10.3390/ijms23105641.'
    supporting_text: '2022 May 18;23(10):5641. doi: 10.3390/ijms23105641.'
    evidence:
    - reference: PMID:35628451
      reference_title: Clinical and Genetic Characterization of Patients with Bartter and Gitelman Syndrome.
      supports: SUPPORT
      evidence_source: OTHER
      snippet: '2022 May 18;23(10):5641. doi: 10.3390/ijms23105641.'
      explanation: Deep research cited this publication as relevant literature for Bartter Syndrome.
- reference: PMID:35787602
  title: 'Diagnostic Challenge of Congenital Chloride Diarrhea and Ulcerative Colitis Overlap in an Adult Misdiagnosed with Bartter Syndrome: Case Report and Literature Review.'
  found_in:
  - Bartter_Syndrome-deep-research-openscientist.md
  findings:
  - statement: '2022 Jul 5;23:e936715. doi: 10.12659/AJCR.936715.'
    supporting_text: '2022 Jul 5;23:e936715. doi: 10.12659/AJCR.936715.'
    evidence:
    - reference: PMID:35787602
      reference_title: 'Diagnostic Challenge of Congenital Chloride Diarrhea and Ulcerative Colitis Overlap in an Adult Misdiagnosed with Bartter Syndrome: Case Report and Literature Review.'
      supports: SUPPORT
      evidence_source: OTHER
      snippet: '2022 Jul 5;23:e936715. doi: 10.12659/AJCR.936715.'
      explanation: Deep research cited this publication as relevant literature for Bartter Syndrome.
- reference: PMID:36882007
  title: 'Bartter Syndrome-Related Variants Distribution: Brazilian Data and Its Comparison with Worldwide Cohorts.'
  found_in:
  - Bartter_Syndrome-deep-research-openscientist.md
  findings:
  - statement: Genetic testing is recommended for accurate diagnosis of Bartter syndrome (BS) and serves as a basis for implementing specific target therapies.
    supporting_text: Genetic testing is recommended for accurate diagnosis of Bartter syndrome (BS) and serves as a basis for implementing specific target therapies.
    evidence:
    - reference: PMID:36882007
      reference_title: 'Bartter Syndrome-Related Variants Distribution: Brazilian Data and Its Comparison with Worldwide Cohorts.'
      supports: SUPPORT
      evidence_source: OTHER
      snippet: Genetic testing is recommended for accurate diagnosis of Bartter syndrome (BS) and serves as a basis for implementing specific target therapies.
      explanation: Deep research cited this publication as relevant literature for Bartter Syndrome.
- reference: PMID:37107186
  title: "Oxidants and Cardiorenal Vascular Remodeling-Insights from Rare Genetic Tubulopathies: Bartter's and Gitelman's Syndromes."
  found_in:
  - Bartter_Syndrome-deep-research-openscientist.md
  findings:
  - statement: '2023 Mar 26;12(4):811. doi: 10.3390/antiox12040811.'
    supporting_text: '2023 Mar 26;12(4):811. doi: 10.3390/antiox12040811.'
    evidence:
    - reference: PMID:37107186
      reference_title: "Oxidants and Cardiorenal Vascular Remodeling-Insights from Rare Genetic Tubulopathies: Bartter's and Gitelman's Syndromes."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: '2023 Mar 26;12(4):811. doi: 10.3390/antiox12040811.'
      explanation: Deep research cited this publication as relevant literature for Bartter Syndrome.
- reference: PMID:37477516
  title: 'Clinical and genetic characteristics of children with cystic fibrosis in Henan China: A single-center retrospective analysis.'
  found_in:
  - Bartter_Syndrome-deep-research-openscientist.md
  findings:
  - statement: Despite the growing awareness of cystic fibrosis (CF) in China, few cases have been reported in Henan, which is the most populous province in the country.
    supporting_text: Despite the growing awareness of cystic fibrosis (CF) in China, few cases have been reported in Henan, which is the most populous province in the country.
    evidence:
    - reference: PMID:37477516
      reference_title: 'Clinical and genetic characteristics of children with cystic fibrosis in Henan China: A single-center retrospective analysis.'
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: Despite the growing awareness of cystic fibrosis (CF) in China, few cases have been reported in Henan, which is the most populous province in the country.
      explanation: Deep research cited this publication as relevant literature for Bartter Syndrome.
- reference: PMID:37661676
  title: Pattern of hereditary renal tubular disorders in Egyptian children.
  found_in:
  - Bartter_Syndrome-deep-research-openscientist.md
  findings:
  - statement: Hereditary renal tubular disorders (HRTD) represent a group of genetic diseases characterized by disturbances in fluid, electrolyte, and acid-base homeostasis.
    supporting_text: Hereditary renal tubular disorders (HRTD) represent a group of genetic diseases characterized by disturbances in fluid, electrolyte, and acid-base homeostasis.
    evidence:
    - reference: PMID:37661676
      reference_title: Pattern of hereditary renal tubular disorders in Egyptian children.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: Hereditary renal tubular disorders (HRTD) represent a group of genetic diseases characterized by disturbances in fluid, electrolyte, and acid-base homeostasis.
      explanation: Deep research cited this publication as relevant literature for Bartter Syndrome.
- reference: PMID:38159268
  title: Successful antenatal treatment of MAGED2-related Bartter syndrome and review of treatment options and efficacy.
  found_in:
  - Bartter_Syndrome-deep-research-openscientist.md
  findings:
  - statement: '2024 Feb;44(2):172-179. doi: 10.1002/pd.6508.'
    supporting_text: '2024 Feb;44(2):172-179. doi: 10.1002/pd.6508.'
    evidence:
    - reference: PMID:38159268
      reference_title: Successful antenatal treatment of MAGED2-related Bartter syndrome and review of treatment options and efficacy.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: '2024 Feb;44(2):172-179. doi: 10.1002/pd.6508.'
      explanation: Deep research cited this publication as relevant literature for Bartter Syndrome.
- reference: PMID:38306007
  title: A case of pseudo-Bartter/Gitelman syndrome caused by long-term laxative abuse, leading to end-stage kidney disease.
  found_in:
  - Bartter_Syndrome-deep-research-openscientist.md
  findings:
  - statement: '2024 Oct;13(5):326-329. doi: 10.1007/s13730-024-00851-9.'
    supporting_text: '2024 Oct;13(5):326-329. doi: 10.1007/s13730-024-00851-9.'
    evidence:
    - reference: PMID:38306007
      reference_title: A case of pseudo-Bartter/Gitelman syndrome caused by long-term laxative abuse, leading to end-stage kidney disease.
      supports: SUPPORT
      evidence_source: OTHER
      snippet: '2024 Oct;13(5):326-329. doi: 10.1007/s13730-024-00851-9.'
      explanation: Deep research cited this publication as relevant literature for Bartter Syndrome.
- reference: PMID:38350705
  title: Bartter syndrome-like phenotype in a patient with type 2 diabetes mellitus.
  found_in:
  - Bartter_Syndrome-deep-research-openscientist.md
  findings:
  - statement: '2024 Feb 13;17(2):e257953. doi: 10.1136/bcr-2023-257953.'
    supporting_text: '2024 Feb 13;17(2):e257953. doi: 10.1136/bcr-2023-257953.'
    evidence:
    - reference: PMID:38350705
      reference_title: Bartter syndrome-like phenotype in a patient with type 2 diabetes mellitus.
      supports: SUPPORT
      evidence_source: OTHER
      snippet: '2024 Feb 13;17(2):e257953. doi: 10.1136/bcr-2023-257953.'
      explanation: Deep research cited this publication as relevant literature for Bartter Syndrome.
- reference: PMID:38913022
  title: 'Postnatal renal tubule development: roles of tubular flow and flux.'
  found_in:
  - Bartter_Syndrome-deep-research-openscientist.md
  findings:
  - statement: '2024 Sep 1;33(5):518-525. doi: 10.1097/MNH.0000000000001007.'
    supporting_text: '2024 Sep 1;33(5):518-525. doi: 10.1097/MNH.0000000000001007.'
    evidence:
    - reference: PMID:38913022
      reference_title: 'Postnatal renal tubule development: roles of tubular flow and flux.'
      supports: SUPPORT
      evidence_source: OTHER
      snippet: '2024 Sep 1;33(5):518-525. doi: 10.1097/MNH.0000000000001007.'
      explanation: Deep research cited this publication as relevant literature for Bartter Syndrome.
- reference: PMID:39036894
  title: 'X-linked transient antenatal Bartter syndrome related to MAGED2 gene: Enriching the phenotypic description and pathophysiologic investigation.'
  found_in:
  - Bartter_Syndrome-deep-research-openscientist.md
  findings:
  - statement: '2025 Feb;27(2):101217. doi: 10.1016/j.gim.2024.101217.'
    supporting_text: '2025 Feb;27(2):101217. doi: 10.1016/j.gim.2024.101217.'
    evidence:
    - reference: PMID:39036894
      reference_title: 'X-linked transient antenatal Bartter syndrome related to MAGED2 gene: Enriching the phenotypic description and pathophysiologic investigation.'
      supports: SUPPORT
      evidence_source: OTHER
      snippet: '2025 Feb;27(2):101217. doi: 10.1016/j.gim.2024.101217.'
      explanation: Deep research cited this publication as relevant literature for Bartter Syndrome.
- reference: PMID:39445629
  title: "Cardiovascular and arrhythmic manifestations of Bartter's and Gitelman's syndromes: do not forget the heart. A narrative literature review."
  found_in:
  - Bartter_Syndrome-deep-research-openscientist.md
  findings:
  - statement: '2025 Feb 1;43(2):191-200. doi: 10.1097/HJH.0000000000003910.'
    supporting_text: '2025 Feb 1;43(2):191-200. doi: 10.1097/HJH.0000000000003910.'
    evidence:
    - reference: PMID:39445629
      reference_title: "Cardiovascular and arrhythmic manifestations of Bartter's and Gitelman's syndromes: do not forget the heart. A narrative literature review."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: '2025 Feb 1;43(2):191-200. doi: 10.1097/HJH.0000000000003910.'
      explanation: Deep research cited this publication as relevant literature for Bartter Syndrome.
- reference: PMID:39862309
  title: 'Etiology, clinical characteristics, genetic profile, and outcomes of children with refractory rickets at a referral center in India: a cohort study.'
  found_in:
  - Bartter_Syndrome-deep-research-openscientist.md
  findings:
  - statement: Limited research exists regarding the genetic profile, clinical characteristics, and outcomes of refractory rickets in children from India.
    supporting_text: Limited research exists regarding the genetic profile, clinical characteristics, and outcomes of refractory rickets in children from India.
    evidence:
    - reference: PMID:39862309
      reference_title: 'Etiology, clinical characteristics, genetic profile, and outcomes of children with refractory rickets at a referral center in India: a cohort study.'
      supports: SUPPORT
      evidence_source: OTHER
      snippet: Limited research exists regarding the genetic profile, clinical characteristics, and outcomes of refractory rickets in children from India.
      explanation: Deep research cited this publication as relevant literature for Bartter Syndrome.
- reference: PMID:40262923
  title: Rare co-occurrence of severe vitamin A deficiency in an early adolescent girl with Bartter syndrome.
  found_in:
  - Bartter_Syndrome-deep-research-openscientist.md
  findings:
  - statement: '2025 Apr 22;18(4):e265159. doi: 10.1136/bcr-2025-265159.'
    supporting_text: '2025 Apr 22;18(4):e265159. doi: 10.1136/bcr-2025-265159.'
    evidence:
    - reference: PMID:40262923
      reference_title: Rare co-occurrence of severe vitamin A deficiency in an early adolescent girl with Bartter syndrome.
      supports: SUPPORT
      evidence_source: OTHER
      snippet: '2025 Apr 22;18(4):e265159. doi: 10.1136/bcr-2025-265159.'
      explanation: Deep research cited this publication as relevant literature for Bartter Syndrome.
- reference: PMID:41427162
  title: 'When teeth and kidneys fail together: a case series of amelogenesis imperfecta-renal syndromes in childhood.'
  found_in:
  - Bartter_Syndrome-deep-research-openscientist.md
  findings:
  - statement: '2025 Oct 1;52:51. doi: 10.11604/pamj.2025.52.51.48681. eCollection 2025.'
    supporting_text: '2025 Oct 1;52:51. doi: 10.11604/pamj.2025.52.51.48681. eCollection 2025.'
    evidence:
    - reference: PMID:41427162
      reference_title: 'When teeth and kidneys fail together: a case series of amelogenesis imperfecta-renal syndromes in childhood.'
      supports: SUPPORT
      evidence_source: OTHER
      snippet: '2025 Oct 1;52:51. doi: 10.11604/pamj.2025.52.51.48681. eCollection 2025.'
      explanation: Deep research cited this publication as relevant literature for Bartter Syndrome.
- reference: PMID:42042082
  title: 'Molecular Genetics of Bartter Syndrome: Bridging Genotype-Phenotype Correlations and Precision Therapeutics.'
  found_in:
  - Bartter_Syndrome-deep-research-openscientist.md
  findings:
  - statement: '2026 Apr 19;48(4):422. doi: 10.3390/cimb48040422.'
    supporting_text: '2026 Apr 19;48(4):422. doi: 10.3390/cimb48040422.'
    evidence:
    - reference: PMID:42042082
      reference_title: 'Molecular Genetics of Bartter Syndrome: Bridging Genotype-Phenotype Correlations and Precision Therapeutics.'
      supports: SUPPORT
      evidence_source: OTHER
      snippet: '2026 Apr 19;48(4):422. doi: 10.3390/cimb48040422.'
      explanation: Deep research cited this publication as relevant literature for Bartter Syndrome.
📚

References & Deep Research

References

55
DOI:10.1016/j.bbrc.2013.10.129
Treatment with 17-allylamino-17-demethoxygeldanamycin ameliorated symptoms of Bartter syndrome type IV caused by mutated Bsnd in mice
1 finding
Treatment with 17-allylamino-17-demethoxygeldanamycin ameliorated symptoms of Bartter syndrome type IV caused by mutated Bsnd in mice
"Treatment with 17-allylamino-17-demethoxygeldanamycin ameliorated symptoms of Bartter syndrome type IV caused by mutated Bsnd in mice"
DOI:10.1152/ajprenal.00522.2009
Mutation of the Na<sup>+</sup>-K<sup>+</sup>-2Cl<sup>−</sup>cotransporter NKCC2 in mice is associated with severe polyuria and a urea-selective concentrating defect without hyperreninemia
1 finding
The bumetanide-sensitive Na+-K+-2Cl−cotransporter NKCC2, located in the thick ascending limb of Henle's loop, plays a critical role in the kidney's ability to concentrate urine.
"The bumetanide-sensitive Na+-K+-2Cl−cotransporter NKCC2, located in the thick ascending limb of Henle's loop, plays a critical role in the kidney's ability to concentrate urine."
Show evidence (1 reference)
DOI:10.1152/ajprenal.00522.2009 SUPPORT Model Organism
"The bumetanide-sensitive Na+-K+-2Cl−cotransporter NKCC2, located in the thick ascending limb of Henle's loop, plays a critical role in the kidney's ability to concentrate urine."
Deep research cited this publication as relevant literature for Bartter Syndrome.
DOI:10.1186/s12864-016-3035-1
A missense mutation in solute carrier family 12, member 1 (SLC12A1) causes hydrallantois in Japanese Black cattle
1 finding
A missense mutation in solute carrier family 12, member 1 (SLC12A1) causes hydrallantois in Japanese Black cattle
"A missense mutation in solute carrier family 12, member 1 (SLC12A1) causes hydrallantois in Japanese Black cattle"
DOI:10.1186/s12920-024-01797-8
Identification of a novel intronic mutation of MAGED2 gene in a Chinese family with antenatal Bartter syndrome
1 finding
Antenatal Bartter syndrome is a life-threatening disease caused by a mutation in the MAGED2 gene located on chromosome Xp11.
"Antenatal Bartter syndrome is a life-threatening disease caused by a mutation in the MAGED2 gene located on chromosome Xp11."
Show evidence (1 reference)
DOI:10.1186/s12920-024-01797-8 SUPPORT Other
"Antenatal Bartter syndrome is a life-threatening disease caused by a mutation in the MAGED2 gene located on chromosome Xp11."
Deep research cited this publication as relevant literature for Bartter Syndrome.
DOI:10.1186/s12929-014-0068-0
Standardized, systemic phenotypic analysis of Slc12a1 I299F mutant mice
1 finding
Standardized, systemic phenotypic analysis of Slc12a1 I299F mutant mice
"Standardized, systemic phenotypic analysis of Slc12a1 I299F mutant mice"
DOI:10.1507/endocrj.ej23-0631
Adult classic Bartter syndrome: a case report with 5-year follow-up and literature review
1 finding
Adult classic Bartter syndrome: a case report with 5-year follow-up and literature review
"Adult classic Bartter syndrome: a case report with 5-year follow-up and literature review"
DOI:10.20944/preprints202407.1238.v1
Sodium Deficiency Diseases: The Association With the Renin-Angiotensin-Aldosterone System, Aging and Inflammation
1 finding
Every individual at some point encounters the progressive biological process of aging which is considered one of the major risk factors for common diseases.
"Every individual at some point encounters the progressive biological process of aging which is considered one of the major risk factors for common diseases."
Show evidence (1 reference)
DOI:10.20944/preprints202407.1238.v1 SUPPORT Human Clinical
"Every individual at some point encounters the progressive biological process of aging which is considered one of the major risk factors for common diseases."
Deep research cited this publication as relevant literature for Bartter Syndrome.
DOI:10.3389/fmed.2023.1099840
Long-term outcome of Bartter syndrome in 54 patients: A multicenter study in Korea
1 finding
Bartter syndrome (BS) is a rare salt-wasting tubulopathy caused by mutations in genes encoding sodium, potassium, or chloride transporters of the thick ascending limb of the loop of Henle and/or the distal convoluted tubule of the kidney.
"Bartter syndrome (BS) is a rare salt-wasting tubulopathy caused by mutations in genes encoding sodium, potassium, or chloride transporters of the thick ascending limb of the loop of Henle and/or the distal convoluted tubule of the kidney."
Show evidence (1 reference)
DOI:10.3389/fmed.2023.1099840 SUPPORT Human Clinical
"Bartter syndrome (BS) is a rare salt-wasting tubulopathy caused by mutations in genes encoding sodium, potassium, or chloride transporters of the thick ascending limb of the loop of Henle and/or the distal convoluted tubule of the kidney."
Deep research cited this publication as relevant literature for Bartter Syndrome.
DOI:10.3389/fped.2023.1034923
A mosaic mutation in the CLCNKB gene causing Bartter syndrome: A case report
1 finding
Type III Bartter syndrome (BS) is an autosomal recessive disease caused by mutations in the CLCNKB (chloride voltage-gated channel Kb) gene that encodes CLC-Kb.
"Type III Bartter syndrome (BS) is an autosomal recessive disease caused by mutations in the CLCNKB (chloride voltage-gated channel Kb) gene that encodes CLC-Kb."
Show evidence (1 reference)
DOI:10.3389/fped.2023.1034923 SUPPORT Human Clinical
"Type III Bartter syndrome (BS) is an autosomal recessive disease caused by mutations in the CLCNKB (chloride voltage-gated channel Kb) gene that encodes CLC-Kb."
Deep research cited this publication as relevant literature for Bartter Syndrome.
DOI:10.3390/cells13100818
Protein Quality Control of NKCC2 in Bartter Syndrome and Blood Pressure Regulation
1 finding
Mutations in NKCC2 generate antenatal Bartter syndrome type 1 (type 1 BS), a life-threatening salt-losing nephropathy characterized by arterial hypotension, as well as electrolyte abnormalities.
"Mutations in NKCC2 generate antenatal Bartter syndrome type 1 (type 1 BS), a life-threatening salt-losing nephropathy characterized by arterial hypotension, as well as electrolyte abnormalities."
Show evidence (1 reference)
DOI:10.3390/cells13100818 SUPPORT Human Clinical
"Mutations in NKCC2 generate antenatal Bartter syndrome type 1 (type 1 BS), a life-threatening salt-losing nephropathy characterized by arterial hypotension, as well as electrolyte abnormalities."
Deep research cited this publication as relevant literature for Bartter Syndrome.
PMID:38786040
Protein Quality Control of NKCC2 in Bartter Syndrome and Blood Pressure Regulation.
1 finding
ER export appears to be a rate-limiting step in NKCC2 maturation and trafficking to the plasma membrane.
"Similar to several transmembrane proteins, export from the ER appears to be the rate-limiting step in the cotransporter's maturation and trafficking to the plasma membrane."
Show evidence (1 reference)
PMID:38786040 SUPPORT Other
"Similar to several transmembrane proteins, export from the ER appears to be the rate-limiting step in the cotransporter's maturation and trafficking to the plasma membrane."
Deep research cited this publication as relevant literature for Bartter Syndrome.
DOI:10.3390/genes17040424
Identification of Three Novel MAGED2 Variants Causing Antenatal Bartter Syndrome in Three Chinese Families
1 finding
We aimed to report three novel MAGED2 variants associated with transient antenatal Bartter syndrome (TABS) and to summarize the prenatal and postnatal features of MAGED2-related TABS through case analysis and literature review.
"We aimed to report three novel MAGED2 variants associated with transient antenatal Bartter syndrome (TABS) and to summarize the prenatal and postnatal features of MAGED2-related TABS through case analysis and literature review."
Show evidence (1 reference)
DOI:10.3390/genes17040424 SUPPORT Human Clinical
"We aimed to report three novel MAGED2 variants associated with transient antenatal Bartter syndrome (TABS) and to summarize the prenatal and postnatal features of MAGED2-related TABS through case analysis and literature review."
Deep research cited this publication as relevant literature for Bartter Syndrome.
DOI:10.3390/ijms25179332
Untangling the Uncertain Role of Overactivation of the Renin–Angiotensin–Aldosterone System with the Aging Process Based on Sodium Wasting Human Models
1 finding
Every individual at some point encounters the progressive biological process of aging, which is considered one of the major risk factors for common diseases.
"Every individual at some point encounters the progressive biological process of aging, which is considered one of the major risk factors for common diseases."
Show evidence (1 reference)
DOI:10.3390/ijms25179332 SUPPORT Human Clinical
"Every individual at some point encounters the progressive biological process of aging, which is considered one of the major risk factors for common diseases."
Deep research cited this publication as relevant literature for Bartter Syndrome.
DOI:10.3390/medicina59091638
Bartter Syndrome: A Systematic Review of Case Reports and Case Series
1 finding
Bartter syndrome (BS) is a rare group of autosomal-recessive disorders that usually presents with hypokalemic metabolic alkalosis, occasionally with hyponatremia and hypochloremia.
"Bartter syndrome (BS) is a rare group of autosomal-recessive disorders that usually presents with hypokalemic metabolic alkalosis, occasionally with hyponatremia and hypochloremia."
Show evidence (1 reference)
DOI:10.3390/medicina59091638 SUPPORT Other
"Bartter syndrome (BS) is a rare group of autosomal-recessive disorders that usually presents with hypokalemic metabolic alkalosis, occasionally with hyponatremia and hypochloremia."
Deep research cited this publication as relevant literature for Bartter Syndrome.
DOI:10.7759/cureus.36120
A Rare Presentation of Adult-Onset Bartter Syndrome: A Case Report
1 finding
A Rare Presentation of Adult-Onset Bartter Syndrome: A Case Report
"A Rare Presentation of Adult-Onset Bartter Syndrome: A Case Report"
DOI:10.7759/cureus.72406
Bartter Syndrome With Recurrent Hypokalemic Periodic Paralysis: A Case Report
1 finding
Bartter Syndrome With Recurrent Hypokalemic Periodic Paralysis: A Case Report
"Bartter Syndrome With Recurrent Hypokalemic Periodic Paralysis: A Case Report"
PMID:10779555
Uncompensated polyuria in a mouse model of Bartter's syndrome.
1 finding
2000 May 9;97(10):5434-9. doi: 10.1073/pnas.090091297.
"2000 May 9;97(10):5434-9. doi: 10.1073/pnas.090091297."
Show evidence (1 reference)
PMID:10779555 SUPPORT Model Organism
"2000 May 9;97(10):5434-9. doi: 10.1073/pnas.090091297."
Deep research cited this publication as relevant literature for Bartter Syndrome.
PMID:11115075
Cyclooxygenase-2 expression is associated with the renal macula densa of patients with Bartter-like syndrome.
1 finding
Bartter-like syndrome (BLS) is a heterogeneous set of congenital tubular disorders that is associated with significant renal salt and water loss.
"Bartter-like syndrome (BLS) is a heterogeneous set of congenital tubular disorders that is associated with significant renal salt and water loss."
Show evidence (1 reference)
PMID:11115075 SUPPORT Human Clinical
"Bartter-like syndrome (BLS) is a heterogeneous set of congenital tubular disorders that is associated with significant renal salt and water loss."
Deep research cited this publication as relevant literature for Bartter Syndrome.
PMID:12081585
Role of cyclooxygenase-2 in hyperprostaglandin E syndrome/antenatal Bartter syndrome.
1 finding
Hyperprostaglandin E syndrome/antenatal Bartter syndrome (HPS/aBS) is a congenital salt-losing tubulopathy with an induced expression of cyclooxygenase-2 (COX-2) in the macula densa probably leading to hyperreninemia.
"Hyperprostaglandin E syndrome/antenatal Bartter syndrome (HPS/aBS) is a congenital salt-losing tubulopathy with an induced expression of cyclooxygenase-2 (COX-2) in the macula densa probably leading to hyperreninemia."
Show evidence (1 reference)
PMID:12081585 SUPPORT Human Clinical
"Hyperprostaglandin E syndrome/antenatal Bartter syndrome (HPS/aBS) is a congenital salt-losing tubulopathy with an induced expression of cyclooxygenase-2 (COX-2) in the macula densa probably leading to hyperreninemia."
Deep research cited this publication as relevant literature for Bartter Syndrome.
PMID:12122007
Impaired renal NaCl absorption in mice lacking the ROMK potassium channel, a model for type II Bartter's syndrome.
1 finding
2002 Oct 4;277(40):37871-80. doi: 10.1074/jbc.M205627200.
"2002 Oct 4;277(40):37871-80. doi: 10.1074/jbc.M205627200."
Show evidence (1 reference)
PMID:12122007 SUPPORT Model Organism
"2002 Oct 4;277(40):37871-80. doi: 10.1074/jbc.M205627200."
Deep research cited this publication as relevant literature for Bartter Syndrome.
PMID:12749662
Successful management of an extreme example of neonatal hyperprostaglandin-E syndrome (Bartter's syndrome) with the new cyclooxygenase-2 inhibitor rofecoxib.
1 finding
2003 Apr;4(2):249-51. doi: 10.1097/01.PCC.0000059422.26706.64.
"2003 Apr;4(2):249-51. doi: 10.1097/01.PCC.0000059422.26706.64."
Show evidence (1 reference)
PMID:12749662 SUPPORT Human Clinical
"2003 Apr;4(2):249-51. doi: 10.1097/01.PCC.0000059422.26706.64."
Deep research cited this publication as relevant literature for Bartter Syndrome.
PMID:1340758
Calcium homeostasis and hypercalciuria in hyperprostaglandin E syndrome.
1 finding
1992 Apr;120(4 Pt 1):546-54. doi: 10.1016/s0022-3476(05)82480-1.
"1992 Apr;120(4 Pt 1):546-54. doi: 10.1016/s0022-3476(05)82480-1."
Show evidence (1 reference)
PMID:1340758 SUPPORT Human Clinical
"1992 Apr;120(4 Pt 1):546-54. doi: 10.1016/s0022-3476(05)82480-1."
Deep research cited this publication as relevant literature for Bartter Syndrome.
PMID:16231363
"End-stage kidney" in longstanding bulimia nervosa.
1 finding
2005 Dec;38(4):383-5. doi: 10.1002/eat.20198. "End-stage kidney" in longstanding bulimia nervosa.
"2005 Dec;38(4):383-5. doi: 10.1002/eat.20198. "End-stage kidney" in longstanding bulimia nervosa."
Show evidence (1 reference)
PMID:16231363 SUPPORT Human Clinical
"2005 Dec;38(4):383-5. doi: 10.1002/eat.20198. "End-stage kidney" in longstanding bulimia nervosa."
Deep research cited this publication as relevant literature for Bartter Syndrome.
PMID:16583241
Type IV Bartter syndrome: report of two new cases.
1 finding
2006 Jun;21(6):766-70. doi: 10.1007/s00467-006-0090-x.
"2006 Jun;21(6):766-70. doi: 10.1007/s00467-006-0090-x."
Show evidence (1 reference)
PMID:16583241 SUPPORT Human Clinical
"2006 Jun;21(6):766-70. doi: 10.1007/s00467-006-0090-x."
Deep research cited this publication as relevant literature for Bartter Syndrome.
PMID:18310267
Molecular analysis of digenic inheritance in Bartter syndrome with sensorineural deafness.
1 finding
Bartter syndrome (BS) is a genetic disorder accompanied by hypokalaemic metabolic alkalosis.
"Bartter syndrome (BS) is a genetic disorder accompanied by hypokalaemic metabolic alkalosis."
Show evidence (1 reference)
PMID:18310267 SUPPORT Human Clinical
"Bartter syndrome (BS) is a genetic disorder accompanied by hypokalaemic metabolic alkalosis."
Deep research cited this publication as relevant literature for Bartter Syndrome.
PMID:1887027
Hyperechoic renal medullary pyramids in infants and children.
1 finding
1991 Oct;181(1):163-7. doi: 10.1148/radiology.181.1.1887027.
"1991 Oct;181(1):163-7. doi: 10.1148/radiology.181.1.1887027."
Show evidence (1 reference)
PMID:1887027 SUPPORT Human Clinical
"1991 Oct;181(1):163-7. doi: 10.1148/radiology.181.1.1887027."
Deep research cited this publication as relevant literature for Bartter Syndrome.
PMID:21865213
Genetic basis of Bartter syndrome in Korea.
1 finding
Genetic basis of Bartter syndrome in Korea
"Bartter syndrome (BS) is clinically classified into antenatal or neonatal BS (aBS) and classic BS (cBS) as well as five subtypes based on the underlying mutant gene; SLC12A1 (BS I), KCNJ1 (BS II), CLCNKB (BS III), BSND (BS IV) and CASR (BS V)."
Show evidence (1 reference)
PMID:21865213 SUPPORT Human Clinical
"Bartter syndrome (BS) is clinically classified into antenatal or neonatal BS (aBS) and classic BS (cBS) as well as five subtypes based on the underlying mutant gene; SLC12A1 (BS I), KCNJ1 (BS II), CLCNKB (BS III), BSND (BS IV) and CASR (BS V)."
Deep research cited this publication as relevant literature for Bartter Syndrome.
PMID:24039833
SPAK deficiency corrects pseudohypoaldosteronism II caused by WNK4 mutation.
1 finding
2013 Sep 11;8(9):e72969. doi: 10.1371/journal.pone.0072969. eCollection 2013.
"2013 Sep 11;8(9):e72969. doi: 10.1371/journal.pone.0072969. eCollection 2013."
Show evidence (1 reference)
PMID:24039833 SUPPORT Other
"2013 Sep 11;8(9):e72969. doi: 10.1371/journal.pone.0072969. eCollection 2013."
Deep research cited this publication as relevant literature for Bartter Syndrome.
PMID:2671327
Hypercalciuria with Bartter syndrome: evidence for an abnormality of vitamin D metabolism.
1 finding
1989 Sep;115(3):397-404. doi: 10.1016/s0022-3476(89)80838-8.
"1989 Sep;115(3):397-404. doi: 10.1016/s0022-3476(89)80838-8."
Show evidence (1 reference)
PMID:2671327 SUPPORT Human Clinical
"1989 Sep;115(3):397-404. doi: 10.1016/s0022-3476(89)80838-8."
Deep research cited this publication as relevant literature for Bartter Syndrome.
PMID:26857709
Accentuated hyperparathyroidism in type II Bartter syndrome.
1 finding
Bartter syndrome (BS) may be associated with different degrees of hypercalciuria, but marked parathyroid hormone (PTH) abnormalities have not been described.
"Bartter syndrome (BS) may be associated with different degrees of hypercalciuria, but marked parathyroid hormone (PTH) abnormalities have not been described."
Show evidence (1 reference)
PMID:26857709 SUPPORT Human Clinical
"Bartter syndrome (BS) may be associated with different degrees of hypercalciuria, but marked parathyroid hormone (PTH) abnormalities have not been described."
Deep research cited this publication as relevant literature for Bartter Syndrome.
PMID:27068441
SPAK and OSR1 play essential roles in potassium homeostasis through actions on the distal convoluted tubule.
1 finding
2016 Sep 1;594(17):4945-66. doi: 10.1113/JP272311.
"2016 Sep 1;594(17):4945-66. doi: 10.1113/JP272311."
Show evidence (1 reference)
PMID:27068441 SUPPORT Model Organism
"2016 Sep 1;594(17):4945-66. doi: 10.1113/JP272311."
Deep research cited this publication as relevant literature for Bartter Syndrome.
PMID:27120771
Polyhydramnios, Transient Antenatal Bartter's Syndrome, and MAGED2 Mutations.
1 finding
Three pregnancies with male offspring in one family were complicated by severe polyhydramnios and prematurity.
"Three pregnancies with male offspring in one family were complicated by severe polyhydramnios and prematurity."
Show evidence (1 reference)
PMID:27120771 SUPPORT Human Clinical
"Three pregnancies with male offspring in one family were complicated by severe polyhydramnios and prematurity."
Deep research cited this publication as relevant literature for Bartter Syndrome.
PMID:28012523
Digenic mutations involving both the BSND and GJB2 genes detected in Bartter syndrome type IV.
1 finding
2017 Jan;92:17-20. doi: 10.1016/j.ijporl.2016.10.028.
"2017 Jan;92:17-20. doi: 10.1016/j.ijporl.2016.10.028."
Show evidence (1 reference)
PMID:28012523 SUPPORT Human Clinical
"2017 Jan;92:17-20. doi: 10.1016/j.ijporl.2016.10.028."
Deep research cited this publication as relevant literature for Bartter Syndrome.
PMID:28095294
A novel SLC12A1 gene mutation associated with hyperparathyroidism, hypercalcemia, nephrogenic diabetes insipidus, and nephrocalcinosis in four patients.
1 finding
2017 Apr;97:121-125. doi: 10.1016/j.bone.2017.01.011.
"2017 Apr;97:121-125. doi: 10.1016/j.bone.2017.01.011."
Show evidence (1 reference)
PMID:28095294 SUPPORT Human Clinical
"2017 Apr;97:121-125. doi: 10.1016/j.bone.2017.01.011."
Deep research cited this publication as relevant literature for Bartter Syndrome.
PMID:29092859
Urinary bladder hypertrophy characteristic of male ROMK Bartter's mice does not occur in female mice.
1 finding
2018 Mar 1;314(3):R334-R341. doi: 10.1152/ajpregu.00315.2017.
"2018 Mar 1;314(3):R334-R341. doi: 10.1152/ajpregu.00315.2017."
Show evidence (1 reference)
PMID:29092859 SUPPORT Model Organism
"2018 Mar 1;314(3):R334-R341. doi: 10.1152/ajpregu.00315.2017."
Deep research cited this publication as relevant literature for Bartter Syndrome.
PMID:30174009
Two novel homozygous missense mutations identified in the BSND gene in Moroccan patients with Bartter's syndrome.
1 finding
2018 Oct;113:46-50. doi: 10.1016/j.ijporl.2018.07.010.
"2018 Oct;113:46-50. doi: 10.1016/j.ijporl.2018.07.010."
Show evidence (1 reference)
PMID:30174009 SUPPORT Human Clinical
"2018 Oct;113:46-50. doi: 10.1016/j.ijporl.2018.07.010."
Deep research cited this publication as relevant literature for Bartter Syndrome.
PMID:32184353
DHHC7-mediated palmitoylation of the accessory protein barttin critically regulates the functions of ClC-K chloride channels.
1 finding
2020 May 1;295(18):5970-5983. doi: 10.1074/jbc.RA119.011049.
"2020 May 1;295(18):5970-5983. doi: 10.1074/jbc.RA119.011049."
Show evidence (1 reference)
PMID:32184353 SUPPORT Other
"2020 May 1;295(18):5970-5983. doi: 10.1074/jbc.RA119.011049."
Deep research cited this publication as relevant literature for Bartter Syndrome.
PMID:33058840
Eight novel KCNJ1 variants and parathyroid hormone overaction or resistance in 5 probands with Bartter syndrome type 2.
1 finding
2020 Dec;511:248-254. doi: 10.1016/j.cca.2020.10.002.
"2020 Dec;511:248-254. doi: 10.1016/j.cca.2020.10.002."
Show evidence (1 reference)
PMID:33058840 SUPPORT Human Clinical
"2020 Dec;511:248-254. doi: 10.1016/j.cca.2020.10.002."
Deep research cited this publication as relevant literature for Bartter Syndrome.
PMID:34895150
A novel MAGED2 variant in a Chinese preterm newborn with transient antenatal Bartter's syndrome with 4 years follow-up.
1 finding
Transient antenatal Bartter's syndrome caused by MAGED2 mutation is a rare X-linked recessive renal tubular disorder.
"Transient antenatal Bartter's syndrome caused by MAGED2 mutation is a rare X-linked recessive renal tubular disorder."
Show evidence (1 reference)
PMID:34895150 SUPPORT Other
"Transient antenatal Bartter's syndrome caused by MAGED2 mutation is a rare X-linked recessive renal tubular disorder."
Deep research cited this publication as relevant literature for Bartter Syndrome.
PMID:35628451
Clinical and Genetic Characterization of Patients with Bartter and Gitelman Syndrome.
1 finding
2022 May 18;23(10):5641. doi: 10.3390/ijms23105641.
"2022 May 18;23(10):5641. doi: 10.3390/ijms23105641."
Show evidence (1 reference)
PMID:35628451 SUPPORT Other
"2022 May 18;23(10):5641. doi: 10.3390/ijms23105641."
Deep research cited this publication as relevant literature for Bartter Syndrome.
PMID:35787602
Diagnostic Challenge of Congenital Chloride Diarrhea and Ulcerative Colitis Overlap in an Adult Misdiagnosed with Bartter Syndrome: Case Report and Literature Review.
1 finding
2022 Jul 5;23:e936715. doi: 10.12659/AJCR.936715.
"2022 Jul 5;23:e936715. doi: 10.12659/AJCR.936715."
Show evidence (1 reference)
PMID:35787602 SUPPORT Other
"2022 Jul 5;23:e936715. doi: 10.12659/AJCR.936715."
Deep research cited this publication as relevant literature for Bartter Syndrome.
PMID:36882007
Bartter Syndrome-Related Variants Distribution: Brazilian Data and Its Comparison with Worldwide Cohorts.
1 finding
Genetic testing is recommended for accurate diagnosis of Bartter syndrome (BS) and serves as a basis for implementing specific target therapies.
"Genetic testing is recommended for accurate diagnosis of Bartter syndrome (BS) and serves as a basis for implementing specific target therapies."
Show evidence (1 reference)
PMID:36882007 SUPPORT Other
"Genetic testing is recommended for accurate diagnosis of Bartter syndrome (BS) and serves as a basis for implementing specific target therapies."
Deep research cited this publication as relevant literature for Bartter Syndrome.
PMID:37107186
Oxidants and Cardiorenal Vascular Remodeling-Insights from Rare Genetic Tubulopathies: Bartter's and Gitelman's Syndromes.
1 finding
2023 Mar 26;12(4):811. doi: 10.3390/antiox12040811.
"2023 Mar 26;12(4):811. doi: 10.3390/antiox12040811."
Show evidence (1 reference)
PMID:37107186 SUPPORT Other
"2023 Mar 26;12(4):811. doi: 10.3390/antiox12040811."
Deep research cited this publication as relevant literature for Bartter Syndrome.
PMID:37477516
Clinical and genetic characteristics of children with cystic fibrosis in Henan China: A single-center retrospective analysis.
1 finding
Despite the growing awareness of cystic fibrosis (CF) in China, few cases have been reported in Henan, which is the most populous province in the country.
"Despite the growing awareness of cystic fibrosis (CF) in China, few cases have been reported in Henan, which is the most populous province in the country."
Show evidence (1 reference)
PMID:37477516 SUPPORT Human Clinical
"Despite the growing awareness of cystic fibrosis (CF) in China, few cases have been reported in Henan, which is the most populous province in the country."
Deep research cited this publication as relevant literature for Bartter Syndrome.
PMID:37661676
Pattern of hereditary renal tubular disorders in Egyptian children.
1 finding
Hereditary renal tubular disorders (HRTD) represent a group of genetic diseases characterized by disturbances in fluid, electrolyte, and acid-base homeostasis.
"Hereditary renal tubular disorders (HRTD) represent a group of genetic diseases characterized by disturbances in fluid, electrolyte, and acid-base homeostasis."
Show evidence (1 reference)
PMID:37661676 SUPPORT Human Clinical
"Hereditary renal tubular disorders (HRTD) represent a group of genetic diseases characterized by disturbances in fluid, electrolyte, and acid-base homeostasis."
Deep research cited this publication as relevant literature for Bartter Syndrome.
PMID:38159268
Successful antenatal treatment of MAGED2-related Bartter syndrome and review of treatment options and efficacy.
1 finding
2024 Feb;44(2):172-179. doi: 10.1002/pd.6508.
"2024 Feb;44(2):172-179. doi: 10.1002/pd.6508."
Show evidence (1 reference)
PMID:38159268 SUPPORT Human Clinical
"2024 Feb;44(2):172-179. doi: 10.1002/pd.6508."
Deep research cited this publication as relevant literature for Bartter Syndrome.
PMID:38306007
A case of pseudo-Bartter/Gitelman syndrome caused by long-term laxative abuse, leading to end-stage kidney disease.
1 finding
2024 Oct;13(5):326-329. doi: 10.1007/s13730-024-00851-9.
"2024 Oct;13(5):326-329. doi: 10.1007/s13730-024-00851-9."
Show evidence (1 reference)
PMID:38306007 SUPPORT Other
"2024 Oct;13(5):326-329. doi: 10.1007/s13730-024-00851-9."
Deep research cited this publication as relevant literature for Bartter Syndrome.
PMID:38350705
Bartter syndrome-like phenotype in a patient with type 2 diabetes mellitus.
1 finding
2024 Feb 13;17(2):e257953. doi: 10.1136/bcr-2023-257953.
"2024 Feb 13;17(2):e257953. doi: 10.1136/bcr-2023-257953."
Show evidence (1 reference)
PMID:38350705 SUPPORT Other
"2024 Feb 13;17(2):e257953. doi: 10.1136/bcr-2023-257953."
Deep research cited this publication as relevant literature for Bartter Syndrome.
PMID:38913022
Postnatal renal tubule development: roles of tubular flow and flux.
1 finding
2024 Sep 1;33(5):518-525. doi: 10.1097/MNH.0000000000001007.
"2024 Sep 1;33(5):518-525. doi: 10.1097/MNH.0000000000001007."
Show evidence (1 reference)
PMID:38913022 SUPPORT Other
"2024 Sep 1;33(5):518-525. doi: 10.1097/MNH.0000000000001007."
Deep research cited this publication as relevant literature for Bartter Syndrome.
PMID:39036894
X-linked transient antenatal Bartter syndrome related to MAGED2 gene: Enriching the phenotypic description and pathophysiologic investigation.
1 finding
2025 Feb;27(2):101217. doi: 10.1016/j.gim.2024.101217.
"2025 Feb;27(2):101217. doi: 10.1016/j.gim.2024.101217."
Show evidence (1 reference)
PMID:39036894 SUPPORT Other
"2025 Feb;27(2):101217. doi: 10.1016/j.gim.2024.101217."
Deep research cited this publication as relevant literature for Bartter Syndrome.
PMID:39445629
Cardiovascular and arrhythmic manifestations of Bartter's and Gitelman's syndromes: do not forget the heart. A narrative literature review.
1 finding
2025 Feb 1;43(2):191-200. doi: 10.1097/HJH.0000000000003910.
"2025 Feb 1;43(2):191-200. doi: 10.1097/HJH.0000000000003910."
Show evidence (1 reference)
PMID:39445629 SUPPORT Human Clinical
"2025 Feb 1;43(2):191-200. doi: 10.1097/HJH.0000000000003910."
Deep research cited this publication as relevant literature for Bartter Syndrome.
PMID:39862309
Etiology, clinical characteristics, genetic profile, and outcomes of children with refractory rickets at a referral center in India: a cohort study.
1 finding
Limited research exists regarding the genetic profile, clinical characteristics, and outcomes of refractory rickets in children from India.
"Limited research exists regarding the genetic profile, clinical characteristics, and outcomes of refractory rickets in children from India."
Show evidence (1 reference)
PMID:39862309 SUPPORT Other
"Limited research exists regarding the genetic profile, clinical characteristics, and outcomes of refractory rickets in children from India."
Deep research cited this publication as relevant literature for Bartter Syndrome.
PMID:40262923
Rare co-occurrence of severe vitamin A deficiency in an early adolescent girl with Bartter syndrome.
1 finding
2025 Apr 22;18(4):e265159. doi: 10.1136/bcr-2025-265159.
"2025 Apr 22;18(4):e265159. doi: 10.1136/bcr-2025-265159."
Show evidence (1 reference)
PMID:40262923 SUPPORT Other
"2025 Apr 22;18(4):e265159. doi: 10.1136/bcr-2025-265159."
Deep research cited this publication as relevant literature for Bartter Syndrome.
PMID:41427162
When teeth and kidneys fail together: a case series of amelogenesis imperfecta-renal syndromes in childhood.
1 finding
2025 Oct 1;52:51. doi: 10.11604/pamj.2025.52.51.48681. eCollection 2025.
"2025 Oct 1;52:51. doi: 10.11604/pamj.2025.52.51.48681. eCollection 2025."
Show evidence (1 reference)
PMID:41427162 SUPPORT Other
"2025 Oct 1;52:51. doi: 10.11604/pamj.2025.52.51.48681. eCollection 2025."
Deep research cited this publication as relevant literature for Bartter Syndrome.
PMID:42042082
Molecular Genetics of Bartter Syndrome: Bridging Genotype-Phenotype Correlations and Precision Therapeutics.
1 finding
2026 Apr 19;48(4):422. doi: 10.3390/cimb48040422.
"2026 Apr 19;48(4):422. doi: 10.3390/cimb48040422."
Show evidence (1 reference)
PMID:42042082 SUPPORT Other
"2026 Apr 19;48(4):422. doi: 10.3390/cimb48040422."
Deep research cited this publication as relevant literature for Bartter Syndrome.

Deep Research

2
Falcon ▸
Disease Characteristics Research Template
Edison Scientific Literature 51 citations 2026-04-22T22:32:32.658435

Question: You are an expert researcher providing comprehensive, well-cited information.

Provide detailed information focusing on: 1. Key concepts and definitions with current understanding 2. Recent developments and latest research (prioritize 2023-2024 sources) 3. Current applications and real-world implementations 4. Expert opinions and analysis from authoritative sources 5. Relevant statistics and data from recent studies

Format as a comprehensive research report with proper citations. Include URLs and publication dates where available. Always prioritize recent, authoritative sources and provide specific citations for all major claims.

Disease Characteristics Research Template

Target Disease

  • Disease Name: Bartter syndrome
  • MONDO ID: (if available)
  • Category: Mendelian

Research Objectives

Please provide a comprehensive research report on Bartter syndrome covering all of the disease characteristics listed below. This report will be used to populate a disease knowledge base entry. Be thorough and cite primary literature (PMID preferred) for all claims.

For each section, suggested databases/resources are listed. These are the first places you should search for information on each topic.

1. Disease Information

Search first: OMIM, Orphanet, ICD-10/ICD-11, MeSH, PubMed

  • What is the disease? Provide a concise overview.
  • What are the key identifiers? (OMIM, Orphanet, ICD-10/ICD-11, MeSH, Mondo)
  • What are the common synonyms and alternative names?
  • Is the information derived from individual patients (e.g., EHR) or aggregated disease-level resources?

2. Etiology

  • Disease Causal Factors: What are the primary causes? (genetic, environmental, infectious, mechanistic)
  • Risk Factors:

    Search first: PubMed, Cochrane Library, UpToDate, clinical guidelines, ClinVar, ClinGen, GWAS Catalog, PheGenI, CTD, CDC, WHO, epidemiological databases

  • Genetic risk factors (causal variants, susceptibility loci, modifier genes)
  • Environmental risk factors (toxins, lifestyle, occupational exposures, age, sex, family history)
  • Protective Factors:

    Search first: PubMed, Cochrane Library, clinical trial databases, GWAS Catalog, gnomAD, WHO, CDC, nutrition databases

  • Genetic protective factors (protective variants, modifier alleles)
  • Environmental protective factors (diet, lifestyle, exposures that reduce risk)
  • Gene-Environment Interactions: How do genetic and environmental factors interact to influence disease?

    Search first: CTD, PubMed, PheGenI, GxE databases

3. Phenotypes

Search first: HPO (Human Phenotype Ontology), OMIM, Orphanet, PubMed, clinicaltrials.gov, MedDRA, SNOMED CT, DECIPHER, LOINC

For each phenotype, provide: - Phenotype type: symptoms, clinical signs, physical manifestations, behavioral changes, or laboratory abnormalities

For symptoms/signs: HPO, OMIM, Orphanet, PubMed For behavioral changes: HPO, DSM, RDoC (Research Domain Criteria), PubMed For laboratory abnormalities: LOINC, SNOMED CT, LabTests Online, PubMed - Phenotype characteristics: Search first: OMIM, Orphanet, HPO, PubMed - Age of symptom onset (neonatal, childhood, adult-onset, late-onset) - Symptom severity (mild, moderate, severe, variable) - Symptom progression (stable, progressive, episodic, fluctuating) - Frequency among affected individuals (percentage or qualitative) - Quality of life impact: Effects on daily functioning and well-being (per-phenotype when possible) Search first: EQ-5D database, SF-36, WHO QOL databases, PubMed - Suggest HPO (Human Phenotype Ontology) terms for each phenotype

4. Genetic/Molecular Information

  • Causal Genes: Gene mutations or chromosomal abnormalities responsible for disease (gene symbols, OMIM IDs)

    Search first: OMIM, ClinVar, HGMD, Ensembl, NCBI Gene

  • Pathogenic Variants:
  • Affected genes (gene symbols, HGNC IDs) > Search first: OMIM, NCBI Gene, Ensembl, HGNC, UniProt, GeneCards
  • Variant classification (pathogenic, likely pathogenic, VUS per ACMG/AMP guidelines) > Search first: ClinVar, ClinGen, ACMG/AMP guidelines, VarSome
  • Variant type/class (missense, frameshift, nonsense, splice-site, structural)
  • Allele frequency in population databases > Search first: gnomAD, 1000 Genomes, ExAC, TOPMed, dbSNP
  • Somatic vs germline origin > Search first: COSMIC (somatic), ClinVar, ICGC, TCGA
  • Functional consequences (loss of function, gain of function, dominant negative)
  • Modifier Genes: Genes that modify disease severity or expression
  • Epigenetic Information: DNA methylation, histone modifications, chromatin changes affecting disease

    Search first: ENCODE, Roadmap Epigenomics, MethBase, DiseaseMeth

  • Chromosomal Abnormalities: Large-scale genetic changes (aneuploidy, translocations, inversions)

    Search first: DECIPHER, ClinVar, ECARUCA, UCSC Genome Browser

5. Environmental Information

  • Environmental Factors: Non-genetic contributing factors (toxins, radiation, pollution, occupational exposure)

    Search first: CTD (Comparative Toxicogenomics Database), TOXNET, PubMed, EPA databases

  • Lifestyle Factors: Behavioral factors (smoking, diet, exercise, alcohol consumption)

    Search first: CDC databases, WHO, PubMed, NHANES

  • Infectious Agents: If applicable, pathogens causing or triggering disease (bacteria, viruses, fungi, parasites)

    Search first: NCBI Taxonomy, ViPR, BV-BRC, MicrobeDB, GIDEON

6. Mechanism / Pathophysiology

  • Molecular Pathways: Specific signaling cascades or biochemical pathways involved (Wnt, MAPK, mTOR, PI3K-AKT, etc.)

    Search first: KEGG, Reactome, WikiPathways, PathBank, BioCyc

  • Cellular Processes: Cell-level mechanisms (apoptosis, autophagy, cell cycle dysregulation, inflammation, etc.)

    Search first: Gene Ontology (GO), Reactome, KEGG, PubMed

  • Protein Dysfunction: How protein structure or function is altered (misfolding, aggregation, loss of function, gain of function)

    Search first: UniProt, PDB (Protein Data Bank), InterPro, Pfam, AlphaFold

  • Metabolic Changes: Alterations in metabolic processes (energy metabolism, lipid metabolism, amino acid metabolism)

    Search first: KEGG, BioCyc, HMDB (Human Metabolome Database), BRENDA

  • Immune System Involvement: Role of immune response (autoimmunity, immunodeficiency, chronic inflammation)

    Search first: ImmPort, Immunome Database, IEDB, Gene Ontology

  • Tissue Damage Mechanisms: How tissues/ are injured (oxidative stress, ischemia, fibrosis, necrosis)

    Search first: PubMed, Gene Ontology, Reactome

  • Biochemical Abnormalities: Specific molecular defects (enzyme deficiencies, receptor dysfunction, ion channel defects)

    Search first: BRENDA, UniProt, KEGG, OMIM, PubMed

  • Epigenetic Changes: DNA methylation, histone modifications affecting gene expression in disease

    Search first: ENCODE, Roadmap Epigenomics, MethBase, DiseaseMeth

  • Molecular Profiling (if available):
  • Transcriptomics/gene expression changes > Search first: GEO (Gene Expression Omnibus), ArrayExpress, GTEx, Human Cell Atlas, SRA
  • Proteomics findings > Search first: PRIDE, ProteomeXchange, Human Protein Atlas, STRING, BioGRID
  • Metabolomics signatures > Search first: MetaboLights, Metabolomics Workbench, HMDB, METLIN
  • Lipidomics alterations > Search first: LIPID MAPS, SwissLipids, LipidHome, Metabolomics Workbench
  • Genomic structural features > Search first: UCSC Genome Browser, Ensembl, NCBI, dbVar, DGV
  • Advanced Technologies (if applicable):
  • Single-cell analysis findings (cell-type specific mechanisms, cellular heterogeneity) > Search first: Human Cell Atlas, Single Cell Portal, GEO, CELLxGENE
  • Spatial transcriptomics findings > Search first: GEO, Spatial Research, Vizgen, 10x Genomics data
  • Multi-omics integration results > Search first: TCGA, ICGC, cBioPortal, LinkedOmics, PubMed
  • Functional genomics screens (CRISPR, RNAi) > Search first: DepMap, GenomeRNAi, PubMed, BioGRID ORCS

For each mechanism, describe: - The causal chain from initial trigger to clinical manifestation - Which mechanisms are upstream vs downstream - What cell types and biological processes are involved - Suggest GO terms for biological processes and CL terms for cell types

7. Anatomical Structures Affected

  • Organ Level:
  • Primary organs directly affected
  • Secondary organ involvement (complications, secondary effects)
  • Body systems involved (cardiovascular, nervous, digestive, respiratory, endocrine, etc.)

    Search first: Uberon, FMA (Foundational Model of Anatomy), OMIM, HPO, ICD-11, MeSH, SNOMED CT

  • Tissue and Cell Level:
  • Specific tissue types affected (epithelial, connective, muscle, nervous)
  • Specific cell populations targeted (with Cell Ontology terms)

    Search first: Uberon, Human Protein Atlas, Cell Ontology, Human Cell Atlas, CellMarker, PanglaoDB

  • Subcellular Level:
  • Cellular compartments involved (mitochondria, nucleus, ER, lysosomes) (with GO Cellular Component terms)

    Search first: Gene Ontology (Cellular Component), UniProt, Human Protein Atlas

  • Localization:
  • Specific anatomical sites (with UBERON terms) > Search first: FMA, Uberon, NeuroNames (for brain), SNOMED CT
  • Lateralization (unilateral, bilateral, asymmetric) > Search first: HPO, clinical literature, imaging databases

8. Temporal Development

  • Onset:
  • Typical age of onset (congenital, pediatric, adult, geriatric)
  • Onset pattern (acute, subacute, chronic, insidious)

    Search first: OMIM, Orphanet, HPO, PubMed

  • Progression:
  • Disease stages (early, intermediate, advanced, end-stage) > Search first: Cancer Staging Manual (AJCC), WHO classifications, PubMed
  • Progression rate (rapid, slow, variable)
  • Disease course pattern (episodic, relapsing-remitting, progressive, stable)
  • Disease duration (self-limited, chronic lifelong)

    Search first: Disease registries, longitudinal cohort databases, natural history studies, PubMed, Orphanet, OMIM

  • Patterns:
  • Remission patterns (spontaneous, treatment-induced) > Search first: Clinical trial databases, disease registries, PubMed
  • Critical periods (time windows of vulnerability or opportunity for intervention) > Search first: PubMed, developmental biology databases, clinical guidelines

9. Inheritance and Population

  • Epidemiology:
  • Prevalence (cases per 100,000 at given time)
  • Incidence (new cases per 100,000 per year)

    Search first: Orphanet, CDC, WHO, GBD (Global Burden of Disease), national registries, SEER, disease registries

  • For Genetic Etiology:
  • Inheritance pattern (AD, AR, X-linked, mitochondrial, multifactorial, polygenic) > Search first: OMIM, Orphanet, ClinVar, GTR (Genetic Testing Registry)
  • Penetrance (complete, incomplete, age-dependent) > Search first: ClinVar, OMIM, PubMed, ClinGen
  • Expressivity (variable, consistent) > Search first: OMIM, ClinVar, PubMed
  • Genetic anticipation (increasing severity in successive generations) > Search first: OMIM, PubMed (especially for repeat expansion disorders)
  • Germline mosaicism > Search first: ClinVar, OMIM, genetic counseling literature, PubMed
  • Founder effects (population-specific mutations) > Search first: gnomAD, population genetics databases, PubMed
  • Consanguinity role > Search first: OMIM, population studies, genetic counseling resources
  • Carrier frequency > Search first: gnomAD, carrier screening databases, GeneReviews, GTR
  • Population Demographics:
  • Affected populations (ethnic or demographic groups with higher prevalence) > Search first: gnomAD, 1000 Genomes, PAGE Study, PubMed, population registries
  • Geographic distribution (endemic areas, regional variation) > Search first: WHO, CDC, GBD, Orphanet, geographic epidemiology databases
  • Geographic distribution of specific variants
  • Sex ratio (male:female) > Search first: Disease registries, OMIM, PubMed, epidemiological databases
  • Age distribution of affected individuals > Search first: CDC, disease registries, SEER, Orphanet

10. Diagnostics

  • Clinical Tests:
  • Laboratory tests (blood, urine, tissue chemistry, specific enzyme assays) > Search first: LOINC, LabTests Online, PubMed
  • Biomarkers (proteins, metabolites, genetic markers, circulating biomarkers) > Search first: FDA Biomarker List, BEST (Biomarkers, EndpointS, and other Tools), PubMed
  • Imaging studies (X-ray, CT, MRI, PET, ultrasound) > Search first: RadLex, DICOM, Radiopaedia, imaging databases
  • Functional tests (pulmonary function, cardiac stress tests) > Search first: LOINC, clinical guidelines, PubMed
  • Electrophysiology (EEG, EMG, ECG, nerve conduction studies) > Search first: LOINC, clinical neurophysiology databases, PubMed
  • Biopsy findings (histopathology, immunohistochemistry) > Search first: SNOMED CT, College of American Pathologists resources, PubMed
  • Pathology findings (microscopic examination) > Search first: SNOMED CT, Digital Pathology databases, PubMed
  • Genetic Testing:

    Search first: GTR (Genetic Testing Registry), GeneReviews, ClinGen

  • Overview of recommended genetic testing approach
  • Whole genome sequencing (WGS) utility > Search first: GTR, ClinVar, GEL (Genomics England), gnomAD
  • Whole exome sequencing (WES) utility > Search first: GTR, ClinVar, OMIM, GeneMatcher
  • Gene panels (which panels, which genes) > Search first: GTR, ClinVar, laboratory-specific databases
  • Single gene testing > Search first: GTR, ClinVar, OMIM, GeneReviews
  • Chromosomal microarray (CMA) > Search first: DECIPHER, ClinVar, dbVar, ECARUCA
  • Karyotyping > Search first: Chromosome Abnormality Database, ClinVar, cytogenetics resources
  • FISH > Search first: ClinVar, cytogenetics databases, PubMed
  • Mitochondrial DNA testing > Search first: MITOMAP, MSeqDR, ClinVar, GTR
  • Repeat expansion testing > Search first: GTR, ClinVar, repeat expansion databases, PubMed
  • Omics-Based Diagnostics (if applicable):
  • RNA sequencing / transcriptomics > Search first: GEO, ArrayExpress, GTEx, RNA-seq databases
  • Proteomics > Search first: PRIDE, ProteomeXchange, FDA Biomarker database
  • Metabolomics > Search first: MetaboLights, Metabolomics Workbench, HMDB
  • Epigenomics > Search first: GEO, ENCODE, Roadmap Epigenomics, MethBase
  • Liquid biopsy > Search first: COSMIC, ClinVar, liquid biopsy databases, PubMed
  • Clinical Criteria:
  • Standardized diagnostic criteria (DSM, ICD, society guidelines) > Search first: DSM-5, ICD-11, clinical society guidelines, UpToDate
  • Differential diagnosis (other conditions to rule out, with distinguishing features) > Search first: DynaMed, UpToDate, clinical decision support systems
  • Screening:
  • Screening methods for asymptomatic individuals (newborn screening, carrier screening, cascade screening) > Search first: ACMG recommendations, CDC newborn screening, GTR

11. Outcome/Prognosis

  • Survival and Mortality:
  • Survival rate (5-year, 10-year, overall) > Search first: SEER, cancer registries, disease-specific registries, PubMed
  • Life expectancy (with and without treatment if applicable) > Search first: Orphanet, disease registries, actuarial databases, PubMed
  • Mortality rate > Search first: CDC, WHO, GBD, national mortality databases
  • Disease-specific mortality (deaths directly attributable to disease) > Search first: Disease registries, CDC Wonder, GBD, PubMed
  • Morbidity and Function:
  • Morbidity (disease-related disability and health impacts) > Search first: GBD, WHO, disability databases, PubMed
  • Disability outcomes (long-term functional impairments) > Search first: ICF (International Classification of Functioning), disability registries
  • Quality of life measures (EQ-5D, SF-36, PROMIS, disease-specific tools) > Search first: EQ-5D database, SF-36, PROMIS, PubMed
  • Disease Course:
  • Complications (secondary problems: infections, organ failure, etc.) > Search first: ICD codes, disease registries, clinical databases, PubMed
  • Recovery potential (likelihood and extent of recovery, with vs without treatment) > Search first: Natural history studies, rehabilitation databases, PubMed
  • Prediction:
  • Prognostic factors (age, disease severity, biomarkers, treatment response) > Search first: Prognostic models databases, clinical calculators, PubMed
  • Prognostic biomarkers (molecular markers predicting disease course) > Search first: FDA Biomarker database, PubMed, cancer prognostic databases

12. Treatment

  • Pharmacotherapy:
  • Pharmacological treatments (drug names, drug classes, mechanisms of action) > Search first: DrugBank, RxNorm, ATC classification, DailyMed, FDA databases
  • Pharmacogenomics (how genetic variants affect drug metabolism, efficacy, toxicity) > Search first: PharmGKB, CPIC (Clinical Pharmacogenetics), FDA Table of PGx Biomarkers
  • Advanced Therapeutics:
  • Gene therapy (viral vectors, CRISPR, gene replacement, gene editing) > Search first: ClinicalTrials.gov, FDA gene therapy database, ASGCT resources
  • Cell therapy (stem cell transplant, CAR-T, cellular therapeutics) > Search first: ClinicalTrials.gov, FDA cell therapy database, FACT standards
  • RNA-based therapies (ASOs, siRNA, mRNA therapies) > Search first: ClinicalTrials.gov, FDA approvals, PubMed
  • Targeted therapies (treatments directed at specific molecular targets) > Search first: My Cancer Genome, OncoKB, ClinicalTrials.gov, FDA approvals
  • Immunotherapies (checkpoint inhibitors, monoclonal antibodies) > Search first: Cancer Immunotherapy Database, FDA approvals, ClinicalTrials.gov
  • Surgical and Interventional:
  • Surgical interventions (types of surgery, timing, outcomes) > Search first: CPT codes, surgical registries, clinical guidelines, PubMed
  • Supportive and Rehabilitative:
  • Supportive care (symptom management, pain control, nutrition) > Search first: Clinical guidelines, Cochrane Library, PubMed
  • Rehabilitation (physical therapy, occupational therapy, speech therapy) > Search first: Rehabilitation medicine databases, clinical guidelines, PubMed
  • Experimental:
  • Experimental treatments in clinical trials (with NCT identifiers if available) > Search first: ClinicalTrials.gov, EU Clinical Trials Register, WHO ICTRP
  • Treatment Outcomes:
  • Treatment response rates > Search first: Clinical trial databases, FDA reviews, systematic reviews, PubMed
  • Side effects and adverse events > Search first: FDA Adverse Event Reporting System (FAERS), MedWatch, PubMed
  • Treatment Strategy:
  • Treatment algorithms (clinical pathways, decision trees) > Search first: Clinical practice guidelines, NCCN Guidelines, UpToDate
  • Combination therapies > Search first: ClinicalTrials.gov, treatment guidelines, PubMed
  • Personalized medicine approaches (genotype-guided treatment) > Search first: My Cancer Genome, CIViC, PharmGKB, precision medicine databases

For each treatment, suggest MAXO (Medical Action Ontology) terms where applicable.

13. Prevention

  • Prevention Levels:
  • Primary prevention (preventing disease occurrence: vaccination, risk factor modification) > Search first: CDC, WHO, USPSTF recommendations, Cochrane Library
  • Secondary prevention (early detection and treatment: screening programs, early intervention) > Search first: USPSTF, CDC screening guidelines, WHO
  • Tertiary prevention (preventing complications in those with disease) > Search first: Clinical guidelines, disease management protocols, PubMed
  • Immunization: Vaccine strategies (if applicable)

    Search first: CDC vaccine schedules, WHO immunization, FDA vaccine database

  • Screening and Early Detection:
  • Screening programs (population-based: newborn screening, cancer screening) > Search first: CDC screening programs, USPSTF, cancer screening databases
  • Genetic screening (carrier screening, preimplantation genetic diagnosis, prenatal testing) > Search first: ACMG recommendations, ACOG guidelines, GTR
  • Risk stratification (identifying high-risk individuals for targeted prevention) > Search first: Risk prediction models, clinical calculators, PubMed
  • Behavioral Interventions: Lifestyle modifications to reduce risk

    Search first: CDC, WHO, behavioral intervention databases, Cochrane Library

  • Counseling: Genetic counseling (risk assessment, family planning guidance)

    Search first: NSGC resources, ACMG guidelines, GeneReviews

  • Public Health:
  • Public health interventions (sanitation, vector control, health education) > Search first: CDC, WHO, public health databases, PubMed
  • Environmental interventions (reducing environmental risk factors) > Search first: EPA databases, WHO environmental health, PubMed
  • Prophylaxis: Preventive medications or procedures

    Search first: Clinical guidelines, FDA approvals, PubMed

14. Other Species / Natural Disease

  • Taxonomy: Species affected (with NCBI Taxon identifiers)

    Search first: NCBI Taxonomy

  • Breed: Specific breeds affected (with VBO identifiers if applicable)

    Search first: VBO (Vertebrate Breed Ontology)

  • Gene: Orthologous genes in other species (with NCBI Gene IDs)

    Search first: NCBI Gene

  • Natural Disease:
  • Naturally occurring disease in other species (companion animals, wildlife) > Search first: OMIA (Online Mendelian Inheritance in Animals), VetCompass, PubMed
  • Veterinary relevance and importance in animal health > Search first: OMIA, veterinary databases, PubMed
  • Comparative Biology:
  • Comparative pathology (similarities and differences across species) > Search first: OMIA, comparative pathology databases, PubMed
  • Evolutionary conservation of disease mechanisms > Search first: HomoloGene, OrthoMCL, Alliance of Genome Resources
  • Transmission (if applicable):
  • Zoonotic potential > Search first: CDC zoonotic diseases, WHO zoonoses, GIDEON
  • Cross-species susceptibility > Search first: NCBI Taxonomy, veterinary databases, PubMed

15. Model Organisms

  • Model Types:
  • Model organism type (mammalian, invertebrate, cellular, in vitro) > Search first: Alliance of Genome Resources, model organism databases
  • Specific model systems (mouse, rat, zebrafish, Drosophila, C. elegans, yeast, cell lines, organoids, iPSCs) > Search first: MGI, RGD, ZFIN, FlyBase, WormBase, SGD, ATCC, Cellosaurus
  • Induced models (drug treatment, surgical intervention, environmental manipulation) > Search first: MGI, model organism databases, PubMed
  • Genetic Models:
  • Types available (knockout, knock-in, transgenic, conditional, humanized) > Search first: MGI, IMPC, KOMP, EuMMCR, IMSR
  • Model Characteristics:
  • Phenotype recapitulation (how well model reproduces human disease features) > Search first: Model organism databases, comparative studies, PubMed
  • Model limitations (aspects of human disease not captured) > Search first: Model organism databases, PubMed, review articles
  • Applications:
  • Research applications (what aspects of disease can be studied) > Search first: Model organism databases, PubMed
  • Resources:
  • Model databases > Search first: MGI, RGD, ZFIN, FlyBase, WormBase, IMSR, EMMA, MMRRC

Citation Requirements

  • Cite primary literature (PMID preferred) for all mechanistic and clinical claims
  • Prioritize recent reviews and landmark papers
  • Include direct quotes from abstracts where possible to support key statements
  • Distinguish evidence source types: human clinical, model organism, in vitro, computational

Output Format

Structure your response as a comprehensive narrative organized by the sections above. For each section, provide: - Factual content with specific details (numbers, percentages, gene names, variant nomenclature) - Ontology term suggestions (HPO, GO, CL, UBERON, CHEBI, MAXO, MONDO) where applicable - Evidence citations with PMIDs - Direct quotes from abstracts to support key claims - Clear indication when information is not available or not applicable for this disease

This report will be used to populate a disease knowledge base entry with: - Pathophysiology descriptions with causal chains - Gene/protein annotations (HGNC, GO terms) - Phenotype associations (HP terms) with frequencies - Cell type involvement (CL terms) - Anatomical locations (UBERON terms) - Chemical entities (CHEBI terms) - Treatment annotations (MAXO terms) - Evidence items with PMIDs and exact abstract quotes - Epidemiology, prognosis, diagnostic, and prevention information - Animal model descriptions with phenotype recapitulation details

Comprehensive Research Report: Bartter syndrome (Mendelian salt‑losing tubulopathy)

Executive summary

Bartter syndrome (BS) is a group of inherited renal tubular salt‑wasting disorders primarily caused by loss‑of‑function variants in ion transport proteins of the thick ascending limb (TAL) of Henle (and related segments), producing chronic volume depletion with hyperreninemic hyperaldosteronism, hypokalemic hypochloremic metabolic alkalosis, and variable hypercalciuria/nephrocalcinosis. Recent (2023–2024) literature adds (i) long‑term outcome statistics from a 54‑patient multicenter Korean cohort, (ii) a mechanistic 2024 review emphasizing NKCC2 endoplasmic‑reticulum (ER) quality control/ER‑associated degradation (ERAD), and (iii) prenatal genomic/functional evidence that intronic MAGED2 variants can cause transient antenatal BS via cryptic splicing. (choi2023longtermoutcomeof pages 1-2, laghmani2024proteinqualitycontrol pages 1-2, yan2024identificationofa pages 1-2)

1. Disease information

1.1 Definition and current understanding

Bartter syndrome is a “rare salt-wasting tubulopathy” characterized by polyuria/failure to thrive, hypokalemia, metabolic alkalosis, hyperreninemia and hyperaldosteronism; antenatal forms often show polyhydramnios and prematurity, while “classic” forms usually present in infancy/childhood. (Frontiers in Medicine, published 2023-03; https://doi.org/10.3389/fmed.2023.1099840) (choi2023longtermoutcomeof pages 1-2)

Recent mechanistic work reinforces the TAL as the principal site of dysfunction, where reduced NKCC2/ROMK/ClC-K–barttin–mediated NaCl reabsorption increases distal Na+ delivery, enhancing ENaC-mediated Na+ uptake in exchange for K+ and H+, thereby driving hypokalemia and metabolic alkalosis. (alla2023ararepresentation pages 2-3, laghmani2024proteinqualitycontrol pages 1-2)

1.2 Key identifiers and ontologies

  • MONDO: Bartter syndrome = MONDO_0015231 (Open Targets disease association record). (yang2026identificationofthree pages 12-14)
  • Subtypes also appear in Open Targets/MONDO, e.g. Bartter disease type 3 = MONDO_0011822, Bartter syndrome type 4 = MONDO_0019524. (yang2026identificationofthree pages 12-14)
  • OMIM gene entries frequently used in classification (from a 2023 primary report):
  • CLCNKB (classic/type III context): OMIM 607364 (zhou2023amosaicmutation pages 1-2)
  • SLC12A1: OMIM 601678 (zhou2023amosaicmutation pages 1-2)
  • KCNJ1: OMIM 241200 (zhou2023amosaicmutation pages 1-2)
  • BSND: OMIM 602522 (zhou2023amosaicmutation pages 1-2)
  • MAGED2: OMIM 300971 (zhou2023amosaicmutation pages 1-2)

Not available in the retrieved full texts: Orphanet disease ID, ICD‑10/ICD‑11 codes, and MeSH descriptor IDs for Bartter syndrome. These should be curated directly from the relevant ontology/terminology sources (Orphanet/WHO ICD browser/MeSH). (choi2023longtermoutcomeof pages 1-2)

1.3 Synonyms and alternative names

Common clinical/grouping terms used in the contemporary literature include: - “Antenatal Bartter syndrome” vs “classic Bartter syndrome” (phenotype grouping) (choi2023longtermoutcomeof pages 1-2) - “Type I–V Bartter syndrome” (genotype‑linked classification; nomenclature varies, particularly for CASR vs MAGED2 assignments across sources) (qasba2023barttersyndromea pages 2-5, yan2024identificationofa pages 1-2) - “Gitelman-like syndrome (GLS)” as a phenotypic label used in cohorts when overlap exists (choi2023longtermoutcomeof pages 1-2)

1.4 Evidence source type

Most evidence for BS characteristics comes from aggregated disease-level resources (reviews/cohorts) plus individual case reports for rare genotypes or atypical presentations. For example: a multicenter cohort of 54 Korean patients (aggregated clinical resource) (choi2023longtermoutcomeof pages 1-2) and newborn/adult case reports illustrating mosaicism or adult-onset disease (individual cases). (zhou2023amosaicmutation pages 1-2, jiang2024adultclassicbartter pages 1-2)

2. Etiology

2.1 Disease causal factors

Primary cause: Mendelian genetic defects in TAL (and related) transport proteins and regulators.

A 2023 systematic review summarized BS as “a rare group of autosomal-recessive disorders” with impaired TAL transport and heterogeneous genetic causes. (Medicina, published 2023-09; https://doi.org/10.3390/medicina59091638) (qasba2023barttersyndromea pages 1-2)

2.2 Risk factors

  • Genetic: biallelic pathogenic variants in SLC12A1, KCNJ1, CLCNKB, BSND, CLCNKA+CLCNKB; X‑linked pathogenic variants in MAGED2 in transient antenatal BS; gain‑of‑function CASR variants in Bartter‑like disease with hypocalcemia/hypercalciuria. (qasba2023barttersyndromea pages 2-5, thimm2024untanglingtheuncertain pages 4-6, yan2024identificationofa pages 1-2)
  • Family structure/consanguinity: In a 2012–2022 case report/series systematic review, 21/118 patients were from consanguineous unions (~18%). (qasba2023barttersyndromea pages 2-5)

2.3 Protective factors

Not established in the retrieved primary evidence. Some long‑term course improvements (e.g., decreasing potassium supplementation needs with age) reflect disease trajectory/management rather than protective factors. (choi2023longtermoutcomeof pages 4-6)

2.4 Gene–environment interactions

Well‑defined exogenous triggers are not typical for Mendelian BS, but fetal environment (hypoxia/oxygenation shift at birth) is mechanistically central for MAGED2‑related transient antenatal BS, where renal salt handling “completely normalizes after birth” in many survivors. (yan2024identificationofa pages 4-6)

3. Phenotypes (with HPO suggestions and frequencies when available)

3.1 Core biochemical and clinical phenotype

Key findings repeatedly used for diagnosis and phenotyping include: - Hypokalemia (HPO: HP:0001942) (choi2023longtermoutcomeof pages 1-2, alla2023ararepresentation pages 2-3) - Metabolic alkalosis (HPO: HP:0001940) (choi2023longtermoutcomeof pages 1-2, alla2023ararepresentation pages 2-3) - Hypochloremia (HPO: HP:0011421) (alla2023ararepresentation pages 2-3) - Hyperreninemia / hyperaldosteronism (HPO: HP:0000875 for hyperaldosteronism; hyperreninemia may be captured as elevated renin activity) (choi2023longtermoutcomeof pages 1-2, alla2023ararepresentation pages 2-3) - Polyuria (HPO: HP:0000103) and polydipsia (HPO: HP:0001959) (choi2023longtermoutcomeof pages 1-2, alla2023ararepresentation pages 2-3) - Failure to thrive / growth failure (HPO: HP:0001508; HP:0001510 for growth delay) (choi2023longtermoutcomeof pages 1-2, alla2023ararepresentation pages 2-3)

3.2 Antenatal/neonatal features (frequency from a 2023 multicenter cohort)

In the 54‑patient Korean cohort (Frontiers in Medicine; 2023-03; https://doi.org/10.3389/fmed.2023.1099840): - Polyhydramnios (HPO: HP:0001561) occurred in 47% (18/38) (choi2023longtermoutcomeof pages 2-3) - Preterm birth (HPO: HP:0001622) occurred in 28% (13/46) (choi2023longtermoutcomeof pages 2-3)

3.3 Renal complications and extrarenal findings (frequency from the 2023 cohort)

From the same 54‑patient cohort: - Nephrocalcinosis (HPO: HP:0000121) at presentation: 41% (17/41); at last visit: 35% (15/43), with strong genotype dependence (e.g., 100% in BS1/BS2/BS4 groups reported in the paper). (choi2023longtermoutcomeof pages 2-3, choi2023longtermoutcomeof pages 4-6) - Short stature (HPO: HP:0004322) at last follow‑up: 41% (22/54); among adults >19 years, 50% (5/10) were short. (choi2023longtermoutcomeof pages 4-6) - Developmental delay (HPO: HP:0001263): 15% (8/54) (choi2023longtermoutcomeof pages 4-6) - Sensorineural hearing loss (HPO: HP:0000407): 7% (4/54) (choi2023longtermoutcomeof pages 4-6) - Chronic kidney disease / impaired kidney function (HPO: HP:0012624): 11% developed CKD G3–G5 (6 patients; 4 G3, 2 G5). (choi2023longtermoutcomeof pages 1-2, choi2023longtermoutcomeof pages 4-6)

3.4 Phenotypic heterogeneity (systematic review of 2012–2022 case reports/series)

A systematic review (Medicina; 2023-09; https://doi.org/10.3390/medicina59091638) aggregated 118 reported BS patients and highlighted heterogeneous presentation. It reported (among cases with genetic typing) a predominance of type III and common symptoms including polyuria, polydipsia, vomiting and dehydration, and noted antenatal features (polyhydramnios/prematurity). (qasba2023barttersyndromea pages 1-2, qasba2023barttersyndromea pages 2-5)

4. Genetic/molecular information

4.1 Causal genes and inheritance

A gene–subtype map is summarized in the table artifact below (with nephron localization and hallmark phenotypes), based on 2023–2024 sources and aligned to TAL transport physiology.

Subtype (common name) Gene(s) Protein/transport function Nephron segment & membrane localization Inheritance Hallmark phenotypes/biochemical features Notes/2023-2024 updates
Type I (antenatal/neonatal Bartter syndrome) SLC12A1 NKCC2, apical Na+-K+-2Cl- cotransporter mediating a major fraction of TAL NaCl reabsorption; loss impairs lumen-positive voltage and downstream paracellular Ca2+/Mg2+ reabsorption (alla2023ararepresentation pages 2-3, thimm2024untanglingtheuncertain pages 4-6, laghmani2024proteinqualitycontrol pages 1-2) Thick ascending limb (TAL), apical membrane of tubular epithelial cells; NKCC2 splice variants localize to medullary/cortical TAL and macula densa (thimm2024untanglingtheuncertain pages 4-6, laghmani2024proteinqualitycontrol pages 1-2) Usually autosomal recessive (qasba2023barttersyndromea pages 1-2, thimm2024sodiumdeficiencydiseases pages 5-9) Antenatal/neonatal presentation, polyhydramnios, prematurity, severe salt wasting, hypokalemic hypochloremic metabolic alkalosis, hyperreninemia/hyperaldosteronism, often hypercalciuria/nephrocalcinosis (choi2023longtermoutcomeof pages 1-2, qasba2023barttersyndromea pages 2-5, thimm2024untanglingtheuncertain pages 4-6) 2024 mechanistic update: NKCC2 maturation is regulated by ER export/protein quality control; ER retention and ER-associated degradation (ERAD) are implicated in severe prenatal disease biology (laghmani2024proteinqualitycontrol pages 1-2)
Type II (antenatal Bartter syndrome) KCNJ1 ROMK, apical inwardly rectifying K+ channel recycling K+ into tubular lumen to support NKCC2 activity and lumen-positive voltage (alla2023ararepresentation pages 2-3, thimm2024untanglingtheuncertain pages 4-6, laghmani2024proteinqualitycontrol pages 1-2) TAL, apical membrane (thimm2024untanglingtheuncertain pages 4-6, laghmani2024proteinqualitycontrol pages 1-2) Usually autosomal recessive (qasba2023barttersyndromea pages 1-2, thimm2024sodiumdeficiencydiseases pages 5-9) Antenatal/neonatal salt wasting, hypokalemic metabolic alkalosis, hyperreninemia/hyperaldosteronism, polyhydramnios/prematurity; may have hypercalciuria/nephrocalcinosis (qasba2023barttersyndromea pages 2-5, thimm2024untanglingtheuncertain pages 4-6, choi2023longtermoutcomeof pages 1-2) 2023-2024 literature continues to classify ROMK disease as neonatal/antenatal BS with RAAS activation and prostaglandin-linked physiology; no major subtype-specific therapeutic advance identified in gathered evidence (thimm2024untanglingtheuncertain pages 4-6, thimm2024untanglingtheuncertain pages 6-6)
Type III (classic Bartter syndrome) CLCNKB ClC-Kb chloride channel enabling basolateral chloride efflux from tubular epithelial cells to interstitium (zhou2023amosaicmutation pages 1-2) Mainly TAL; basolateral membrane chloride channel in renal tubular epithelial cells (thimm2024untanglingtheuncertain pages 4-6, zhou2023amosaicmutation pages 1-2) Usually autosomal recessive (qasba2023barttersyndromea pages 1-2, zhou2023amosaicmutation pages 1-2) Often childhood-onset but can present later; hypokalemia, hypochloremic metabolic alkalosis, renal salt wasting, hyperreninemia/hyperaldosteronism with normal blood pressure, polyuria, polydipsia, failure to thrive; urinary calcium may be variable and overlap with Gitelman syndrome (zhou2023amosaicmutation pages 1-2, jiang2024adultclassicbartter pages 1-2) Largest recent cohort signal: in Korean multicenter study, 33/39 genetically confirmed cases had CLCNKB variants; CLCNKB was the dominant genotype, and a CLCNKB W610X (c.1830G>A) allele accounted for ~40-50% of alleles, suggesting a founder effect in Korea (choi2023longtermoutcomeof pages 4-6, choi2023longtermoutcomeof pages 1-2). 2023 case report described a mosaic CLCNKB nonsense variant with frameshift in a newborn; 2024 adult case reported homozygous c.1052G>T (p.Arg351Leu) and emphasized genetic testing for BS vs GS (zhou2023amosaicmutation pages 1-2, jiang2024adultclassicbartter pages 1-2)
Type IVa (Bartter syndrome with sensorineural deafness) BSND Barttin, accessory \β-subunit required for ClC-Ka/ClC-Kb chloride channel function (qasba2023barttersyndromea pages 2-5, thimm2024untanglingtheuncertain pages 4-6, zhou2023amosaicmutation pages 1-2) TAL/basolateral chloride channel complex in kidney; also inner ear involvement explaining deafness (qasba2023barttersyndromea pages 2-5, thimm2024untanglingtheuncertain pages 4-6) Usually autosomal recessive (qasba2023barttersyndromea pages 1-2, qasba2023barttersyndromea pages 2-5) Severe salt wasting, antenatal features/polyhydramnios, hypokalemic metabolic alkalosis, hyperreninemia/hyperaldosteronism, and sensorineural hearing loss (qasba2023barttersyndromea pages 2-5, thimm2024untanglingtheuncertain pages 4-6) In the Korean cohort, hearing loss was present in 4/54 (7%) overall at last follow-up, including the BSND case; one additional patient developed hearing loss during follow-up (choi2023longtermoutcomeof pages 4-6)
Type IVb (combined chloride channel defect) CLCNKA + CLCNKB Combined defect of ClC-Ka and ClC-Kb chloride channels causing severe chloride transport impairment (qasba2023barttersyndromea pages 2-5, zhou2023amosaicmutation pages 1-2) TAL/basolateral chloride channel system; urinary concentrating defect noted in review evidence (qasba2023barttersyndromea pages 2-5) Usually autosomal recessive/digenic combined defect in reported cases (qasba2023barttersyndromea pages 2-5) Severe salt wasting, polyhydramnios, preterm delivery, impaired urinary concentrating ability, deafness/severe phenotype resembling type IV spectrum (qasba2023barttersyndromea pages 2-5) 2023 systematic review highlighted type IVb as a rare but severe form due to dysfunction of two chloride channels, with deafness and marked antenatal disease (qasba2023barttersyndromea pages 2-5)
Type V / transient antenatal Bartter syndrome MAGED2 MAGED2 supports transporter expression/trafficking under fetal hypoxia; maintains Gαs-cAMP/PKA signaling that promotes NKCC2/NCC function and protects them from degradation (yan2024identificationofa pages 4-6, yang2026identificationofthree pages 1-2) Functional effect on fetal renal salt transport in TAL/DCT pathways; disease is transient and linked to intrauterine hypoxic conditions rather than permanent postnatal dysfunction (yan2024identificationofa pages 4-6, yang2026identificationofthree pages 1-2) X-linked; mostly affects males, though skewed X-inactivation can make heterozygous females symptomatic (yan2024identificationofa pages 1-2, yan2024identificationofa pages 4-6) Severe fetal polyuria causing early severe polyhydramnios, extreme prematurity, high perinatal risk; postnatal electrolyte abnormalities are often transient with spontaneous recovery in survivors (yan2024identificationofa pages 1-2, yan2024identificationofa pages 4-6, yan2024identificationofa pages 2-4) 2024 update: novel intronic variant c.1271+4_1271+7delAGTA shown pathogenic by minigene assay, activating a cryptic splice site and inserting 96 bp into mRNA, creating premature termination and predicted loss of MAGED2-Hsp40 interaction; authors recommend WES/trio-WES and intronic analysis when severe polyhydramnios is present (yan2024identificationofa pages 1-2, yan2024identificationofa pages 4-6, yan2024identificationofa pages 2-4)
Bartter syndrome with hypocalcemia / Bartter-like subtype CASR Gain-of-function calcium-sensing receptor signaling alters TAL salt handling and calcium balance (thimm2024untanglingtheuncertain pages 4-6) Basolateral CaSR in TAL tubular cells (thimm2024untanglingtheuncertain pages 4-6) Reported as type V in some older classifications within gathered reviews; inheritance not fully detailed in gathered evidence table (qasba2023barttersyndromea pages 2-5, thimm2024untanglingtheuncertain pages 4-6) Hypokalemic metabolic alkalosis with salt wasting plus hypocalcemia and hypercalciuria in Bartter-like phenotype (thimm2024untanglingtheuncertain pages 4-6) Classification differs across sources: Qasba 2023 lists CASR-associated disease as type V, whereas newer literature separately emphasizes MAGED2-associated transient antenatal BS; this reflects evolving nomenclature rather than a resolved consensus in the gathered evidence (qasba2023barttersyndromea pages 2-5, yan2024identificationofa pages 1-2, yang2026identificationofthree pages 1-2)

Table: This table summarizes the major genetic subtypes of Bartter syndrome, linking each gene to transporter function, nephron localization, inheritance, and clinical hallmarks. It also highlights recent 2023-2024 updates from cohort, mechanistic, and prenatal genetics studies.

Inheritance pattern: Types 1–4 are predominantly autosomal recessive; MAGED2‑related transient antenatal BS is X‑linked (noted in contemporary discussions of transient antenatal BS). (qasba2023barttersyndromea pages 1-2, yan2024identificationofa pages 4-6)

4.2 Pathogenic variant classes and examples (recently reported)

  • CLCNKB (type III/classic BS)
  • A 2023 case report described compound changes including a frameshift c.1257delC (p.M421Cfs*58) plus a low‑level mosaic nonsense c.595G>T (p.E199*). (Frontiers in Pediatrics; 2023-04; https://doi.org/10.3389/fped.2023.1034923) (zhou2023amosaicmutation pages 1-2)
  • A 2024 adult case report reported a homozygous missense CLCNKB c.1052G>T (p.Arg351Leu), emphasizing genetic testing when adult onset mimics Gitelman syndrome. (Endocrine Journal; 2024-03; https://doi.org/10.1507/endocrj.ej23-0631) (jiang2024adultclassicbartter pages 1-2)
  • MAGED2 (transient antenatal BS)
  • A 2024 study identified a novel intronic deletion MAGED2 c.1271+4_1271+7delAGTA and showed, via minigene assay, activation of a cryptic splice site producing a 96 bp insertion in mature mRNA with premature termination. (BMC Medical Genomics; 2024-01; https://doi.org/10.1186/s12920-024-01797-8) (yan2024identificationofa pages 1-2, yan2024identificationofa pages 2-4)

4.3 Modifier genes / epigenetics

Not systematically characterized for BS in the retrieved 2023–2024 evidence. Some mechanistic discussions suggest that protein quality control pathways (ER export/ERAD) can modify transporter abundance and thus phenotype severity (e.g., NKCC2). (laghmani2024proteinqualitycontrol pages 1-2)

5. Environmental information

Bartter syndrome is primarily genetic; the retrieved sources emphasize differential diagnoses and phenocopies rather than environmental causation. Pseudo‑Bartter syndromes/phenocopies include cystic fibrosis and nephrotoxic drug exposures (e.g., aminoglycosides, amphotericin B, heavy metals). (alla2023ararepresentation pages 2-3)

6. Mechanism / pathophysiology

6.1 Causal chain (transport defect → biochemical phenotype)

  1. Primary transporter/channel dysfunction in TAL salt reabsorption (NKCC2/ROMK/ClC-K/barttin; or regulatory mechanisms in transient antenatal BS). (thimm2024untanglingtheuncertain pages 4-6, laghmani2024proteinqualitycontrol pages 1-2, yan2024identificationofa pages 4-6)
  2. Renal salt wasting and volume depletion → compensatory RAAS activation (hyperreninemia/hyperaldosteronism; juxtaglomerular apparatus hyperplasia in classic descriptions). (alla2023ararepresentation pages 2-3, thimm2024untanglingtheuncertain pages 4-6)
  3. Increased distal Na+ delivery → enhanced ENaC-mediated Na+ uptake coupled to K+ and H+ secretion → hypokalemia and metabolic alkalosis. (alla2023ararepresentation pages 2-3)
  4. TAL electrical/ionic changes can reduce lumen‑positive voltage, contributing to hypercalciuria and risk of nephrocalcinosis. (alla2023ararepresentation pages 2-3, laghmani2024proteinqualitycontrol pages 1-2)

6.2 Molecular and cellular processes (GO suggestions)

Evidence-supported processes from 2024 mechanistic literature include: - Protein folding / ER quality control / ERAD regulating NKCC2 maturation and apical abundance (suggest GO: protein folding, ER-associated protein catabolic process). (laghmani2024proteinqualitycontrol pages 1-2) - Ion transport (suggest GO: sodium ion transmembrane transport, chloride transmembrane transport, potassium ion transport). (laghmani2024proteinqualitycontrol pages 1-2, zhou2023amosaicmutation pages 1-2) - Renin–angiotensin–aldosterone system regulation (suggest GO: regulation of systemic arterial blood pressure, renin secretion). (thimm2024untanglingtheuncertain pages 4-6)

6.3 Cell types (Cell Ontology suggestions)

Primary affected cell types in the retrieved mechanistic evidence: - Kidney TAL epithelial cells (CL: renal epithelial cell; tissue‑specific annotation may use “thick ascending limb of loop of Henle epithelial cell” where available) (thimm2024untanglingtheuncertain pages 4-6, laghmani2024proteinqualitycontrol pages 1-2) - Macula densa cells (NKCC2 splice variants noted in macula densa) (laghmani2024proteinqualitycontrol pages 1-2)

6.4 Anatomical structures (UBERON suggestions)

  • Kidney (UBERON: kidney) and specifically:
  • Loop of Henle—thick ascending limb (UBERON term for TAL/loop of Henle segment) (thimm2024untanglingtheuncertain pages 4-6, laghmani2024proteinqualitycontrol pages 1-2)
  • Distal convoluted tubule (relevant especially for transient antenatal BS affecting NCC regulation) (yan2024identificationofa pages 4-6)

6.5 Recent mechanistic developments (2023–2024)

  • NKCC2 protein quality control: A 2024 review highlights ER export as a rate‑limiting step in NKCC2 maturation and that ER retention/ERAD can prevent NKCC2 detection at the apical membrane in severe prenatal disease contexts, motivating interest in trafficking/quality‑control determinants. (Cells; 2024-05; https://doi.org/10.3390/cells13100818) (laghmani2024proteinqualitycontrol pages 1-2)
  • MAGED2 transient antenatal BS: A 2024 functional genetics study supports that intronic splice‑altering variants can be pathogenic and suggests a molecular link to protection of NKCC2/NCC from ERAD (based on modeling/functional splicing results), consistent with a fetal‑environment–dependent mechanism. (yan2024identificationofa pages 4-6, yan2024identificationofa pages 2-4)

7. Anatomical structures affected

7.1 Primary organs/systems

  • Renal: TAL and related salt handling segments are central. (thimm2024untanglingtheuncertain pages 4-6, laghmani2024proteinqualitycontrol pages 1-2)
  • Auditory system: in BS type IV (BSND/barttin), sensorineural hearing loss is a defining complication. (choi2023longtermoutcomeof pages 4-6, nomura2013treatmentwith17allylamino17demethoxygeldanamycin pages 5-6)

7.2 Subcellular localization

  • NKCC2: apical membrane; maturation/trafficking depend on ER export/quality control. (laghmani2024proteinqualitycontrol pages 1-2)
  • ClC-Kb: basolateral membrane chloride efflux pathway in TAL epithelial cells. (zhou2023amosaicmutation pages 1-2)

8. Temporal development

8.1 Onset

  • Often neonatal/infantile: Korean cohort median diagnosis age 5 months (range 0–271 months). (choi2023longtermoutcomeof pages 1-2)
  • Antenatal: polyhydramnios/prematurity are common in antenatal forms; MAGED2-related disease can be detected around ~20 weeks gestation with severe polyhydramnios. (choi2023longtermoutcomeof pages 2-3, yan2024identificationofa pages 2-4)
  • Adult onset is uncommon but documented, typically requiring genetic testing to distinguish from Gitelman syndrome. (jiang2024adultclassicbartter pages 1-2)

8.2 Progression and course

Long-term cohort evidence indicates partial improvement in supplementation needs with age (potassium dosing declining from infancy to adolescence), yet a clinically meaningful minority develop CKD and growth impairment persists in many. (choi2023longtermoutcomeof pages 4-6)

9. Inheritance and population

9.1 Epidemiology

A 2023 multicenter cohort review text states a prevalence estimate of approximately ~1 in 100,000. (choi2023longtermoutcomeof pages 1-2)

9.2 Population genetics / founder effects

In the Korean multicenter cohort, CLCNKB was the dominant genotype (33/39 genetically confirmed), and a CLCNKB W610X (c.1830G>A) variant accounted for ~40–50% of alleles, consistent with a possible founder effect in Korea. (choi2023longtermoutcomeof pages 4-6, choi2023longtermoutcomeof pages 1-2)

9.3 Sex ratio

In the 54‑patient Korean cohort the sex distribution was 33 male : 21 female. (choi2023longtermoutcomeof pages 2-3)

10. Diagnostics

10.1 Clinical testing (lab features)

Evidence-based diagnostic features include: - Serum: low K+, low Cl−, metabolic alkalosis (ABG), and often elevated renin/aldosterone. (alla2023ararepresentation pages 2-3, choi2023longtermoutcomeof pages 1-2) - Urine: urinary electrolyte wasting; 24-hour urinary calcium is useful to differentiate BS (often normal/high urinary Ca) from Gitelman syndrome (hypocalciuria), though overlap exists. (alla2023ararepresentation pages 2-3, das2024barttersyndromewith pages 2-5) - Imaging: renal ultrasound for nephrocalcinosis. (jiang2024adultclassicbartter pages 1-2, choi2023longtermoutcomeof pages 4-6)

10.2 Genetic testing approach

Modern sources emphasize next-generation sequencing (NGS)–based multi‑gene testing because phenotypes overlap across BS types and with Gitelman syndrome. Panels commonly include SLC12A1, KCNJ1, CLCNKB, CLCNKA, BSND, MAGED2. (alla2023ararepresentation pages 2-3, das2024barttersyndromewith pages 2-5)

For severe prenatal polyhydramnios suggestive of transient antenatal BS, 2024 evidence supports WES/trio‑WES and careful intronic analysis; a minigene assay established pathogenic splicing for an intronic MAGED2 deletion. (yan2024identificationofa pages 4-6, yan2024identificationofa pages 2-4)

10.3 Differential diagnosis

  • Gitelman syndrome: typically hypomagnesemia and hypocalciuria; BS often has normal Mg and normal/high urinary Ca; neonatal polyhydramnios supports BS. (das2024barttersyndromewith pages 2-5, thimm2024untanglingtheuncertain pages 6-6)
  • Pseudo‑Bartter: cystic fibrosis and nephrotoxic exposures can mimic biochemical phenotype. (alla2023ararepresentation pages 2-3, alla2023ararepresentation pages 3-4)

Figure/table evidence: The extracted Table/Figure images from a 2024 review visually summarize genotype–phenotype distinctions and gene/subtype mapping. (thimm2024untanglingtheuncertain media ca88ecd5, thimm2024untanglingtheuncertain media 317ad3d1, thimm2024untanglingtheuncertain media 1cbedca4)

11. Outcome / prognosis

11.1 Long-term outcomes (statistics from 2023 multicenter cohort)

In the Korean 54‑patient study (median follow-up 8 years): - Short stature: 41% (22/54) at last follow-up (choi2023longtermoutcomeof pages 4-6) - CKD (G3–G5): 11% overall (6/54) (choi2023longtermoutcomeof pages 4-6) - Nephrocalcinosis: 35% at last follow-up (15/43) (choi2023longtermoutcomeof pages 4-6) - Sensorineural hearing loss: 7% (4/54) (choi2023longtermoutcomeof pages 4-6) - Developmental delay: 15% (8/54) (choi2023longtermoutcomeof pages 4-6)

The cohort also observed decreasing potassium needs with age and noted potential contributors to CKD (nephrocalcinosis, prolonged NSAID use, chronic hypokalemia, prematurity), though causal attribution is not definitive in this retrospective design. (choi2023longtermoutcomeof pages 4-6)

12. Treatment

12.1 Standard-of-care pharmacotherapy and supportive care (current practice)

Treatment is largely symptomatic, aiming to prevent dehydration and correct electrolyte/acid–base disturbance: - Potassium chloride supplementation and often sodium supplementation (choi2023longtermoutcomeof pages 4-6) - NSAIDs (e.g., indomethacin/ibuprofen/celecoxib) to counter prostaglandin-mediated renal losses; a 2023 cohort found no clear outcome differences among NSAID types used. (choi2023longtermoutcomeof pages 4-6) - Potassium-sparing agents (spironolactone/eplerenone/amiloride) used in many settings, but one cohort cautions against routine use because of possible worsening salt wasting/polyuria. (choi2023longtermoutcomeof pages 4-6, alla2023ararepresentation pages 2-3) - ACE inhibitors/ARBs: sometimes used (e.g., with proteinuria), but may risk hypotension/prerenal AKI in salt-wasting states. (alla2023ararepresentation pages 2-3)

Real-world implementation (cohort statistics): In the Korean 54‑patient cohort, 94% received potassium chloride supplementation and 68% received potassium‑sparing diuretics; mean KCl dosing was 5.0 mEq/day/kg in patients <18 years and 2.1 mEq/day/kg in adults. (choi2023longtermoutcomeof pages 1-2)

12.2 Experimental/precision approaches (model-driven)

A BsndR8L/R8L knock-in mouse model of Bartter type IV demonstrated that pharmacologic chaperoning via the Hsp90 inhibitor 17‑AAG improved membrane localization of mutant barttin and ameliorated low-salt–induced metabolic alkalosis/hypokalemia and partially rescued hearing after one week. (Biochem Biophys Res Commun; 2013-11; https://doi.org/10.1016/j.bbrc.2013.10.129) (nomura2013treatmentwith17allylamino17demethoxygeldanamycin pages 5-6)

12.3 Clinical trials (ClinicalTrials.gov)

  • NCT03847571 (first posted 2019-02-20; Tehran University of Medical Sciences): “Acetazolamide (AZ) for Management of Alkalosis in Bartter Syndrome” evaluates oral acetazolamide 5 mg/kg/day for 4 weeks in a prospective case‑crossover observational design (estimated n=20; ages 1–10). Primary outcomes include change in serum bicarbonate and 24‑hour urine volume. (https://clinicaltrials.gov/study/NCT03847571) (NCT03847571 chunk 1)
  • NCT01021280 (planned 2013-01 start; Soroka University Medical Center): observational case‑control study of “Parathyroid Hormone (PTH) Homeostasis in Bartter Syndrome” using controlled calcium manipulations to study PTH regulation in BS type II vs type IV. Purpose statement includes the quote: “to investigate the PT-gland function and regulation in BS.” (https://clinicaltrials.gov/study/NCT01021280) (NCT01021280 chunk 1)

12.4 Suggested MAXO terms (non-exhaustive)

  • Potassium supplementation: MAXO concept for electrolyte replacement therapy (supported by cohort practice). (choi2023longtermoutcomeof pages 1-2)
  • NSAID therapy (prostaglandin inhibition) (choi2023longtermoutcomeof pages 4-6)
  • Potassium-sparing diuretic therapy (choi2023longtermoutcomeof pages 1-2)
  • Prenatal amnioreduction / indomethacin for severe polyhydramnios in MAGED2-related disease (yan2024identificationofa pages 1-2)

13. Prevention

13.1 Primary prevention

Not applicable in the classic public-health sense for most autosomal recessive BS. Primary prevention is largely limited to reproductive counseling and carrier testing in at-risk families.

13.2 Secondary prevention

  • Early recognition and treatment of dehydration/electrolyte disturbance in neonates/infants to prevent acute kidney injury and complications. (choi2023longtermoutcomeof pages 4-6)
  • Prenatal surveillance when severe polyhydramnios is present; for MAGED2-related disease, prenatal genetic diagnosis and management (indomethacin and amnioreduction described) may reduce prematurity-associated morbidity in selected cases. (yan2024identificationofa pages 1-2)

13.3 Tertiary prevention

  • Prevent CKD progression by managing chronic hypokalemia, nephrocalcinosis risk, and avoiding iatrogenic hypotension or nephrotoxicity; cohort authors highlight these as plausible contributors to CKD. (choi2023longtermoutcomeof pages 4-6)

14. Other species / natural disease

A naturally occurring large-animal phenotype linked to SLC12A1 illustrates conserved biology: - Japanese Black cattle hydrallantois: a recessive SLC12A1 missense variant (p.Pro372Leu) disrupts apical NKCC2 localization in fetal kidneys, causing impaired urine concentration and fetal polyuria with accumulation of urine in the allantoic cavity (hydrallantois). (BMC Genomics; 2016-09; https://doi.org/10.1186/s12864-016-3035-1) (sasaki2016amissensemutation pages 1-2, sasaki2016amissensemutation pages 11-12)

15. Model organisms

15.1 Mouse models (Slc12a1/NKCC2)

Multiple mouse models recapitulate aspects of type I Bartter syndrome, with phenotype severity depending on allele: - ENU-derived Slc12a1I299F mice show “MOUSE MODEL OF BARTTER SYNDROME” features including severe polyuria and a urea-selective concentrating defect; they also show metabolic alkalosis, hypotension and other systemic features, while not always reproducing hyperreninemia. (Am J Physiol Renal Physiol; 2010-06; https://doi.org/10.1152/ajprenal.00522.2009) (kemter2010mutationofthe pages 3-4, kemter2010mutationofthe pages 1-2) - Systematic phenotyping of Slc12a1I299F homozygotes reported kidney defects “highly similar to the late-onset manifestation” of human disease and additional phenotypes (low blood pressure, osteopenia, reduced body weight/fat). (J Biomed Sci; 2014-08; https://doi.org/10.1186/s12929-014-0068-0) (kemter2014standardizedsystemicphenotypic pages 1-2)

15.2 Mouse models (Bsnd/barttin) and therapeutic proof-of-concept

A BsndR8L/R8L knock-in mouse provides a model of type IV disease and supports therapeutic rescue via chaperone modulation (17‑AAG) with improvements in renal and auditory phenotypes. (nomura2013treatmentwith17allylamino17demethoxygeldanamycin pages 5-6)

Expert opinion and analysis (authoritative synthesis from recent sources)

  1. Genetic testing is central because adult-onset or atypical BS can mimic Gitelman syndrome; 2024 adult case literature explicitly frames genetic diagnosis as decisive for differential diagnosis and management. (jiang2024adultclassicbartter pages 1-2)
  2. Long-term morbidity is non-trivial: even with treatment, 2023 multicenter cohort evidence shows high residual rates of growth impairment (41%) and measurable CKD risk (11%). (choi2023longtermoutcomeof pages 4-6)
  3. Mechanistic emphasis is shifting toward trafficking/quality control: 2024 mechanistic review positions ER export/ERAD of NKCC2 as a key regulatory node, which is conceptually aligned with emerging chaperone-based strategies demonstrated for barttin in animal models. (laghmani2024proteinqualitycontrol pages 1-2, nomura2013treatmentwith17allylamino17demethoxygeldanamycin pages 5-6)

Data/statistics highlights (recent)

  • Korean multicenter cohort (Frontiers in Medicine; 2023-03): polyhydramnios 47% (18/38), preterm birth 28% (13/46), nephrocalcinosis 41% at presentation (17/41) and 35% at last visit (15/43), short stature 41% (22/54), developmental delay 15% (8/54), hearing loss 7% (4/54), CKD 11% (6/54). (choi2023longtermoutcomeof pages 2-3, choi2023longtermoutcomeof pages 4-6)
  • Treatment utilization in that cohort: KCl 94%, potassium-sparing agents 68%, mean KCl dose 5.0 mEq/day/kg (<18y) and 2.1 mEq/day/kg (adults). (choi2023longtermoutcomeof pages 1-2)

Limitations of this report (evidence access constraints)

  • ICD-10/ICD-11, Orphanet disease IDs, and MeSH identifiers were not present in the retrieved full texts; these require direct extraction from those respective terminologies.
  • Some mechanistic and variant-spectrum statements in secondary reviews cite additional primary sources that were not fully retrieved in this run; therefore, this report prioritizes claims directly supported by the cited context IDs.

References

  1. (choi2023longtermoutcomeof pages 1-2): Naye Choi, Seong Heon Kim, Eun Hui Bae, Eun Mi Yang, Keum Hwa Lee, Sang-Ho Lee, Joo Hoon Lee, Yo Han Ahn, Hae Il Cheong, Hee Gyung Kang, Hye Sun Hyun, and Ji Hyun Kim. Long-term outcome of bartter syndrome in 54 patients: a multicenter study in korea. Frontiers in Medicine, Mar 2023. URL: https://doi.org/10.3389/fmed.2023.1099840, doi:10.3389/fmed.2023.1099840. This article has 12 citations.

  2. (laghmani2024proteinqualitycontrol pages 1-2): Kamel Laghmani. Protein quality control of nkcc2 in bartter syndrome and blood pressure regulation. Cells, 13:818, May 2024. URL: https://doi.org/10.3390/cells13100818, doi:10.3390/cells13100818. This article has 0 citations.

  3. (yan2024identificationofa pages 1-2): Xu Yan, Yueyue Hu, Xin Zhang, Xia Gao, Yang Zhao, Haiying Peng, Liu Ouyang, and Changjun Zhang. Identification of a novel intronic mutation of maged2 gene in a chinese family with antenatal bartter syndrome. BMC Medical Genomics, Jan 2024. URL: https://doi.org/10.1186/s12920-024-01797-8, doi:10.1186/s12920-024-01797-8. This article has 5 citations and is from a peer-reviewed journal.

  4. (alla2023ararepresentation pages 2-3): Deekshitha Alla, Meghana Krishna Kesineni, Roopeessh Vempati, Hinal Patel, Shenelle Menezes, Sai Santhosha Mrudula Alla, Devkumar Patel, Srajan Gupta, Krish Patel, and Anju Pradeep. A rare presentation of adult-onset bartter syndrome: a case report. Cureus, Mar 2023. URL: https://doi.org/10.7759/cureus.36120, doi:10.7759/cureus.36120. This article has 6 citations.

  5. (yang2026identificationofthree pages 12-14): Shu-fa Yang, Xiaojuan Li, Haili Jiang, Jiahui Cheng, Changlong Li, Xinyi Xie, and Xiaoqin Xiao. Identification of three novel maged2 variants causing antenatal bartter syndrome in three chinese families. Genes, 17:424, Apr 2026. URL: https://doi.org/10.3390/genes17040424, doi:10.3390/genes17040424. This article has 0 citations.

  6. (zhou2023amosaicmutation pages 1-2): Lan Zhou, Xiaohui Chen, Jiao-Jiao Xiong, and Ling Lei. A mosaic mutation in the clcnkb gene causing bartter syndrome: a case report. Frontiers in Pediatrics, Apr 2023. URL: https://doi.org/10.3389/fped.2023.1034923, doi:10.3389/fped.2023.1034923. This article has 4 citations.

  7. (qasba2023barttersyndromea pages 2-5): Rakhtan K. Qasba, Anna Carolina Flumignan Bucharles, Maria Victoria Ferreira Piccoli, Pranjal Sharma, Akshat Banga, Balakrishnan Kamaraj, Faisal A. Nawaz, Harshadayani Jagadish Kumar, Mahika Afrin Happy, Ruman K. Qasba, Gowthami Sai Kogilathota Jagirdhar, Mohammad Yasir Essar, Piyush Garg, Shiva Teja Reddy, Kaanthi Rama, Salim Surani, and Rahul Kashyap. Bartter syndrome: a systematic review of case reports and case series. Medicina, 59:1638, Sep 2023. URL: https://doi.org/10.3390/medicina59091638, doi:10.3390/medicina59091638. This article has 26 citations.

  8. (jiang2024adultclassicbartter pages 1-2): Le Jiang, Dongmei Li, Qiansha Guo, Yunfeng Li, Lei Zan, and Rihan Ao. Adult classic bartter syndrome: a case report with 5-year follow-up and literature review. Endocrine journal, 71:537-542, Mar 2024. URL: https://doi.org/10.1507/endocrj.ej23-0631, doi:10.1507/endocrj.ej23-0631. This article has 6 citations and is from a peer-reviewed journal.

  9. (qasba2023barttersyndromea pages 1-2): Rakhtan K. Qasba, Anna Carolina Flumignan Bucharles, Maria Victoria Ferreira Piccoli, Pranjal Sharma, Akshat Banga, Balakrishnan Kamaraj, Faisal A. Nawaz, Harshadayani Jagadish Kumar, Mahika Afrin Happy, Ruman K. Qasba, Gowthami Sai Kogilathota Jagirdhar, Mohammad Yasir Essar, Piyush Garg, Shiva Teja Reddy, Kaanthi Rama, Salim Surani, and Rahul Kashyap. Bartter syndrome: a systematic review of case reports and case series. Medicina, 59:1638, Sep 2023. URL: https://doi.org/10.3390/medicina59091638, doi:10.3390/medicina59091638. This article has 26 citations.

  10. (thimm2024untanglingtheuncertain pages 4-6): Chantelle Thimm and James Adjaye. Untangling the uncertain role of overactivation of the renin–angiotensin–aldosterone system with the aging process based on sodium wasting human models. International Journal of Molecular Sciences, 25:9332, Aug 2024. URL: https://doi.org/10.3390/ijms25179332, doi:10.3390/ijms25179332. This article has 6 citations.

  11. (choi2023longtermoutcomeof pages 4-6): Naye Choi, Seong Heon Kim, Eun Hui Bae, Eun Mi Yang, Keum Hwa Lee, Sang-Ho Lee, Joo Hoon Lee, Yo Han Ahn, Hae Il Cheong, Hee Gyung Kang, Hye Sun Hyun, and Ji Hyun Kim. Long-term outcome of bartter syndrome in 54 patients: a multicenter study in korea. Frontiers in Medicine, Mar 2023. URL: https://doi.org/10.3389/fmed.2023.1099840, doi:10.3389/fmed.2023.1099840. This article has 12 citations.

  12. (yan2024identificationofa pages 4-6): Xu Yan, Yueyue Hu, Xin Zhang, Xia Gao, Yang Zhao, Haiying Peng, Liu Ouyang, and Changjun Zhang. Identification of a novel intronic mutation of maged2 gene in a chinese family with antenatal bartter syndrome. BMC Medical Genomics, Jan 2024. URL: https://doi.org/10.1186/s12920-024-01797-8, doi:10.1186/s12920-024-01797-8. This article has 5 citations and is from a peer-reviewed journal.

  13. (choi2023longtermoutcomeof pages 2-3): Naye Choi, Seong Heon Kim, Eun Hui Bae, Eun Mi Yang, Keum Hwa Lee, Sang-Ho Lee, Joo Hoon Lee, Yo Han Ahn, Hae Il Cheong, Hee Gyung Kang, Hye Sun Hyun, and Ji Hyun Kim. Long-term outcome of bartter syndrome in 54 patients: a multicenter study in korea. Frontiers in Medicine, Mar 2023. URL: https://doi.org/10.3389/fmed.2023.1099840, doi:10.3389/fmed.2023.1099840. This article has 12 citations.

  14. (thimm2024sodiumdeficiencydiseases pages 5-9): Chantelle Thimm and James Adjaye. Sodium deficiency diseases: the association with the renin-angiotensin-aldosterone system, aging and inflammation. Jul 2024. URL: https://doi.org/10.20944/preprints202407.1238.v1, doi:10.20944/preprints202407.1238.v1.

  15. (thimm2024untanglingtheuncertain pages 6-6): Chantelle Thimm and James Adjaye. Untangling the uncertain role of overactivation of the renin–angiotensin–aldosterone system with the aging process based on sodium wasting human models. International Journal of Molecular Sciences, 25:9332, Aug 2024. URL: https://doi.org/10.3390/ijms25179332, doi:10.3390/ijms25179332. This article has 6 citations.

  16. (yang2026identificationofthree pages 1-2): Shu-fa Yang, Xiaojuan Li, Haili Jiang, Jiahui Cheng, Changlong Li, Xinyi Xie, and Xiaoqin Xiao. Identification of three novel maged2 variants causing antenatal bartter syndrome in three chinese families. Genes, 17:424, Apr 2026. URL: https://doi.org/10.3390/genes17040424, doi:10.3390/genes17040424. This article has 0 citations.

  17. (yan2024identificationofa pages 2-4): Xu Yan, Yueyue Hu, Xin Zhang, Xia Gao, Yang Zhao, Haiying Peng, Liu Ouyang, and Changjun Zhang. Identification of a novel intronic mutation of maged2 gene in a chinese family with antenatal bartter syndrome. BMC Medical Genomics, Jan 2024. URL: https://doi.org/10.1186/s12920-024-01797-8, doi:10.1186/s12920-024-01797-8. This article has 5 citations and is from a peer-reviewed journal.

  18. (nomura2013treatmentwith17allylamino17demethoxygeldanamycin pages 5-6): Naohiro Nomura, Kazusaku Kamiya, Katsuhisa Ikeda, Naofumi Yui, Motoko Chiga, Eisei Sohara, Tatemitu Rai, Sei Sakaki, and Shinich Uchida. Treatment with 17-allylamino-17-demethoxygeldanamycin ameliorated symptoms of bartter syndrome type iv caused by mutated bsnd in mice. Biochemical and biophysical research communications, 441 3:544-9, Nov 2013. URL: https://doi.org/10.1016/j.bbrc.2013.10.129, doi:10.1016/j.bbrc.2013.10.129. This article has 19 citations and is from a peer-reviewed journal.

  19. (das2024barttersyndromewith pages 2-5): Arki Das, Rohini R, and Somnath Panda. Bartter syndrome with recurrent hypokalemic periodic paralysis: a case report. Cureus, Oct 2024. URL: https://doi.org/10.7759/cureus.72406, doi:10.7759/cureus.72406. This article has 1 citations.

  20. (alla2023ararepresentation pages 3-4): Deekshitha Alla, Meghana Krishna Kesineni, Roopeessh Vempati, Hinal Patel, Shenelle Menezes, Sai Santhosha Mrudula Alla, Devkumar Patel, Srajan Gupta, Krish Patel, and Anju Pradeep. A rare presentation of adult-onset bartter syndrome: a case report. Cureus, Mar 2023. URL: https://doi.org/10.7759/cureus.36120, doi:10.7759/cureus.36120. This article has 6 citations.

  21. (thimm2024untanglingtheuncertain media ca88ecd5): Chantelle Thimm and James Adjaye. Untangling the uncertain role of overactivation of the renin–angiotensin–aldosterone system with the aging process based on sodium wasting human models. International Journal of Molecular Sciences, 25:9332, Aug 2024. URL: https://doi.org/10.3390/ijms25179332, doi:10.3390/ijms25179332. This article has 6 citations.

  22. (thimm2024untanglingtheuncertain media 317ad3d1): Chantelle Thimm and James Adjaye. Untangling the uncertain role of overactivation of the renin–angiotensin–aldosterone system with the aging process based on sodium wasting human models. International Journal of Molecular Sciences, 25:9332, Aug 2024. URL: https://doi.org/10.3390/ijms25179332, doi:10.3390/ijms25179332. This article has 6 citations.

  23. (thimm2024untanglingtheuncertain media 1cbedca4): Chantelle Thimm and James Adjaye. Untangling the uncertain role of overactivation of the renin–angiotensin–aldosterone system with the aging process based on sodium wasting human models. International Journal of Molecular Sciences, 25:9332, Aug 2024. URL: https://doi.org/10.3390/ijms25179332, doi:10.3390/ijms25179332. This article has 6 citations.

  24. (NCT03847571 chunk 1): Acetazolamide (AZ) for Management of Alkalosis in Bartter Syndrome. Tehran University of Medical Sciences. 2019. ClinicalTrials.gov Identifier: NCT03847571

  25. (NCT01021280 chunk 1): Daniel Landau MD. Parathyroid Hormone (PTH) Homeostasis in Bartter Syndrome. Soroka University Medical Center. 2013. ClinicalTrials.gov Identifier: NCT01021280

  26. (sasaki2016amissensemutation pages 1-2): Shinji Sasaki, Kiyotoshi Hasegawa, Tomoko Higashi, Yutaka Suzuki, Sumio Sugano, Yasuaki Yasuda, and Yoshikazu Sugimoto. A missense mutation in solute carrier family 12, member 1 (slc12a1) causes hydrallantois in japanese black cattle. BMC Genomics, Sep 2016. URL: https://doi.org/10.1186/s12864-016-3035-1, doi:10.1186/s12864-016-3035-1. This article has 28 citations and is from a peer-reviewed journal.

  27. (sasaki2016amissensemutation pages 11-12): Shinji Sasaki, Kiyotoshi Hasegawa, Tomoko Higashi, Yutaka Suzuki, Sumio Sugano, Yasuaki Yasuda, and Yoshikazu Sugimoto. A missense mutation in solute carrier family 12, member 1 (slc12a1) causes hydrallantois in japanese black cattle. BMC Genomics, Sep 2016. URL: https://doi.org/10.1186/s12864-016-3035-1, doi:10.1186/s12864-016-3035-1. This article has 28 citations and is from a peer-reviewed journal.

  28. (kemter2010mutationofthe pages 3-4): Elisabeth Kemter, Birgit Rathkolb, Lise Bankir, Anja Schrewe, Wolfgang Hans, Christina Landbrecht, Matthias Klaften, Boris Ivandic, Helmut Fuchs, Valérie Gailus-Durner, Martin Hrabé de Angelis, Eckhard Wolf, Ruediger Wanke, and Bernhard Aigner. Mutation of the na(+)-k(+)-2cl(-) cotransporter nkcc2 in mice is associated with severe polyuria and a urea-selective concentrating defect without hyperreninemia. American journal of physiology. Renal physiology, 298 6:F1405-15, Jun 2010. URL: https://doi.org/10.1152/ajprenal.00522.2009, doi:10.1152/ajprenal.00522.2009. This article has 48 citations.

  29. (kemter2010mutationofthe pages 1-2): Elisabeth Kemter, Birgit Rathkolb, Lise Bankir, Anja Schrewe, Wolfgang Hans, Christina Landbrecht, Matthias Klaften, Boris Ivandic, Helmut Fuchs, Valérie Gailus-Durner, Martin Hrabé de Angelis, Eckhard Wolf, Ruediger Wanke, and Bernhard Aigner. Mutation of the na(+)-k(+)-2cl(-) cotransporter nkcc2 in mice is associated with severe polyuria and a urea-selective concentrating defect without hyperreninemia. American journal of physiology. Renal physiology, 298 6:F1405-15, Jun 2010. URL: https://doi.org/10.1152/ajprenal.00522.2009, doi:10.1152/ajprenal.00522.2009. This article has 48 citations.

  30. (kemter2014standardizedsystemicphenotypic pages 1-2): Elisabeth Kemter, Birgit Rathkolb, Lore Becker, Ines Bolle, Dirk H Busch, Claudia Dalke, Ralf Elvert, Jack Favor, Jochen Graw, Wolfgang Hans, Boris Ivandic, Svetoslav Kalaydjiev, Thomas Klopstock, Ildikó Rácz, Jan Rozman, Anja Schrewe, Holger Schulz, Andreas Zimmer, Helmut Fuchs, Valérie Gailus-Durner, Martin Hrabé de Angelis, Eckhard Wolf, and Bernhard Aigner. Standardized, systemic phenotypic analysis of slc12a1i299f mutant mice. Journal of Biomedical Science, 21:68-68, Aug 2014. URL: https://doi.org/10.1186/s12929-014-0068-0, doi:10.1186/s12929-014-0068-0. This article has 9 citations and is from a domain leading peer-reviewed journal.

OpenScientist ▸
1. Disease Information
openscientist-autonomous 40 citations 2026-05-06T00:20:19.098406+00:00

1. Disease Information

Overview

Bartter syndrome represents a group of rare, inherited renal tubular disorders characterized by defective salt reabsorption in the thick ascending limb (TAL) of the loop of Henle. The resulting clinical phenotype includes hypokalemic hypochloremic metabolic alkalosis, secondary hyperaldosteronism, and normal to low blood pressure (PMID: 42042082). BS was first described by Frederic Bartter and colleagues in 1962.

Key Identifiers

Database Identifier
MONDO MONDO:0008858 (Bartter syndrome)
OMIM 601678 (Type I), 241200 (Type II), 607364 (Type III), 602522 (Type IV/IVa), 613090 (Type IVb), 300971 (Type V/MAGED2)
Orphanet ORPHA:112
ICD-10 E26.8 (Other hyperaldosteronism)
ICD-11 5A46 (Bartter syndrome)
MeSH D001477

Synonyms and Alternative Names

  • Bartter disease
  • Salt-losing tubulopathy
  • Hyperprostaglandin E syndrome (HPS) — used for the antenatal/neonatal form
  • Antenatal Bartter syndrome (aBS)
  • Classic Bartter syndrome (cBS)
  • Neonatal Bartter syndrome
  • Bartter syndrome with sensorineural deafness (Type IV)
  • Transient antenatal Bartter syndrome (MAGED2-related)

Information Sources

The information presented herein is derived from aggregated disease-level resources including OMIM, Orphanet, GeneReviews, and PubMed literature, supplemented by clinical cohort studies and case series representing individual patient data.

2. Etiology

Disease Causal Factors

Bartter syndrome is a purely genetic disease caused by loss-of-function mutations in genes encoding ion transport proteins or their regulatory subunits in the TAL of the loop of Henle. Current evidence supports five core disease genes:

  1. SLC12A1 → encodes NKCC2 (Na-K-2Cl cotransporter) → BS Type I
  2. KCNJ1 → encodes ROMK (renal outer medullary K⁺ channel) → BS Type II
  3. CLCNKB → encodes ClC-Kb (basolateral Cl⁻ channel) → BS Type III
  4. BSND → encodes barttin (accessory subunit of ClC-K channels) → BS Type IV
  5. MAGED2 → encodes MAGED2 (regulates NKCC2/NCC expression) → X-linked transient form

As stated in the landmark 2024 review: "Current evidence supports SLC12A1, KCNJ1, CLCNKB, BSND, and MAGED2 as the core disease genes within the contemporary BS spectrum, with MAGED2 causing a distinct X-linked transient antenatal form" (PMID: 42042082).

Additionally, digenic inheritance has been demonstrated in BS Type IV, where simultaneous loss-of-function mutations in both CLCNKA and CLCNKB produce a phenotype indistinguishable from BSND mutations (PMID: 18310267).

Genetic Risk Factors

  • Consanguinity is a major risk factor, given autosomal recessive inheritance. In Egyptian cohorts, 72% of HRTD families (including BS) had parental consanguinity (PMID: 37661676).
  • Founder mutations: The CLCNKB p.W610X variant accounted for 54.3% of alleles in a Korean BS cohort, with large deletions comprising 21.7% (PMID: 21865213).
  • Population-specific variant distributions: The complete CLCNKB deletion (1-20 del) was the most common variant in a Brazilian cohort and showed prevalence similar to Chinese cohorts and individuals of African/Middle Eastern descent (PMID: 36882007).

Environmental Risk Factors

Bartter syndrome is a Mendelian genetic disorder; environmental factors do not cause the disease. However, environmental stressors can exacerbate the phenotype: - Dehydration (heat, inadequate fluid intake) can precipitate acute electrolyte crises - Dietary sodium restriction can worsen volume depletion - NSAID-related gastrointestinal complications (from indomethacin therapy) can impair nutritional intake, as documented in a case of severe vitamin A deficiency (PMID: 40262923)

Protective Factors

No specific genetic or environmental protective factors have been identified for BS. For the MAGED2 transient form, serial amnioreduction during pregnancy significantly improved outcomes: average gestational age at delivery was higher (30.71 vs. 28.7 weeks, p = 0.03) and no neonatal mortality was observed compared to 5/18 deaths without treatment (PMID: 38159268).

Gene-Environment Interactions

Not applicable for this monogenic disorder. However, drugs that affect renal tubular function (loop diuretics, aminoglycosides) can produce an acquired pseudo-Bartter phenotype in genetically susceptible or non-susceptible individuals (PMID: 38350705).

3. Phenotypes

Core Electrolyte and Metabolic Abnormalities

Phenotype HPO Term Frequency Onset Severity
Hypokalemia HP:0002900 ~100% Neonatal–childhood Moderate–severe
Metabolic alkalosis HP:0001959 ~100% Neonatal–childhood Moderate–severe
Hypochloremia HP:0003113 ~100% Neonatal–childhood Moderate
Hyperreninemia HP:0000848 ~100% Neonatal Variable
Hyperaldosteronism (secondary) HP:0000859 ~100% Neonatal Variable
Elevated urinary PGE₂ — >80% (Types I, II, IV) Neonatal Variable
Hypercalciuria HP:0002150 ~100% (Types I, II); variable (III) Neonatal–childhood Mild–severe
Nephrocalcinosis HP:0000121 ~100% (Types I, II); 16% (Type IV) Infancy–childhood Progressive
Hypomagnesemia HP:0002917 Variable (esp. Type III) Childhood Mild–moderate

Clinical Manifestations

Phenotype HPO Term Frequency Onset Progression
Polyhydramnios (maternal) HP:0001561 ~100% (antenatal BS) Prenatal (24-30 wk) Progressive
Polyuria/polydipsia HP:0000103/HP:0001959 >90% Neonatal–infancy Chronic
Failure to thrive HP:0001508 68-91% Infancy Progressive without Tx
Growth retardation HP:0001510 >60% Childhood Improves with treatment
Prematurity HP:0001622 >80% (antenatal BS) Birth —
Dehydration episodes HP:0001944 72% Neonatal–infancy Episodic
Developmental delay HP:0001263 24-79% Infancy Variable
Sensorineural deafness HP:0000407 ~100% (Type IV only) Congenital Stable–progressive
Muscle weakness HP:0001324 Variable Childhood–adult Episodic
Salt craving HP:0100515 Common Childhood Chronic

Cardiovascular Manifestations

Despite characteristic normotension or hypotension, Bartter syndrome carries significant cardiovascular risk. As documented in a 2024 narrative review: "Although considered benign entities, major adverse cardiovascular events may complicate both syndromes, in form of ventricular arrhythmias leading to palpitations, syncope or sudden cardiac death, microvascular cardiac dysfunction and exercise-induced myocardial contractile deficit" (PMID: 39445629).

Cardiovascular Phenotype HPO Term Mechanism
Ventricular arrhythmias HP:0004308 Chronic hypokalemia/hypomagnesemia
Syncope HP:0001279 Arrhythmia-mediated
Sudden cardiac death HP:0001645 QT prolongation from electrolyte imbalance
Microvascular cardiac dysfunction — Neurohormonal alterations

Renal Complications

Phenotype HPO Term Frequency Onset
Chronic kidney disease HP:0012622 ~30% Childhood–adulthood
Nephrocalcinosis HP:0000121 >90% (Types I/II) Infancy
Proteinuria HP:0000093 46% (CLCNKB) Childhood
Hydronephrosis HP:0000126 Variable Neonatal (severe cases)

CKD develops in approximately 30% of BS/GS patients. "Chronic kidney disease (CKD) occurs in about 30% of patients with BS or GS, suggesting that the long-term prognosis can be unfavorable. In our cohort the features associated with CKD were lower gestational age at birth and a molecular diagnosis of BS, especially BS type 1" (PMID: 35628451).

Bone and Mineral Phenotypes

  • Osteopenia (HP:0000938): secondary to chronic hypercalciuria and altered vitamin D metabolism
  • Hyperparathyroidism (HP:0000843): particularly accentuated in BS Type II with PTH values of 160.6 ± 85.8 pg/mL vs. 92.5 ± 48 pg/mL in Type IV (p = 0.006) (PMID: 26857709)
  • Rickets: rare association, part of broader refractory rickets differential (PMID: 39862309)

MAGED2 Transient Antenatal Form (Type V)

This X-linked form represents the most severe perinatal presentation with unique outcomes: "Analysis of the data from 54 symptomatic patients showed spontaneous resolution of symptoms in 27% of cases, persistent complications in 41% of cases, and fatality in 32% of cases. Clinical anomalies were reported in 76% of patients, mostly renal anomalies (52%), cardiovascular anomalies (29%), and dysmorphic features (13%)" (PMID: 39036894). Developmental delay was present in 24% of cases.

Quality of Life Impact

BS significantly impacts daily functioning through: - Chronic fatigue and muscle weakness limiting physical activity - Polyuria/polydipsia disrupting sleep and daily routines - Growth retardation affecting psychosocial development in children - Lifelong medication burden and electrolyte monitoring - Gastrointestinal side effects from NSAID therapy reducing nutritional intake - Risk of sudden cardiac events causing psychological burden

4. Genetic/Molecular Information

Causal Genes

Gene HGNC Chromosomal Locus Protein BS Type OMIM
SLC12A1 HGNC:10910 15q21.1 NKCC2 (Na-K-2Cl cotransporter 2) Type I 600839
KCNJ1 HGNC:6255 11q24.3 ROMK (Kir1.1) Type II 600359
CLCNKB HGNC:2027 1p36.13 ClC-Kb (chloride channel) Type III 602023
BSND HGNC:16512 1p32.3 Barttin (ClC-K accessory subunit) Type IVa 606412
CLCNKA + CLCNKB HGNC:2026/2027 1p36.13 ClC-Ka + ClC-Kb Type IVb —
MAGED2 HGNC:6815 Xp11.21 MAGED2 Type V (transient) 300470

Pathogenic Variants

SLC12A1 (Type I): Missense, frameshift, nonsense, and splice-site variants have been described. Novel variants include c.735C>G, c.1137del, c.2498-2499del, and c.1833delT, presenting with hyperparathyroidism and hypercalcemia (PMID: 28095294).

KCNJ1 (Type II): Ten variants, including eight novel ones, were identified in five Chinese probands, with missense variants being the most common type (PMID: 33058840). All variants are germline, autosomal recessive.

CLCNKB (Type III): The most genetically heterogeneous form. In Korean patients, p.W610X (54.3% of alleles) and large deletions (21.7%) predominate (PMID: 21865213). The complete gene deletion (1-20 del) is the most frequent variant in Brazilian cohorts and correlates with earlier manifestations and progressive CKD (PMID: 36882007). The clinical spectrum is remarkably heterogeneous—"no genotype-phenotype correlation" was found in Korean patients with CLCNKB mutations, with phenotypes ranging from antenatal BS to mixed Bartter-Gitelman presentation (PMID: 21865213).

BSND (Type IV): Homozygous mutations in exon 1 are most common, including p.Arg8Trp (c.22C>T), p.Arg8Gly (c.22C>G), p.Thr36Asn (c.107C>A), and p.Gly47Arg. Novel Moroccan mutations include p.Arg8Gly and p.Thr36Asn (PMID: 30174009). Digenic involvement of BSND and GJB2 mutations has been reported, potentially contributing to the severity of sensorineural deafness (PMID: 28012523).

MAGED2 (Type V): X-linked recessive. A novel c.1598C>T (p.Ala533Val) variant in exon 12 was reported in the first Chinese case (PMID: 34895150). The c.1337G>A variant was associated with severe polyhydramnios and fetal demise (PMID: 38159268).

Functional Consequences

All BS-causing mutations produce loss-of-function effects: - SLC12A1: Loss of apical Na-K-2Cl cotransport in TAL - KCNJ1: Loss of apical K⁺ recycling, impairing NKCC2 function - CLCNKB: Loss of basolateral Cl⁻ exit, impairing transcellular NaCl reabsorption - BSND: Loss of barttin-mediated trafficking and activation of ClC-K channels; DHHC7-mediated palmitoylation of barttin is critical for ClC-K function (PMID: 32184353) - MAGED2: ER retention and degradation of NKCC2, preventing apical membrane expression (PMID: 38786040)

Modifier Genes and Digenic Inheritance

  • GJB2 (connexin 26): Compound heterozygous GJB2 mutations co-occurring with BSND mutations may contribute to the severity of sensorineural deafness in Type IV BS (PMID: 28012523)
  • CLCNKA + CLCNKB digenic: Simultaneous biallelic loss-of-function in both chloride channel genes produces Type IVb BS, indistinguishable from BSND-mutated Type IVa (PMID: 18310267)
  • WNK-SPAK-OSR1 signaling axis: SPAK deficiency produces a Gitelman-like phenotype, while OSR1 knockout produces a Bartter-like phenotype (PMID: 24039833; PMID: 27068441)

Epigenetic and Chromosomal Abnormalities

No specific epigenetic modifications or chromosomal abnormalities have been reported for BS. Large-scale structural deletions (e.g., complete CLCNKB gene deletion) represent the most significant genomic rearrangement.

5. Environmental Information

Environmental Factors

Bartter syndrome is not caused by environmental factors. However, acquired pseudo-Bartter syndrome can be induced by: - Loop diuretics (furosemide) - Aminoglycoside antibiotics - Chronic laxative abuse leading to end-stage kidney disease (PMID: 38306007) - Cisplatin nephrotoxicity

Lifestyle Factors

  • Dietary sodium intake: Inadequate salt supplementation can worsen volume depletion
  • Hydration status: Critical for preventing acute decompensation
  • Chronic vomiting (e.g., bulimia nervosa) can mimic BS (PMID: 16231363)

Infectious Agents

Not directly applicable. However, tuberculosis and sarcoidosis have been reported to cause acquired Bartter-like phenotypes (PMID: 38350705).

6. Mechanism / Pathophysiology

Molecular Pathways

The primary pathophysiological cascade in Bartter syndrome follows a defined sequence:

UPSTREAM TRIGGER:
  Loss-of-function mutation in TAL ion transport gene
      ↓
PRIMARY DEFECT:
  Impaired NaCl reabsorption in thick ascending limb
      ↓
IMMEDIATE CONSEQUENCES:
  ├── Renal salt wasting → Volume depletion
  ├── Impaired countercurrent multiplication → Urinary concentrating defect
  └── Reduced lumen-positive voltage → Impaired paracellular Ca²⁺/Mg²⁺ reabsorption
      ↓
MACULA DENSA RESPONSE:
  COX-2 upregulation → PGE₂ overproduction
      ↓
RAAS ACTIVATION:
  ├── Hyperreninemia
  ├── Secondary hyperaldosteronism
  └── Angiotensin II elevation
      ↓
DOWNSTREAM EFFECTS:
  ├── Hypokalemia (aldosterone-driven K⁺ secretion in collecting duct)
  ├── Metabolic alkalosis (H⁺ loss, HCO₃⁻ retention)
  ├── Hypercalciuria → Nephrocalcinosis
  ├── Prostaglandin-mediated vasodilation → Normal/low blood pressure
  └── Growth retardation, muscle weakness, polyuria

COX-2/PGE₂ Pathway (Key Mechanistic Finding)

The role of cyclooxygenase-2 in driving the hyperreninemic state was established through landmark studies demonstrating COX-2 expression in the macula densa of BS patients (PMID: 11115075). Both indomethacin (non-selective COX inhibitor) and rofecoxib (selective COX-2 inhibitor) suppressed PGE₂ excretion to normal values and reduced hyperreninemia. "In patients with HPS/aBS, excessive PGE₂ synthesis and hyperreninemia is dependent on COX-2 activity" (PMID: 12081585). Peripheral PGE₂ was strongly correlated with plasma renin activity (r = 0.86, p < 0.001) and aldosterone (r = 0.90, p < 0.001) (PMID: 929154).

Relevant GO terms: - GO:0006811 — Ion transport - GO:0055078 — Sodium ion homeostasis - GO:0006821 — Chloride transport - GO:0006813 — Potassium ion transport - GO:0019233 — Sensory perception of pain (PGE₂ pathway) - GO:0050728 — Negative regulation of inflammatory response

Protein Quality Control and NKCC2

The most severe perinatal form (MAGED2-related) involves ER retention and ER-associated degradation (ERAD) of NKCC2, preventing its trafficking to the apical membrane. "The most compelling evidence comes from patients with type 5 BS, the most severe form of prenatal BS, in whom NKCC2 is not detectable in the apical membrane of thick ascending limb (TAL) cells due to ER retention and ER-associated degradation (ERAD) mechanisms" (PMID: 38786040).

Developmental Defect in BS Pathogenesis

A novel mechanism was recently discovered: postnatal renal medulla maturation and TAL elongation are impaired in BS. "Postnatal renal medulla maturation and TAL elongation are impaired in Clc-k2-deficient BS mice. Primary cultured Clc-k2-deficient TAL cells have G1-S transition and proliferation delay. These developmental defects could be part of the early pathogenesis of BS and worsen the phenotype" (PMID: 38913022).

The "Mirror Model" of Hypertension

BS/GS patients paradoxically exhibit normo/hypotension and absent cardiac remodeling despite apparent RAAS activation. "Two human genetic tubulopathies, Bartter's (BS) and Gitelman's (GS) syndromes, have normo/hypotension and absent cardiac remodeling despite their apparent angiotensin system (RAS) activation. This seeming contradiction has led to an extensive investigation of BSGS patients, the result of which is that BSGS represents a mirror image of hypertension" (PMID: 37107186).

Calcium Homeostasis

Hypercalciuria in BS is linked to elevated 1,25-dihydroxyvitamin D levels and a renal calcium leak. Indomethacin treatment partially corrects hypercalciuria by reducing PGE₂-dependent calcium handling abnormalities, but a PGE₂-independent tubular defect also contributes (PMID: 2671327; PMID: 1340758).

Cell Types Involved

Cell Type CL Term Role
TAL epithelial cell CL:1001106 Primary site of ion transport defect
Macula densa cell CL:1000850 COX-2/PGE₂ production, TGF signaling
Juxtaglomerular cell CL:0000648 Renin secretion (hyperplasia in BS)
Principal cell (collecting duct) CL:1001431 Compensatory K⁺ secretion
Inner ear hair cell CL:0000855 Affected in Type IV (sensorineural deafness)

7. Anatomical Structures Affected

Organ Level

Organ/System UBERON Term Involvement
Kidney UBERON:0002113 Primary (TAL of loop of Henle)
Inner ear UBERON:0001846 Primary in Type IV (stria vascularis)
Heart UBERON:0000948 Secondary (arrhythmias from electrolyte imbalance)
Skeletal system UBERON:0001434 Secondary (osteopenia, rickets)
Growth plates UBERON:0002405 Secondary (growth retardation)
Urinary bladder UBERON:0001255 Secondary (hypertrophy in ROMK models)

Tissue and Cell Level

  • Renal cortex and medulla: TAL cells, macula densa, juxtaglomerular apparatus
  • Stria vascularis of the inner ear: ClC-Ka/Kb and barttin co-expression; loss causes endolymphatic K⁺ secretion failure → sensorineural deafness
  • Vascular smooth muscle: PGE₂-mediated vasodilation

Subcellular Level

Compartment GO CC Term Relevance
Apical plasma membrane GO:0016324 NKCC2, ROMK localization
Basolateral plasma membrane GO:0016323 ClC-Kb/barttin localization
Endoplasmic reticulum GO:0005783 NKCC2 quality control/ERAD
Mitochondria GO:0005739 ATP supply for active transport

8. Temporal Development

Onset

BS Type Typical Onset Pattern
Type I (SLC12A1) Antenatal (polyhydramnios 24-30 wk) Acute/severe
Type II (KCNJ1) Antenatal/neonatal Acute/severe
Type III (CLCNKB) Childhood (variable: neonatal to adult) Insidious–acute
Type IV (BSND) Antenatal/neonatal Acute/severe
Type V (MAGED2) Antenatal (earlier than other types) Acute → spontaneous resolution

The MAGED2 form presents with "earlier onset of polyhydramnios and labor" than other antenatal BS types (PMID: 27120771), but typically resolves spontaneously within 2 months postnatally.

Progression

  • Disease course: Chronic lifelong for Types I–IV; self-limited for Type V (MAGED2)
  • Progression rate: Variable; depends on subtype and treatment adequacy
  • Critical periods: Neonatal period (risk of fatal dehydration); infancy (growth window); adolescence (bone mineralization)

Stages

There is no formal staging system for BS. Clinically, disease can be categorized as: 1. Acute phase (neonatal/infantile): Life-threatening volume depletion, electrolyte crises 2. Chronic compensated phase: Stable with treatment; ongoing electrolyte monitoring 3. Chronic kidney disease phase: Progressive renal decline in ~30% of patients

9. Inheritance and Population

Epidemiology

  • Prevalence: Estimated at 1–2 per 1,000,000 (Orphanet)
  • Incidence: Approximately 1 in 1,000,000 live births
  • BS is classified as an ultra-rare disease

Inheritance Patterns

BS Type Inheritance Gene
Type I Autosomal recessive SLC12A1
Type II Autosomal recessive KCNJ1
Type III Autosomal recessive CLCNKB
Type IV Autosomal recessive BSND or CLCNKA+CLCNKB
Type V X-linked recessive MAGED2

Genetic Features

  • Penetrance: Complete for homozygous/compound heterozygous pathogenic variants
  • Expressivity: Variable, especially for CLCNKB (Type III), which can present as antenatal BS, classic BS, or mixed Bartter-Gitelman phenotype (PMID: 21865213)
  • Consanguinity: Major contributor in Middle Eastern, North African, and South Asian populations (72% in Egyptian cohorts) (PMID: 37661676)
  • No genetic anticipation (not a repeat expansion disorder)

Population Demographics

  • Sex ratio: Equal for autosomal recessive types; males predominantly affected for MAGED2 (X-linked)
  • Geographic distribution: Worldwide; higher prevalence in regions with high consanguinity rates
  • Population-specific variants: CLCNKB p.W610X is predominant in Korean populations; CLCNKB 1-20 del is common in Brazilian, Chinese, African, and Middle Eastern populations

10. Diagnostics

Clinical Tests

Laboratory Tests: - Serum electrolytes: K⁺ (low), Cl⁻ (low), Na⁺ (normal/low), Mg²⁺ (variable), Ca²⁺ (variable) - Blood gas: Metabolic alkalosis (elevated HCO₃⁻, elevated pH) - Plasma renin activity: Elevated - Plasma aldosterone: Elevated - Urinary PGE₂: Elevated (especially Types I, II, IV) - Urinary calcium: Elevated in Types I, II; variable in Type III - Urinary chloride: Elevated (>40 mmol/24h indicates renal wasting) - GFR assessment: To monitor for CKD progression

Imaging: - Renal ultrasound: Nephrocalcinosis, medullary hyperechogenicity (PMID: 1887027), hydronephrosis in severe cases - Prenatal ultrasound: Polyhydramnios (antenatal BS)

Functional Tests: - Furosemide challenge: Absent/blunted natriuretic response in Types I, II, IV (PMID: 16583241) - Thiazide challenge: To distinguish BS from Gitelman syndrome - Urinary concentrating ability: Impaired in BS (Fishberg test)

Biomarkers: - Urinary PGE₂/PGE-M (prostaglandin metabolites) - Plasma renin activity - Serum PTH (elevated in Type II) (PMID: 26857709)

Genetic Testing

  • Recommended approach: Next-generation sequencing (NGS) gene panels or whole exome sequencing (WES)
  • Diagnostic yield: 77.5–88.5% in well-characterized cohorts (PMID: 39862309; PMID: 21865213)
  • Gene panel: Should include SLC12A1, KCNJ1, CLCNKB, BSND, CLCNKA, MAGED2, and SLC12A3 (Gitelman), SLC26A3 (CCD)
  • Chromosomal microarray: May detect large CLCNKB deletions not captured by sequencing
  • Prenatal testing: Chorionic villus sampling for known familial mutations (PMID: 38159268)

Clinical Criteria and Differential Diagnosis

Clinical diagnostic triad: 1. Hypokalemic hypochloremic metabolic alkalosis 2. Elevated urinary potassium/chloride excretion 3. Normal to low blood pressure

Differential diagnosis:

Condition Distinguishing Feature
Gitelman syndrome Hypocalciuria, hypomagnesemia, later onset
Congenital chloride diarrhea Diarrhea, stool chloride elevated (PMID: 35787602)
Cystic fibrosis (pseudo-Bartter) Elevated sweat chloride, respiratory symptoms (PMID: 37477516)
Chronic vomiting/laxative abuse Clinical history, variable urine Cl⁻ (PMID: 38306007)
Diuretic abuse Drug screening positive
Primary hyperaldosteronism Hypertension (not normotension)
Liddle syndrome Hypertension, low renin/aldosterone

11. Outcome/Prognosis

Survival and Mortality

  • MAGED2 form: 32% perinatal fatality rate; 27% spontaneous resolution; 41% persistent complications (PMID: 39036894)
  • Types I/II/IV (antenatal BS): High neonatal mortality without treatment; survival significantly improved with indomethacin and aggressive fluid/electrolyte management
  • Type III (classic BS): Generally favorable long-term survival with treatment
  • Life expectancy: Near-normal with adequate treatment for most types; reduced in Type IV with CKD progression and in untreated severe antenatal forms

Morbidity

  • CKD: ~30% of BS patients develop CKD; BS Type I and lower gestational age are risk factors (PMID: 35628451)
  • Nephrocalcinosis: Progressive in Types I and II; can contribute to renal decline
  • Growth retardation: Responds to indomethacin therapy
  • Neurodevelopmental: 24% developmental delay in MAGED2 form
  • Cardiovascular: Risk of sudden cardiac death from chronic electrolyte imbalance

Prognostic Factors

Factor Prognostic Implication
BS Type I (SLC12A1) Higher CKD risk
Lower gestational age Higher CKD risk
Homozygous CLCNKB 1-20 del Progressive CKD (PMID: 36882007)
Early treatment initiation Better growth and renal outcomes
MAGED2 genotype Transient course; better long-term prognosis
Persistent proteinuria Marker of progressive renal damage

12. Treatment

Pharmacotherapy

First-line: Indomethacin (MAXO:0000058 — pharmacological treatment) - Non-selective COX inhibitor; reduces PGE₂ production - Corrects hyperreninemia, improves electrolyte balance, promotes growth - Dose: 1–3 mg/kg/day in divided doses - Side effects: GI irritation, impaired nutritional intake (PMID: 40262923) - CHEBI:49662 (indomethacin)

Alternative COX-2 selective inhibitors: - Rofecoxib (CHEBI:8887): Effective in severe neonatal BS refractory to indomethacin. "Four weeks after induction of the new cyclooxygenase-2 inhibitor rofecoxib, the patient was well, on full enteral feeds, thriving" (PMID: 12749662). Note: rofecoxib was withdrawn from market due to cardiovascular concerns. - Celecoxib: Currently used as COX-2 selective alternative

Electrolyte supplementation (MAXO:0001298 — electrolyte replacement): - Potassium chloride (KCl) — oral supplementation, titrated to serum K⁺ - Sodium chloride (NaCl) — especially in antenatal/neonatal BS - Magnesium supplementation — for hypomagnesemia (especially Type III overlap) - CHEBI:32588 (potassium chloride), CHEBI:26710 (sodium chloride)

Potassium-sparing diuretics: - Spironolactone (CHEBI:9020): Aldosterone antagonist; adjunctive for refractory hypokalemia - Amiloride (CHEBI:2639): ENaC blocker; reduces K⁺ secretion

ACE inhibitors/ARBs: - Captopril: Used in combination with indomethacin in severe Type IV BS (PMID: 16583241) - May exacerbate hypotension; use with caution

Supportive Care

  • Fluid management: Critical in neonatal period; may require IV fluids
  • Nutritional support: High-calorie diet; monitoring of fat-soluble vitamins
  • Growth monitoring: Regular anthropometric assessments
  • Audiological management: Hearing aids or cochlear implants for Type IV

Antenatal Treatment (MAGED2 form)

  • Serial amnioreduction: Significantly improves gestational age at delivery (30.71 vs. 28.7 weeks, p = 0.03) and eliminates neonatal mortality in treated cases (PMID: 38159268)
  • Prenatal indomethacin: Used in some centers to reduce polyhydramnios

Experimental Therapies

  • Protein quality control modulation: Targeting ERAD pathways to rescue NKCC2 trafficking from the ER to the apical membrane — particularly relevant for MAGED2-related BS (PMID: 38786040)
  • WNK-SPAK pathway modulators: SPAK may represent a therapeutic target for blood pressure regulation in salt-wasting disorders (PMID: 24039833)

Treatment Algorithm

Bartter Syndrome Treatment Algorithm:

  1. Acute stabilization (neonatal/infant)
     ├── IV fluid resuscitation (NS)
     ├── IV KCl replacement
     └── ICU monitoring

  2. Chronic management
     ├── Indomethacin 1-3 mg/kg/day
     ├── Oral KCl supplementation
     ├── Oral NaCl supplementation (if needed)
     ├── ± Spironolactone/amiloride
     └── ± ACE inhibitor (severe cases)

  3. If refractory to indomethacin
     ├── Switch to COX-2 selective inhibitor
     └── Combination therapy (indomethacin + captopril)

  4. Monitoring
     ├── Serum electrolytes (regular)
     ├── Renal function (eGFR, proteinuria)
     ├── Renal ultrasound (nephrocalcinosis)
     ├── Growth assessment
     ├── Audiometry (Type IV)
     └── Fat-soluble vitamins

13. Prevention

Primary Prevention

  • Genetic counseling (MAXO:0000079): Essential for affected families; risk assessment for future pregnancies
  • Carrier screening: Recommended in consanguineous populations and families with known mutations
  • Prenatal genetic testing: Chorionic villus sampling or amniocentesis for known familial variants
  • Preimplantation genetic diagnosis (PGD): Available for families with identified mutations

Secondary Prevention (Early Detection)

  • Prenatal ultrasonography: Detection of polyhydramnios prompts investigation for antenatal BS
  • Whole exome sequencing of amniotic fluid: Recommended for unexplained second-trimester polyhydramnios (PMID: 38159268)
  • Newborn screening: Not currently part of standard panels; clinical recognition through electrolyte screening in at-risk neonates

Tertiary Prevention (Complication Prevention)

  • Indomethacin therapy: Reduces PGE₂ overproduction, mitigates hypercalciuria and nephrocalcinosis
  • Adequate electrolyte replacement: Prevents arrhythmias and sudden cardiac death
  • Renal function monitoring: Early detection and management of CKD
  • Nutritional assessment: Prevention of fat-soluble vitamin deficiencies
  • Dental screening: Association with amelogenesis imperfecta in enamel-renal syndromes (PMID: 41427162)

14. Other Species / Natural Disease

Animal Orthologs

Species Gene NCBI Gene ID Disease
Mouse (Mus musculus) Slc12a1 20495 NKCC2 knockout model
Mouse Kcnj1 56468 ROMK knockout model
Mouse Clcnk2 (Clcnkb ortholog) — ClC-K2 deficient model
Mouse Bsnd — Barttin knockout model

Natural Disease

  • No naturally occurring Bartter syndrome has been well-documented in companion animals or livestock
  • The closest veterinary parallel is neonatal renal tubular disorders with salt-wasting presentations in various species
  • OMIA does not list a specific Bartter syndrome entry for domestic animals

15. Model Organisms

Mouse Models

NKCC2 Knockout (Slc12a1⁻/⁻): - Homozygous pups show extracellular volume depletion by day 1 (hematocrit 51% vs. 37% wild type) - None survive to weaning without treatment - Indomethacin treatment from day 1 allows ~10% survival, with severe polyuria (10 mL/day), hydronephrosis, hypokalemia, and hypercalciuria as adults - "Absence of NKCC2 in the mouse causes polyuria that is not compensated elsewhere in the nephron" (PMID: 10779555)

ROMK Knockout (Kcnj1⁻/⁻): - ~95% die before 3 weeks; survivors show metabolic acidosis, polyuria, and reduced GFR - Micropuncture reveals reduced but not eliminated NaCl absorption in TAL and severely impaired tubuloglomerular feedback (PMID: 12122007) - Bladder hypertrophy observed in males but not females (PMID: 29092859)

ClC-K2 Deficient Mice: - Impaired postnatal renal medulla maturation and TAL elongation - G1-S cell cycle transition delay in TAL cells (PMID: 38913022)

SPAK/OSR1 Knockout Models: - SPAK⁻/⁻: Gitelman-like phenotype - Kidney-specific OSR1⁻/⁻: Bartter-like phenotype - Double knockouts reveal essential roles in potassium homeostasis through NCC regulation (PMID: 27068441)

Model Characteristics and Limitations

Model Phenotype Recapitulation Limitations
NKCC2⁻/⁻ Severe polyuria, electrolyte imbalance, nephrocalcinosis Near-universal neonatal lethality; requires indomethacin rescue
ROMK⁻/⁻ Salt wasting, impaired TGF, hydronephrosis High neonatal mortality; metabolic acidosis (differs from human alkalosis)
ClC-K2⁻/⁻ Developmental TAL defects Species-specific Cl⁻ channel compensation may differ
Furosemide-treated WT Pharmacological phenocopy of BS Acute model; doesn't capture chronic developmental effects

Key Findings Summary

Finding 1: Five Core Disease Genes Define the Bartter Syndrome Spectrum

Current evidence firmly establishes SLC12A1, KCNJ1, CLCNKB, BSND, and MAGED2 as the core disease genes. The reclassification of CASR gain-of-function variants away from the BS spectrum (formerly "type V") represents an important nosological refinement (PMID: 42042082).

Finding 2: MAGED2 Form Has 32% Perinatal Fatality but Favorable Long-Term Prognosis

The MAGED2-related transient form is paradoxically the most severe at presentation yet the most favorable long-term, with spontaneous resolution in surviving patients. Serial amnioreduction during pregnancy significantly reduces mortality (PMID: 39036894; PMID: 38159268).

Finding 3: Cardiovascular Risk Despite Normotension

Chronic hypokalemia and hypomagnesemia predispose to ventricular arrhythmias, syncope, and sudden cardiac death, despite the absence of hypertension—challenging the assumption that BS is a purely "benign" condition (PMID: 39445629).

Finding 4: COX-2/PGE₂ Pathway Is Central to Pathophysiology

COX-2 expression in the macula densa drives PGE₂ overproduction, which is the proximate cause of hyperreninemia (r = 0.86 correlation, p < 0.001). This provides the mechanistic rationale for indomethacin therapy (PMID: 12081585; PMID: 929154).

Finding 5: CKD in ~30% of Patients with Type-Specific Risk

Progressive renal disease is a major long-term concern, with BS Type I and lower gestational age as key risk factors (PMID: 35628451). Homozygous CLCNKB complete deletion correlates with CKD progression (PMID: 36882007).

Finding 6: Novel Developmental Mechanism in BS Pathogenesis

Impaired postnatal TAL elongation and renal medulla maturation in ClC-K2-deficient models suggests a developmental component to BS pathogenesis beyond simple transport deficiency (PMID: 38913022).

Finding 7: BS/GS as a "Mirror Model" of Hypertension

The paradox of RAAS activation without hypertension or cardiac remodeling in BS provides unique insights into the mechanisms of salt-sensitive blood pressure regulation and Angiotensin II signaling (PMID: 37107186).

Evidence Base

PMID Reference Focus Key Contribution
42042082 Molecular genetics review (2024) Definitive gene classification, reclassification of CASR
39036894 MAGED2 phenotype enrichment Outcome statistics for 54 symptomatic patients
39445629 Cardiovascular complications First comprehensive CV review of BS/GS
12081585 COX-2 in antenatal BS COX-2 dependence of PGE₂/hyperreninemia
929154 PGE₂-RAAS correlation r = 0.86 PGE₂-PRA correlation
35628451 Long-term CKD outcomes 30% CKD rate, prognostic factors
38913022 Developmental pathogenesis TAL maturation defect discovery
37107186 Mirror model of hypertension RAAS activation without remodeling
38786040 NKCC2 protein quality control ERAD mechanisms in BS pathogenesis
10779555 NKCC2 knockout mouse Uncompensated polyuria model
12122007 ROMK knockout mouse Impaired NaCl absorption and TGF
21865213 Korean BS cohort CLCNKB variant spectrum, no genotype-phenotype correlation
36882007 Brazilian cohort / global review Worldwide variant distribution
18310267 Digenic inheritance CLCNKA+CLCNKB digenic BS Type IVb
38159268 Antenatal MAGED2 treatment Amnioreduction efficacy
17185149 Long-term CLCNKB outcomes Proteinuria and GFR decline
32622651 Bartter-Gitelman review Clinical classification and management overview
28381550 BS Type 3 clinical spectrum Genotype-phenotype analysis
15793031 Salt handling in distal nephron Human knockout phenotypes
32184353 DHHC7/barttin palmitoylation ClC-K channel regulation
37887299 Epithelial transport in disease Pathophysiology overview

Limitations and Knowledge Gaps

  1. Genotype-phenotype correlation: Remains poorly understood for CLCNKB (Type III), the most common and clinically heterogeneous subtype. Despite extensive cohort studies, no reliable genotype-phenotype correlations have been established.

  2. Long-term cardiovascular outcomes: While arrhythmia risk is acknowledged, no large prospective studies quantify the lifetime risk of sudden cardiac death or the optimal cardiac monitoring protocol.

  3. CKD pathogenesis: The mechanisms driving renal fibrosis and CKD progression in ~30% of patients are incompletely understood. Whether nephrocalcinosis alone or additional factors (hypokalemic nephropathy, chronic RAAS activation) drive CKD remains unclear.

  4. Limited randomized controlled trials: Treatment recommendations are based on case series and expert consensus rather than RCTs, reflecting the ultra-rare disease status.

  5. Epigenetic and multi-omics data: No transcriptomic, proteomic, or metabolomic profiling studies of BS patient kidneys have been published, limiting understanding of secondary molecular changes.

  6. Modifier gene identification: Beyond the digenic CLCNKA/CLCNKB and BSND/GJB2 interactions, systematic studies of genetic modifiers are lacking.

  7. Quality of life data: No validated disease-specific QoL instruments exist for BS; standardized assessments are needed.

  8. Population prevalence data: Prevalence estimates are imprecise due to under-diagnosis and lack of disease registries in many countries.

  9. Developmental pathogenesis: The novel finding of impaired TAL elongation in BS mouse models requires validation in human tissue and further mechanistic characterization.

  10. Pharmacogenomics: No studies have examined how genetic variation affects indomethacin or other NSAID efficacy/toxicity in BS patients.

Proposed Follow-up Experiments/Actions

Near-term (1–3 years)

  1. Prospective cardiovascular monitoring study: Establish a multicenter cohort of BS patients with serial ECG, Holter monitoring, and echocardiography to quantify arrhythmia burden and sudden cardiac death risk by subtype.

  2. Single-cell RNA sequencing of BS kidney biopsies: Profile cell-type-specific transcriptomic changes in TAL, macula densa, and collecting duct cells to identify secondary molecular pathways and potential therapeutic targets.

  3. CKD biomarker discovery: Identify urinary and plasma biomarkers (e.g., KIM-1, NGAL, uromodulin) that predict CKD progression in BS patients, enabling early intervention.

  4. Genotype-phenotype correlation meta-analysis: Pool data from global BS registries to achieve sufficient sample sizes for meaningful genotype-phenotype correlation analysis in CLCNKB-mutated patients.

  5. Disease-specific quality of life instrument development: Develop and validate a BS-specific patient-reported outcome measure (PROM) for clinical trials and routine care.

Medium-term (3–5 years)

  1. ERAD modulator screening: High-throughput screening for small molecules that rescue NKCC2 trafficking from the ER to the plasma membrane, particularly relevant for MAGED2-mediated BS (PMID: 38786040).

  2. WNK-SPAK pathway clinical translation: Evaluate SPAK inhibitors as potential therapeutic agents for salt-sensitive hypertension, leveraging insights from BS as the "mirror model" (PMID: 24039833).

  3. International BS registry: Establish a global patient registry with standardized phenotyping, genotyping, and longitudinal outcome data to improve natural history understanding and facilitate clinical trials.

Long-term (5+ years)

  1. Gene therapy: Develop AAV-mediated gene replacement strategies for SLC12A1 or KCNJ1, targeting TAL cells with kidney-specific promoters.

  2. Renal organoid models: Generate patient-derived iPSC-based kidney organoids harboring BS mutations for personalized drug screening and mechanistic studies.

Report generated: 2026-05-05 Based on analysis of 66 peer-reviewed publications and 7 confirmed findings Disease: Bartter syndrome (MONDO:0008858)